

Curriculum Vitae –2025
Dr. Norm Campbell BMedSci, MD, FRCPC, DSC (Hon), CM

I. BIOGRAPHICAL DATA

NAME: NORMAN ROBERT CAMERON CAMPBELL

CITIZENSHIP: Canadian

EMAIL: ncampbel@ucalgary.ca

PRESENT RANK: Professor Emeritus (Oct 1, 2019)

DEPARTMENT: Medicine (Adjunct Professor, 2019)

FACULTY: Medicine

INSTITUTION: Libin Cardiovascular Institute of Alberta
O'Brien Institute of Public Health
University of Calgary

II. ACADEMIC RECORD

Final Degree M.D. 1980 Memorial University of Newfoundland/St John's/Canada

i. Undergraduate

B.Med.Sc. 1978 Memorial University of Newfoundland/St John's/Canada

ii. Graduate and Post-Doctoral

1984 – 1985 Resident IV, Internal Medicine, Memorial University of Newfoundland St. John's, Newfoundland, Canada

1982 – 1984 Research Fellow, Mayo Clinic, Rochester, Minnesota. USA

1981 – 1982 Resident II Internal Medicine, Memorial University

1980 – 1981 Straight Internship Internal Medicine, Memorial University

1976 – 1980 Faculty of Medicine, Memorial University

iii. Licensure, Certification and Boards

Medical License; Newfoundland, Canada # 4210, 1985-1990

Alberta, Canada # 010161, 1990-2019

F.R.C.P.(C) 1985

Diplomat in Internal Medicine (American Board of Internal Medicine) 1988

III. AWARDS AND DISTINCTIONS

2024 Graham MacGregor Excellence Award in Dietary Salt Reduction at the Population Level, World Hypertension League

2023 Emeritus member, International Society of Hypertension

2020 Senior Investigator Award, Hypertension Canada.

2019 Excellence in leadership and distinguished service award as President and Past President World Hypertension League.

2019 Doctor of Science (honoris causa), Memorial University of Newfoundland

2018 The Enrique Barnet Prize in Public Health for meritorious contribution to the health of the people. Province of Cienfuegos, Cuba.

2017 World Hypertension League names an award the 'Norman Campbell Excellence Award for Population Hypertension Prevention and Control'.

2016 Excellence Award in Population Blood Pressure Prevention and Control World Hypertension League

2016 Distinguished Service Award, World Hypertension League
 2015 University of Calgary Peaks Scholar nominee
 2015 Health Research Foundation Medal of Honour to recognize excellence and pivotal contributions to health science for Canada, and for the world
 2015 Medal for Distinguished Service, Alberta Medical Association for outstanding personal contribution to the medical profession and to the people of Alberta
 2015 Frederic Newton Gisborne Starr Award, Canadian Medical Association for achievement so outstanding as to serve as an inspiration and a challenge to the medical profession in Canada. The highest award of the Canadian Medical Association.
 2014 Order of Canada
 2014-2019 Fellowship in the Canadian Academy of Health Sciences (FCAHS)
 2014 Dr. Howard N. Segall Award of Merit, Canadian Cardiovascular Society, in recognition of a significant contribution to the prevention of cardiovascular disease or the promotion of cardiovascular health in Canadians
 2014 Distinguished Academic Award, Confederation of Alberta Faculty Associations to recognize an academic staff member who excels in teaching and goes above and beyond in their role as a teacher and has made an outstanding contribution to the wider community beyond the university.
 2014 Team Builder of the Year Award, Department of Medicine, the University of Calgary
 2013 Guenter Award for International Health, Faculty of Medicine, University of Calgary for outstanding contributions to international health.
 2013 Letter of excellence to the Canadian Hypertension Advisory Committee (N Campbell, Founder and Chair of Committee), Hypertension Canada
 2012 JG Fodor award for prevention and control of hypertension to recognize a distinguished record of substantial contributions by individuals or organizations that have increased prevention and/or improved control of blood pressure in Canada. Hypertension Canada.
 2011-2016 HSF CIHR Chair in Hypertension Prevention and Control, Heart and Stroke Foundation - Canadian Institute for Health
 2011 'Special Distinguished Service Award' recognizing activities 2006-2011 as the CIHR Canada Chair in Hypertension Prevention and Control, Hypertension Canada
 2009 Distinguished Service Award, Canadian Hypertension Society 2009
 2008 5th Annual Sourirajan Lecturer, Department of Medicine, University of Ottawa.
 2008 Distinguished Speaker in Cardiovascular Medicine, Division of Cardiology, University of British Columbia
 2007 Leadership Award in Heart Healthy Policy, Heart and Stroke Foundation of Canada
 2006 - 2011 CIHR Canada Chair in Hypertension Prevention & Control, Canadian Institute for Health Research
 2005 Senior Investigator Award, Canadian Society of Internal Medicine
 2005 Distinguished Service Award, Canadian Society for Clinical Pharmacology
 2003 Royal College of Physicians and Surgeons Lecturer, Canadian Society of Internal Medicine
 2002 Osler Award, Canadian Society of Internal Medicine
 2001 Letter for Excellence in Teaching; Aging and Elderly Course, Faculty of Medicine, University of Calgary. Calgary Medical Student Association
 2000 'Grandfathered' Lifelong Specialist in Clinical Hypertension, American Hypertension Society
 1998 Gold Star Letter for Excellence in Lecturing; Aging and Elderly Course, Faculty of Medicine, University of Calgary
 1996 Distinguished Achievement Award (Education and Research), Faculty of Medicine, University of Calgary
 1995 Piafsky Young Investigator Award, Canadian Society for Clinical Pharmacology
 1990-2010 Fellow of the American College of Physicians
 1982 -1984 Merck Foundation International Fellowship in Clinical Pharmacology
 1979 Robert B. Salter Award, Faculty of Medicine, Memorial University
 1979 Atlantic Regional Athletic Bursary-Volleyball, Sports Canada
 1976-1979 Varsity (Intercollegiate) Volleyball, Memorial University of Newfoundland
 1975-1976 Varsity (Intercollegiate) Basketball, Memorial University of Newfoundland

1974-75 Junior Varsity Basketball, Memorial University of Newfoundland

1974 Honors Club, Ridgemont High School, Ottawa Ontario

1974 Athletic Letter, Ridgemont High School, Ottawa Ontario

IV. ACADEMIC APPOINTMENTS

University of Calgary

Oct 2019 - Adjunct Professor of Medicine

Oct 2019 - Emeritus Professor

2009 - Oct 2019 Adjunct Professor of Physiology and Pharmacology

2006 - Oct 2019 Adjunct Professor of Community Health Sciences

1997 - Oct 2019 Professor of Medicine

1997 - 2009 Adjunct Professor of Pharmacology and Therapeutics

1996 - 1998 Division of Nephrology

1995 - Tenure

1992 - 1998 Division of Geriatrics

1991 - 1997 Adjunct Associate Professor of Pharmacology and Therapeutics'

1990 - 1997 Associate Professor of Medicine

1990 - 2019 Division of General Internal Medicine

1990 - 2019 Staff, Foothills Hospital, Calgary Alberta

Memorial University of Newfoundland

1988 – 1990 Tenure

1987 – 1990 Division of Nephrology

1985 – 1987 Division of Clinical Pharmacology

1985 – 1990 Assistant Professor of Medicine

1985 – 1990 Staff; General Hospital, St. John's, Nfld.

1985 – 1990 Consulting Staff; St. Clare's Mercy Hospital, St. John's, Nfld.

V. EDUCATIONAL ACTIVITIES

i. UNDERGRADUATE

Committees:

University of Calgary

1998 – 2000 Research Protocol Committee (course 340), Faculty of Medicine

Professional Societies

1994 Council for Education in Clinical Pharmacology & Therapeutics (Representative for the Canadian Society of Clinical Pharmacology)

Memorial University of Newfoundland

1988 – 1990 Third Year Medicine Therapeutics Course Committee (inaugural Chair)

1988 – 1990 Third Year Medicine Curriculum Committee

1988 – 1990 Third Year Medicine Promotion Committee

1986 – 1990 Medicine Coordinator, LMCC review course

1986 – 1988 Introduction to Clerkship Course Committee

Teaching:

University of Calgary, Medical School

2014

Lecturer, Renal course, Medicine: Public health, blood pressure and hypertension

2013

Lecturer, Renal course, Medicine: Public health, blood pressure and hypertension

2012

Lecturer, Renal course, Medicine: Public health, blood pressure and hypertension

2011

Lecturer, Renal course, Medicine: Public health, blood pressure and hypertension

2007

Lecturer, Aging & the Elderly: Hypertension in the Elderly

2006

Internal Medicine Clerkship Seminars Clinical Pharmacology, 2 x 2.5 hr. tutorials

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

2004

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 2 x 2.5 hr. tutorials

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

2003

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 4 x 2.5 hr. tutorials

Lecturer, Cardiovascular Course, Principals of Clinical Pharmacology

Lecturer, Cardiovascular Course: Pharmacology of Anti-Congestive Heart Failure Medications

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

2002

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 4 x 2.5 hr. tutorials

Lecturer, Cardiovascular Clinical Pharmacology

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

2001

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 4 x 2.5 hr. tutorials

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

Lecturer, Renal and Electrolyte Course, Lifestyle Modification to Prevent and Control Hypertension

Small Group Teaching, Renal and electrolyte course, 2 hrs.

2000

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 4 x 2.5 hr. tutorials

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

Lecturer, Renal and Electrolyte Course, Diagnosis of Hypertension and Measurement of Blood Pressure

Lecturer, Renal and Electrolyte Course, Lifestyle Modification to Prevent and Control Hypertension

1999

Internal Medicine Clerkship Seminars. Clinical Pharmacology, 4 x 2.5 hr. tutorials

Lecturer, Clinical Pharmacology in the Elderly

Lecturer, Hypertension in the Elderly

Lecturer, Renal and Electrolyte Course, Diagnosis of Hypertension and Measurement of Blood Pressure

Lecturer, Renal and Electrolyte Course, Lifestyle Modification to Prevent and Control Hypertension

1998

Lecturer. Clinical Pharmacology in the Elderly. 1 hr.

Lecturer. Hypertension in the Elderly. 1 hr.

Lecturer, Renal and Electrolyte Course, Approach to Hypertension,

Clinical Pharmacology for Clinical Clerks, 10 hours tutorials:

1997

Co-Lecturer, History of Medicine Course. Rivo Ricci and Korotkoff- The Measurement of Blood Pressure

Lecturer. Clinical Pharmacology in the Elderly. 1 hr.

Lecturer. Hypertension in the Elderly. 1 hr.

Tutor, Renal and Electrolyte Course, Measurement of Blood Pressure 2 hrs.

Lecturer, Renal and Electrolyte Course, Nonpharmacological Therapy of Hypertension
Lecturer, Renal and Electrolyte Course, Pharmacological Therapy of Hypertension
Clinical Pharmacology for Clinical Clerks 7.5 hrs. tutorials

1996

Lecturer, Hypertension in the Elderly, Measurement of Blood Pressure, Nonpharmacological therapy of hypertension.
Critical Appraisal Course for Clinical Clerks: 3 hrs.
Clinical Pharmacology for Clinical Clerks: 2 hours
Principals of Clinical Pharmacology for Clinical Clerks, 2 hr. workshop

1995

Lecturer, Pharmacology of Ageing, Drug Interactions
Clinical Pharmacology Tutorial (7.5 hours)
Clinical Skills Tutor: (4 hours)
Critical Appraisal Course for Clinical Clerks (6 hours)

1994

Lecturer, Pharmacology of Ageing, Clinical Pharmacology of NSAIDS and Acetaminophen
Tutor, Pharmacology (Antihypertensives)

1993

Lecturer, Pharmacology of Ageing
Tutor, Pharmacology (Antihypertensives), Critical Appraisal Units I-IV

1992

Tutor, Pharmacology (Sympathomimetics, Antihypertensives, and NSAIDS)
Research Supervisor, M Zibdawi

1991

Lecturer, Pharmacology of Ageing
Tutor, Pharmacology (Antihypertensives, NSAIDS I-II)

Memorial University of Newfoundland

1990

Clinical Skills Tutor, 2nd and 3rd year medicine 12 hours

1989

Clinical Skills Tutor, 2nd and 3rd year medicine 38 hours
Lecturer, Antihypertensives, Renal tubular handling of drugs, Principals of therapeutics, Pharmacology of Steroids.
Tutor, Cardiovascular (Heart Failure), Endocrinology (Lipids, adrenal disorders, calcium, steroids, diabetes mellitus), Therapeutics (Cardiac medications, hypertension, drugs and ageing), Renal (acid and base balance 1-3, renal failure)

1988

Clinical Skills Tutor, 2nd and 3rd year medicine 25 hours
Lecturer, Drug Distribution, Renal tubular handling of drugs, Hypertension treatment, Principals of therapeutics.
Tutor, Pharmacology, Endocrinology (Adrenal disorders, calcium, steroids, diabetes mellitus)

1987

Clinical Skills Tutor, 3rd year medicine 50 hours
Lecturer, Clinical aspects of drug metabolism and renal excretion of drugs, Renal tubular handling of drugs, Antihypertensives, Therapeutic Drug Monitoring
Tutor, Endocrinology (Adrenal disorders)

1986

Clinical Skills Tutor, 2nd and 3rd year medicine 57.5 hours
Lecturer, Drug metabolism, Renal Excretion of Drugs, Renal tubular handling of drugs, Antihypertensives, Therapeutic Drug Monitoring,
Tutor, Endocrinology (Calcium, Adrenal disorders)

1985

Clinical Skills Tutor, 2nd and 3rd year medicine 34 hours

Lecturer, Antihypertensives, Therapeutic Drug Monitoring
Tutor, Neurology (stroke, headache), Endocrinology (Calcium)

ii. GRADUATE

Committees:

Catholic University of Health and Allied Sciences School of Public Health Tanzania

2014 MSc Committee, Helena Mwidowe

Simon Frazer University

2012 PhD Examination Committee, Azadeh Alimadad

Queens University

2010-2013 PhD supervisory committee M Gee.

University of Toronto

2010 PhD examination Committee, J Arcand,

University of Sidney

2010 PhD examination Committee J Webster.

University of Calgary

2015-2017 Supervisory Committee, Hena Qureshi, Masters of Community Health Science

2015 MSc Examination Committee, Barb Dupuis

2006- 2010 Co-supervisor, S Mohan, CIHR HOPE Post doctoral fellow

2000 – 2003 Supervisory Committee Dr. N. Khan, Masters of Community Health Science

1999 – 1995 Supervisory Committee, Dr. J. Schaefer, Masters of Community Health Science

1993 PhD Examination Committee, Hui Xie, Pharmacology

Memorial University of Newfoundland

1988 Supervisory Committee, Ms. J. Hunt, Toxicology Masters

1988 Internal Reviewer, Ms. K. Grewal, Toxicology Masters Thesis

1988-90 Post Doctoral Fellow, M Esquivel

Teaching:

University of Calgary

1994 Lecturer, Cardiovascular Pharmacology (629.03)

1992 Lecturer, Pharmacology (621.1)

1991 Lecturer, Physiology of critical illness (755), Pharmacology (621.1)

Memorial University of Newfoundland

1987 Lecturer Pharmacology, Drug metabolism

1986 Lecturer Pharmacology, Drug metabolism

iii. POSTGRADUATE

Committees:

University of Calgary

1996 – 1998 Subspecialty Education Committee, Nephrology

1994 Internal Reviewer, Nephrology Training Program

1991 – 1992, 1994 Guest Member, Graduate Training Committee, Medicine

1990 – 2000 Subspecialty Education Committee, General Internal Medicine (Chair 1991-1996)

Memorial University of Newfoundland

1988 – 1990 Medical Residents Research Committee, Chair (1989-1990)

1985 – 1987 Medical Residency Committee

1985 – 1987 Coordinator Clinical Teaching Unit II

Teaching:

American Society for Clinical Pharmacology and Therapeutics'

1996 Panel member, the role of clinical pharmacology in primary care specialties. Satellite symposia.

University of Calgary

1990- 2012

General Medicine Inpatient Consultative Service Preceptor

1990-2006

Medical Teaching Unit, General Medicine Preceptor

2000

Medical Teaching Unit,

Hypertension a common risk of death. Nephrology rounds (1 hr.)

1999

Medical Teaching Unit,

R-3 oral examinations, Department of Medicine

R-4 practice oral examinations, Department of Medicine

1998

Medical Teaching Unit,

R-3 oral examinations, Department of Medicine

R-4 practice oral examinations, Department of Medicine

1997

Medical Teaching Unit,

R-3 oral examinations,

Monday Noon Clinical Medicine Rounds, Clinical Tutor, 20 hours

Resident OSCE examiner 4 hours

1996

Medical Teaching Unit,

Judge, Medical Residents Research Day,

1994

Medical Teaching Unit,

Lecturer, Resistant hypertension (medical residents)

Tutor, Clinical Trials Course

1993

Medical Teaching Unit,

Clinical Pharmacology (medical residents), Drugs and ageing (medical residents)

1992

Medical Teaching Unit,

Lecturer, Clinical Pharmacology Cases (medical residents) Clinical Pharmacology (medical residents)

1991

Medical Teaching Unit,

Lecturer, Clinical Pharmacology (medical residents)

1990

Medical Teaching Unit,

Lecturer, Measurement of blood pressure

Memorial University of Newfoundland

1990

Medical Teaching Unit, General Medicine Preceptor

1989

Medical Teaching Unit General Medicine Preceptor

1988

Medical Teaching Unit, General Medicine Preceptor

Lecturer, Hypertensive emergencies, Glomerular hypertension and progressive renal impairment

1987

Medical Teaching Unit, General Medicine Preceptor

Lecturer, Hypertensive emergencies, Catecholamine metabolism

1986

Medical Teaching Unit, General Medicine Preceptor

1985

Medical Teaching Unit, General Medicine Preceptor

Lecturer, Hypertensive emergencies

iv. CONTINUING MEDICAL EDUCATION

Committees:

- 2008-2010 Joint Program Committee, Blood Pressure Canada, Canadian Hypertension Education Program, Canadian Hypertension Society
- 2003 – 2004 Overseeing Committee Canadian Therapeutics Congress ((Founder of Meeting and Inaugural Chair Overseeing Committee first joint meeting of the Canadian Society for Clinical Pharmacology, Pharmacology Society of Canada, Canadian Association for Population Therapeutics and Canadian College of Clinical Pharmacists)
- 2000 Organizer of the Groundbreaking Clinical Trials in Hypertension Symposia, Canadian Cardiovascular Forum (October 30), for the Canadian Hypertension Society
- 2000 Co-Organizer and Co-Chair, Hypertension in Women Symposium, 1st International Conference on Women and Cardiovascular Disease
- 1999 – 2006 Program Committee, Canadian Society of Internal Medicine
- 1998 – 1999, 2002, Annual Meeting Program Committee Member (Co-Chair 1998-1999) Canadian Hypertension Society
- 1997 – 2000 Member Western Canadian Cardiovascular Forum (Chair 2000)
- 1995 – 1999 Organizing Committee, Biannual Advances in Internal Medicine Course, American College of Physicians Banff Regional Meeting (Co-Chair 1999)
- 1995- 2016 Organizing Committee Rocky Mountain Annual General Internal Program Committee (Founder & Inaugural Chair 1995-2000)
- 1995 – 1996, Organizer & Co-Chair for RCPS Symposia on Gene Therapy, for the Canadian Society of Clinical Pharmacology
- 1994 – 2001 Scientific Program Committee, Canadian Society for Clinical Pharmacology
- 1993 – 2000, 2004-6, Medical Education Committee, Canadian Society for Clinical Pharmacology
- 1991 – 1995 Clinical Trials Methodology Course Committee, University of Calgary (Chair 1992)
- 1990 – 1998 Calgary Therapeutics Course Planning Committee, University of Calgary

Teaching:

Please see invited presentations

VI. ADMINISTRATIVE RESPONSIBILITIES

i Departmental

- 2015-2016 Department representative to the Faculty Association
- 2015 Search Committee for Head Division of General Internal Medicine
- 1990 – Division of General Internal Medicine (Head 1994-2000)
- 1996 – 1998 Subspecialty Education Committee (Nephrology)
- 1996 – 1998 Division of Nephrology
- 1995 Search Committee for Department of Medicine Program Director
- 1995 Review Committee, Head Geriatric Medicine
- 1995 Mortality Reviewer, Division of General Internal Medicine
- 1994 – 2000 Executive Committee, Dept of Medicine
- 1992 – 1998 Division of Geriatrics
- 1991 – 1996 Subspecialty Education Director, Division of General Internal Medicine

ii Faculty

University of Calgary

- 2000 – 2002 Search Committee, Head of Internal Medicine

- 1994 – 1995 Department of Pharmacology, Headship Review Committee
- 1993 – 1994 Research Committee
- 1992 – 1995 Conjoint Scientific Review Committee, University of Calgary/Foothills Hospital
- 1990 – 2000 Cardiovascular Research Group, Adjunct member,
- 1990 – 2000 Clinical Pharmacology Unit,

Memorial University of Newfoundland

- 1990 Promotions and Tenure Committee, School of Pharmacy
- 1988 Research Planning Committee, Faculty of Medicine
- 1987 – 1990 Research and Development Committee, Faculty of Medicine
- 1986 – 1990 Pharmacology Resource Group, Faculty of Medicine
- 1986 – 1989 Human Investigation Committee (Secretary 1988)

iii. University

iv. Regional Health Authority (Calgary)

- 2001 – 2002 Search Committee, Dept of Medicine Chair
- 1997 – 2004 Pharmacy & Therapeutics Committee Acute Care Sector (Chair 1997-2000)
- 1997 – 1999 Chief, General Internal Medicine
- 1995 Search Committee for Medical Director, Senior's Health

v. Hospital

Foothills Hospital Calgary Alberta

- 1995 Internal Accreditation Reviewer, Unit 57
- 1994 – 1995 Continuous Quality Assurance Committee
- 1994 – 1999 Chief, Division of General Internal Medicine
- 1990 – 1997 Pharmacy and Therapeutics' Committee

General Hospital St John's Newfoundland

- 1985 – 1990 Pharmacy and Therapeutics' Committee, (Chair 1989-1990)
- 1985 -1986 Bed Utilization Committee

VII. PROFESSIONAL ACTIVITIES

i Membership in Professional and Learned Societies

- International Hypertension Society (1988-2023, Emeritus member 2023-)
- Alberta Medical Association (1990-2020)
- Canadian Hypertension Society (1985-2010)
- Canadian Cardiovascular Society (2011-2012)
- Hypertension Canada (2010-)
- Canadian Society of Internal Medicine (Emeritus member)
- Canadian Society for Clinical Pharmacology (1985-2009)
- Canadian Medical Association (1985-2000)
- American College of Physicians (Fellow 1990-2010, 1987-2010)
- Associate member, Canadian Stroke Network (2002-2014)
- Canadian Academy for Health Sciences (2015-2019)

ii Professional Service

CURRENT

Pan American Health Organization/ World Health Organization.

2016- Temporary advisor, consultant to Pan American Health Organization/ World Health Organization HEARTS in the Americas Initiative for technical cooperation for cardiovascular disease prevention and control programs with emphasis on hypertension control and prevention

World Hypertension League

2019- Special advisor to the board

STRIDE BP Executive Management Board

2023- Ex-officio executive member representing the World Hypertension League

Australian Cardiovascular Alliance (ACvA)

2022- Member International Advisory Board for national hypertension control strategy.

Canadian Hypertension Coalition

2023- Oct 2024 (founder and inaugural Chair)

2023- Executive member

Alberta Environment Network

2021- Member

2021- 2024 Board member, Alberta Environment Network

2021- Founder and Chair, Alberta Health Professions for the Environment

Crowfoot Village Family Practice

2022- Advisor for Hypertension Control Program

Canadian Association of Physicians for the Environment

2021- member

Canadian Doctors for Protection from Guns

2020- member

PAST**INTERNATIONAL****Resolve To Save Lives (RTSL)**

2018-2023 Senior Consultant

World Bank

2021- 2023 Temporary advisor (Samoa and Cambodia NCD programs)

World Health Organization

2021- 2022 Consultant- External resource person HEARTS Initiative. Hypertension indicators

2019- 2021 Consultant- External resource person. WHO NUGAG Subgroup on Diet and Health

2019- 2021 World Health Organization BP devices group member

2012-2022, World Health Organization, Nutrition Advisory Panel-Group, Noncommunicable Disease, (NutNCD group)

2010-2011, WHO Nutrition Guidance Expert Advisory Group (micronutrient subcommittee)

2010, Organizing committee (co-chair national and international organizing committees) WHO Sodium surveillance platform II meeting Oct 2010

2012 Consultant to SEARO region of WHO on salt reduction.

Pan American Health Organization/ World Health Organization. Technical Advisory Group to mobilize cardiovascular disease prevention through dietary salt control policies and interventions.

2012-2022, Co-Chair 2012-2015, member 2012-2022,

2012- 2015, Member, Education-advocacy subgroup

2012-2015, Co-chair Science subgroup

2009-2011, Member Fortification subgroup

2010-2011, Member, Health economies subgroup

Pan American Health Organization/ World Health Organization. Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction

2009 -2011, Chair

2009-2011, Member, Education-advocacy subgroup

2009-2011, Member, Surveillance subgroup

2009-2011, Member Industry subgroup

2009-2011, Member Fortification subgroup

2010-2011, Chair, Health economics subgroup

Salt Smart Consortium

2012-2015, Steering committee member, (Consortium of private sector, government and nongovernment organizations to reduce dietary salt in the America's led by the Pan American Health Organization).

Pan American Health Organization-Centre for Disease Control, United States. Global Standardized Hypertension Treatment (GSHTP) Initiative

2014-2016 External consultant and representative of the World Hypertension League

World Hypertension League

2015-2019, Past President

2013- 2015, President

2013, President elect

2012-2019, Executive board member

1996-9, 2007-2019, Council member (representing Blood Pressure Canada up to 2010 and representing Hypertension Canada after 2010)

TRUE Consortium: inTernational consoRtium for qUality research on dietary sodium/salt (American Heart Association, British and Irish Hypertension Society, Chinese Regional Office of the World Hypertension League, George Institute for Global Health, Hypertension Canada, International Association of National Public Health Institutes, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Hypertension, International Society of Nephrology, Journal of Clinical Hypertension, RESOLVE TO SAVE LIVES, Pan American Health Organization/ World Health Organization, World Hypertension League, World Stroke Organization).

2016-2020, Founder and Inaugural Chair steering committee and expert committee.

International Advisory Panel on reduction of salt and sugar in food. Secretary for Food and Health. Hong Kong

2014- 2018, Member

International Advisory Board, Iran salt reduction program, WHO Iranian office and Ministry of Health of Iran.

2014-2019, Member

Ministry of Health of Iran

2013-14, Member International advisory committee on hypertension control.

Public Health England

2014-2015, External consultant to the Blood Pressure Programme

Centre for Science in the Public Interest

2012-2016, Member scientific advisory board for Nutrition Action Health Letter

World Hypertension Congress

2012-2013, 2019 Member organizing committee.

ProCor (internet-based learning to developing countries)

2005-2009, Hypertension Editor

International Hypertension Society

2006-2010, National Advisory Committee member for 2010 meeting

2013-2015, Council member representing the World Hypertension League

American Heart Association

2012, Writing group member. The Importance of Population-Wide Sodium Reduction as a means to Prevent CVD and Stroke: A Call to Action

American Hypertension Society

1999 – 2001, Canadian Advisory Committee on designation of Hypertension Specialist

American Society for Clinical Pharmacology and Therapeutics.

1994 – 1998, Member Medical Education Committee

Council for Education in Clinical Pharmacology and Therapeutics (USA).

1993 – 1994, Member

NATIONAL**Blood Pressure Assessment Program**

2002 – 2005, Founder and Chair of a National Committee (Heart and Stroke Foundation of Canada, Stroke Network, the Calgary Fire Department) for the development of regional fire department programs across Canada to assess blood pressure for the public in community fire stations.

Canadian Cardiovascular Society

2011-2012, member

2009, Panel 1 Member Lipid recommendations (Canadian Cardiovascular Society Position Statement)

2005 – 2006, Panel 1 Member, Lipid recommendations. (Produced Canadian Cardiovascular Society Position Statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 2006; 22:913-927, Note the publication inadvertently did not acknowledge role).

Blood Pressure Canada (formerly Canadian Coalition for High Blood Pressure Prevention and Control)

2006 – 2009 Founder and Inaugural Chair, Public Education Task Force

2006-2009 Founder and Chair, Sodium Strategic Planning Committee

2007 – 2009 Founder and Member, Sodium Task Force (Co-chair 2008-2009)

2006 – 2010 President

2005 – 2006 President-Elect

1999 – 2002 Past President

1996 – 1999 President

1995 – 1996, President Elect

1995 – 2002, 2005-2010 Executive Member

1994 – 2009 Board Member

1996 – 1999 Steering Committee-Co-chair; National Guidelines for Nonpharmacological Therapy of Hypertension. Chair panel on alcohol

1996 Chair, Scientific Program Committee

1995 – 1997 Working group member to develop national guidelines for patient adherence to blood pressure lowering therapy

1994 – 1995 Chair Working Group to develop guidelines on Self-Measurement of Blood Pressure

1993 – 1994 Working group member on guidelines for measurement of blood pressure, referral and follow-up, and lifestyle counseling

Canadian Heart Health Strategy and Action Plan (initiative of the Heart and Stroke Foundation of Canada, the Government of Canada, the Canadian Institutes of Health Research and the Canadian Cardiovascular Society)

2007 – 2008 Co-Chair, Cardiovascular Risk Group

2006 – 2008, Member Steering Committee

Canadian Hypertension Control Program (AKA Canadian Hypertension Education Program (CHEP))

2000 – 2011, Recommendations Task Force (founder and inaugural chair 2000, 2001)

2002 – 2011, Outcomes Research Task Force (founder and inaugural Chair 2002-2007)

2004-2011, Morbidity and mortality subcommittee (founder and inaugural Chair, 2004-2008),

2003- 2011, National questionnaire surveys subcommittee (founder and inaugural Chair 2003-2011)

2004-2011, Hypertension Outcomes Surveillance Team (founder and co-team lead 2004)

2002-2011, IMS database team, (founder and inaugural Chair 2002- 2006)

2008-2011, Canadian Health Measure Survey Analytic Committee (founder and inaugural Chair 2008-2011)

2002 – 2003, Chair Central Review Committee

2000 – 2010, Implementation Task Force, (founder and Co-Chair, 2003- 2005, member 2003-2010)

2000 – 2011, Steering Committee and Executive Committees (founder and inaugural chair 2000, 2001, 2004-2009, steering committee dissolved in 2010 with merger of CHEP into Hypertension Canada)

Canadian Hypertension Society

1999-2002, 2008-2010, Executive committee member

1994 – 2002, 2008-2010, Board Member

2006, Chair & Organizer, Public Education on Hypertension. “Train the Trainer” session. Symposium, Canadian Hypertension Society/Canadian Cardiovascular Congress

2001 – 2002, 2004-2007, 2009 Chair, Canadian Hypertension Education Recommendations Symposia, Canadian Cardiovascular Congress

2001 – 2004, Canadian Hypertension Society representative to the Canadian Cardiovascular Research Advisory Council

2000 – 2001, Past President

1999 – 2000, President

1999 – 2000, Chair, Strategic Planning Committee

1998 – 1999, President Elect

1997 – 1999, Steering Committee Member for Development of Guidelines for Treatment and Diagnosis of Hypertension

1997 – 1999, Chair, Sub-Committee to Develop Guidelines for Diagnosis of Hypertension

1995, Member, Committee to Develop a Computer Communication Network

1994 – 2002, CHS Representative, Canadian Coalition for High Blood Pressure Prevention and Control (AKA Blood Pressure Canada)

C-Change (AKA Sol, Solide Committee to integrate Canadian CVD risk management recommendations)

2002 Founder and initial co-chair 2002,

2002-2009 Member representing hypertension.

Canadian Medical Association

2006 – 2007, Member, International Advisory Panel for the Canadian Medical Association Guidelines for Clinical Practice & Guidelines for Implementation of Clinical Practice Guidelines

1993 – 1998, Representative to the Canadian Coalition for High Blood Pressure Prevention and Control

Canadian Public Health Association

2006 – 2008, Member, National Advisory Committee on “Public Health Practice in Chronic Disease”

Canadian Society of Internal Medicine

2019- Senior Associate
2006- 2010, Representative to Blood Pressure Canada
2010- 2014, Representative to Canadian Hypertension Advisory Committee
2007- 2014, Health Promotion Committee
2000 – 2004, 2006, Program Committee
1999 – 2004, Councillor
1999 – 2004, Chair, Research Committee
1999 – 2004, Education Committee member
1999 – 2004, Abstract Reviewer
1999 – 2000, Chair, Peri-Operative Research Interest Group

Canadian Society for Clinical Pharmacology

2006, 2008, Ad hoc member of awards committee
2004 – 2005, Past President
2002 – 2004, President
2002 – 2003, Research Committee Chair
2002 – 2003, Chair, Strategic Planning Sessions
2001 – 2002, President Elect
2001 – 2005, Executive Member
1998 – 2005, Board of Directors
1995 – 1999, Abstract Reviewer
1994 – 2004, Awards Committee

Canadian Stroke Network

2006 – 2014, Policy & Priorities Committee member
2002 – 2014, Associate Member

Royal College of Physicians and Surgeons

2002 – 2004, 2009, Corresponding member, Clinical Pharmacology Specialty Committee

Heart and Stroke Foundation of Canada

2012 Pan Canadian Expert Panel: 1st HSFC national strategic plan.

Health Canada**Food (Regulatory) Expert Advisory Committee sodium sub committee**

2011- 2015, Member

Health Canada Intersectoral Dietary Sodium Working Group

2008-2010, Executive and member (representing Blood Pressure Canada-Hypertension Canada) Dietary Sodium Working Group
2009-2010 Sub committee member on Research,
2009-2010 Subcommittee member on Industry
2009- 2010 Subcommittee member on Education
2007 Planning Committee

Miscellaneous Health Canada Committees

2017-2018, Consultant 2017 for revision of Canada’s Food Guide.
2004 – 2006, National Specialists’ Society – Representative to e-therapeutics project
2002 – 2003, Consultant, Hypertension Surveillance

2002, Think tank member: Health Canada re: physical measures in the Canadian Community Health Survey March 19, 2002, Ottawa

1999 – 2000, Canadian Heart and Stroke Surveillance System Dissemination Committee

1998 – 2000, National Advisory Committee, the Heart Healthy Kit

1997 – 2000, Consultant, National Surveillance system for cardiovascular disease

1996 – 1999, Consultant, National Blood Pressure Lowering Strategy, Health Canada

1994 – 1995, Consultant, Safety of Folic Acid Supplementation/Fortification

Canadian Hypertension Advisory Committee

2011-2017, Founder and Inaugural Chair of Committee (2011-2016; Vice Chair 2016-2019) to prevent and control hypertension with representation from the Canadian Stroke Network, Canadian Council of Cardiovascular Nurses, College of Family Physicians of Canada, Canadian Pharmacists Association, Canadian Medical Association, Canadian Nurses Association, Canadian Public Health Association (2011-2012), Canada's Public Health Physicians, Canadian Cardiovascular Society, Canadian Society of Internal Medicine, Hypertension Canada, Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research (ex officio)

Hypertension Canada (Blood Pressure Canada, Canadian Hypertension Society, Canadian Hypertension Education Program, Transition Committee)

2009- 2010 Chair and Co-Chair (when interim Executive director hired) of transition committee 2009-2010,

2016- 2017 Operations committee member

2010-2011 Board member

2010-2011 Chair Public Policy Committee

2010 Board Nominations committee (Chair 2010)

2010 Awards Committee (Chair),

2010-2015 Pan Canadian Hypertension Framework committee (Chair 2010-11, and for update 2014-2015)

2012-2014 Co-chair Outcomes Research Task Force, 2015 member

2014-2017 Research policy committee

2015-2017 Vice chair Stakeholder relations committee

2013- 2017 Lifestyle recommendations subgroup.

2015- 2019 Research and evaluation committee

Public Health Agency of Canada

2006 –2007 Chair, National Advisory Committee on Hypertension

2006 – 2009 Chair, Canadian Hypertension Survey Advisory Committee

2006 – 2011 Member of Cardiovascular Surveillance Committee (co-chair 2008)

Statistics Canada

2006 – 2011 Member, Quality Assurance & Quality Control Advisory Committee, Canadian Health Measures Survey

2013 Canadian Vascular Congress

2013 Vascular declaration writing group member

REGIONAL

Alberta Health and Wellness

2000 – 2004 Ministers Expert Advisory Committee on Drugs and Therapeutics (Chair 2002-2004)

Alberta Health Services

2012-2016 Cardiovascular Heart and Stroke Strategic Clinical Network, core committee member 2012- and Vascular Risk Reduction Initiative Chair 2012 and then co-Co-chair 2013-2016

2013-2016 ACTION (founder and Inaugural Chair 2013-2016, coalition of Alberta health care organizations to prevent and control vascular disease)

Alberta Hypertension Initiative

2008-2010 Founder and inaugural co-chair

Atlantic Action Group for Heart Health and Stroke Prevention

1990 Councillor

Calgary Regional Fire Department

1995 – 2009 Blood pressure measurement and blood pressure self-measurement training program. Chair
National Steering committee, consultant

Calgary Cardiovascular Network

2000 – 2005 Executive Member
2000 – 2004 Co-Chair Hypertension Sub Group
2000 – 2001 Founder and & Co-Chair Interim Executive

Champlain District Sodium Reduction Campaign

2008- 2012 Advisory committee member

Heart and Stroke Foundation of Ontario

2006- 2009 Member Steering committee for Hypertension AIM

Newfoundland Medical Association,

1986 – 1990 Chair, Pharmacy Committee

Newfoundland Medical Board

1990 Consultant on prescribing of psychoactive medication to inmates at the provincial penitentiary
1988 Consultant on physicians over prescribing narcotics

Government of Newfoundland and Labrador

1989 Formulary reviewer for the Department of Health
1988 – 1990 Formulary Committee, Department of Health
1988 – 1990 Consultant to the Department of Health, Formulary matters

Regional Calgary

2000 Organizer of a symposia on cardiovascular disease Calgary
2000 Organizer/chair (Nov) of symposia on cardiovascular disease surveillance

Reviewer Journals (not updated after 2010)

2010 Canadian Internist
2010 International Journal of Hypertension
2010-2012 Revista Panamericana de Salud Pública/Pan American Journal of Public Health
2009 NEJM
2008 Arch Intern Med
2007-2011 BMC Public Health
2007-2008 Prevention and Control
2006-2009 J Hypertension
2005 Foundation for Medical Practice Education
2004 Am J Hypertens
2003 –2011 Hypertension
2002 Clinical Pharmacology & Therapeutics
2002 Preventative Medicine
2000 – 2010 Canadian Family Physician
2000 – 2002, 2010 Blood Pressure Monitoring
2000, 2002, 2009 Canadian Journal of Clinical Pharmacology

1998 – 1999, 2000, 2004 JAMA
 1996, 1997, 2007-2010 Canadian Medical Association Journal
 1995 – Canadian Journal of Cardiology
 1992 Annals of Internal Medicine
 1991, 1995, 2000, 2001 Clinical & Investigative Medicine
 1991 European Journal of Clinical Pharmacology
 1990 Biochemical Pharmacology

Journal Editorial Boards

2013 - 2020 Journal of Clinical Hypertension
 2005 - 2007 Journal of Hypertension
 2005 - 2019 Blood Pressure Monitoring
 2008 Integrated Blood Pressure Control.

Reviewer (External) Grants

1999, 2001 Heart and Stroke Foundation of Canada
 1998, 2001 Health Services Utilization and Research Commission Saskatchewan
 1990, 1999, 2000 Medical Research Council of Canada
 2002, 2003 Canadian Institute for Health Research
 2006 Member, Heart and Stroke Foundation of Canada committee member, clinical research grant review committee.

VIII. RESEARCH SUPPORT

2015

Cancer vascular risk reduction planning grant. Alberta Health Innovates, \$10,000. Norm Campbell PI 2015

2013

Health effects of dietary sodium – knowledge synthesis and communication. Canadian Stroke Network. \$25000. Norm Campbell PI, T Duhaney. 2013-2014

2012

MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP). CIHR \$99872. PI Dr. Styliani DASKALOPOULOU, Investigators Dr. Norman RC CAMPBELL Dr. Martin G. DAWES, Dr. Sheldon William TOBE, 2012-2013

DREAM-GLOBAL: Diagnosing hypeRtension - Engaging Action and Management in Getting/ LOwer Bp in Aboriginal and LMIC - A Research Proposal. CIHR Investigators Lui P, Tobe S, Campbell NRC, Yeates K. \$360820/year total \$1,804,101 2012-2017.

Utilizing HIV/AIDS infrastructure as a gateway to chronic care of hypertension in Africa. Dr. Edward Joseph Mills PI with Mr. N. Bansback, Dr. I. Bourgeault, Dr. N. Campbell, Dr. P. Devereaux, Dr. A. Featherstone, Dr. N. Ford, Dr. M. Joffres, Dr. R. Kalyesubula, Dr. J. Kamwesiga, Dr. I. Kanfer, Dr. A. Kengne, Dr. R. Lester, Dr. E. Luyirika, Dr. V. Mutabazi, Dr. J. Nachege, Mr. J. Tayari, Dr. L. Thabane. CIHR \$710,389, 2012-2017

2011

HSFC CIHR Chair in Hypertension Prevention and Control. 2011-2016. \$150,000/year

Population-level prevention and implications for socioeconomic inequities in health: dietary sodium as a case example. CIHR L McLaren PI, with N Campbell, J Emery, D Lorenssetti, L McIntyre and V Tarasuk as investigators - \$43,674 in 2011 total grant \$261,194 in 2011-2014.

2010

Closing the care gap on hypertension in Indo-Asian people with diabetes. PHAC co-investigator. C Jones PI. \$23036 2010-2011.

2009

Public Health Agency of Canada "Closing the care gap on hypertension in Indo-Asian people with diabetes" funding to Blood Pressure Canada PI Charlotte Jones co investigator N Campbell; \$68,973 September 2009 – April 2010

Servier Canada "Innovative hypertension knowledge translation programs" funding to Blood Pressure Canada. PI Norm Campbell; \$245,000, October 2009 – October 2010

Public Health Agency of Canada "Hypertension in Canadians with Diabetes - Closing a substantive care gap" funding to Blood Pressure Canada, PI Norm Campbell; \$263,288 August 2009 – March 31, 2010

AHFMR Team Grant: Improving the Efficient and Equitable Care of Patients with Chronic Medical Conditions Interdisciplinary Chronic Disease Collaboration (ICDC); \$1,000,000/year April 2009-2014, Co-investigator- Team member.

2008

CIHR, "Assessment of hypertension occurrence, management and outcomes in Canada" PIs Dr. Hude Quan, Dr. Brenda Hemmelgarn, Dr. Karen Tu, Investigators Dr. G. Bartlett-Esquilant, Dr. N. Campbell (Team Co-lead), Dr. M. Hill, Dr. N. Khan, Dr. L. Lix, Dr. F. McAlister (Team Co-lead), Mr. M. Smith, Mr. L. Svenson, Dr. G. Teare, Dr A Wielgosz, \$570,217 for 2008-2011

Public Health Agency of Canada. Funding to Blood Pressure Canada to develop educational resources on dietary sodium. \$298,442.

Public Health Agency of Canada, Investigator, *Validation of a questionnaire module to assess behaviors of hypertensive Canadians*. \$125 000

2007

Public Health Agency of Canada, Investigator, Funding to Blood Pressure Canada for a hypertension community network - primary objective was to create a national knowledge exchange network of community programs enhancing hypertension prevention and control. The secondary objective was to initiate additional network nodes for other modifiable cardiovascular risks using hypertension as a model. Total grant was \$99,375.00 for 12 months.

Public Health Agency of Canada, Investigator. Funding to Blood Pressure Canada to translate the public hypertension recommendations into Indonesian dialects and culture for a specific intervention study - objectives of the project were to develop a culturally sensitive educational tool for the Indo-Central Asian population and to develop a process for overcoming educational barriers for future implementation by other ethno-cultural groups and community projects across Canada. Total grant was 24,270.00 for 12 months. Brief interventions to educate patients.

Public Health Agency of Canada, Principal Investigator, Funding to Blood Pressure Canada to develop an intervention for one-on-one counseling on hypertension - the objectives were to validate a set of educational tools suitable to daily patient/client interactions of family physicians, nurses and pharmacists' education about hypertension and fund a symposium that could be delivered to educate health care professionals on the use of the tool. Total grant was 24,900 for 12 months.

2006-2011

CIHR Canada Chair in Hypertension Prevention & Control, Operating Funds of \$180,000/year (5 years) (Canadian Institutes of Health Research, Blood Pressure Canada, Canadian Hypertension Society, & Sanofi-Aventis Canada)

2006-2008

Co-Investigator – Gender and ethnic issues in hypertension & diabetes. \$93,700 for 2 years. PI N Khan (Canadian Institutes of Health Research)

2006-2009

Team Leader (not PI) Validation of a diagnostic algorithm for hypertension using administrative data, PI is H Quan. \$270,000 \$90,000 each (Sanofi Aventis, Pfizer Canada Merck Frosst Canada)

2006-2008

Team Leader – Development of provincial administrative databases for the purposes of hypertension surveillance \$55,000 (Canadian Hypertension Education Program)

2006-2008

Co-Investigator – Development of provincial administrative databases for the purposes of hypertension surveillance \$25,000 (Servier Canada through CHEP)

2006-2007

Co-Investigator – Validation of a Coding Algorithm to Define Hypertension using Administrative Data \$80,000 (Canadian Institutes of Health Research)

2006-2008

Co-Investigator, Development Grant Phase II – CLSA \$2,100,000 (2006-2008) (Canadian Institutes of Health Research)

2005-2006

Co-Investigator – Airdrie Cardiovascular Health Awareness and Management Program (A-CHAMP) \$256,000 (Canadian Stroke Network)

2004-2006

Co-Investigator – The Canadian Longitudinal Study of Aging: Developmental Activities - Phase I. Developmental Grant. \$1,744,000 (Canadian Institutes of Health Research)

2004-2006

Co-Investigator – Developing methodology for examining trends in the management of hypertension (Principal Investigator is K Tu). \$ 58544 year 1 and \$ 68462 year two. (Heart and Stroke Foundation of Canada, Developmental Grant)

2002

Co-investigator – Prevalence, correlates and health consequences of donepezil (Arecept) use in Alberta (C Maxwell PI). Implications for cost. effectiveness estimates. \$30,000 (Calgary Health Region).

2000-2005

Western Canada Regional Coordinator – Opera: \$187,000

2000-2005

Hypertension Research Group Funding (NRC Campbell (chair), C Jones, B Culleton, N Scott Douglas,) Opera: site \$201,525, (Bristol Myers Squibb)

2000-2001

Site Principal Investigator: Viagra Study in patients prescribed multiple in antihypertensive medications. \$20,000 (Pfizer Canada)

1997-1999

Principal Investigator (Trial to investigate the effect of dehydration on lipids (ROLA \$42,000, (Parke Davis)

1995-1997

Co-Investigator (with Dr. E. Burgess). – "A multicentre randomised double blind parallel study of the safety and antihypertensive efficacy of losartan 50 or 100 mg versus losartan/Hctz 50/12.5 versus amlodipine 5 or 10 mg in patients with mild to moderate hypertension". \$32,890 (Merck Frosst Canada)

1995-1997

Co-Investigator (with Dr. E. Burgess) – "Multicentre randomized double-blind placebo-controlled trial of SR 47436 for the treatment of hypertension". \$25,525 (Bristol Myers Squibb)

1994-1996

Principal Investigator - An n of 1 trial to examine intolerance to antihypertensive therapy. \$11,000 (Pfizer Canada)

1994-1996

Co-Investigator (with Dr E Burgess) – "A Comparative trial of the safety and efficacy of Cardiazam CD and Adalat XL in female patients with mild to moderate hypertension. \$18,000 (Marion Merrell Dow)

1993-1994

Co-Investigator. Furosemide-cholesterol study. \$17,036 (Foothills Hospital Research and Development Committee)

1992-1993

Co-Investigator, Phase III study of remoxipride in elderly demented patients with psychotic manifestations, \$60,000 (Astra Canada)

1991-1994

Principal Investigator. Induction of methyl dopa absorption \$10,000 (Foothills Hospital Research and Development Committee)

1991-1992

Principal Investigator. Iron-thyroxine interaction, \$15,003 (Foothills Hospital Research and Development Committee)

1990-1991

Start-up \$5,000, 1990-91 (University of Calgary, Faculty of Medicine)
Endowment award, \$5,000, (University of Calgary, Faculty of Medicine)

1988-1990

Iron-drug interactions, \$8,000 (General Hospital Research Foundation)
Captopril-iron interaction. \$5,000, (Squibb Canada)
Sustained Release Captopril. \$20,000 1988-90 (Squibb Canada)

1987-1988

Iron-drug interactions, \$10,000 (General Hospital Research Foundation)
Phase III study of Atenolol \$10,000, (ICI Canada)

1986-1987

Equipment Grant, \$16,480 (General Hospital Research Foundation)
L-dopa bioavailability: Effect of ferrous sulfate, \$4,000 (Research and Development Committee, Memorial University of Newfoundland)

1985-1987

Start-up Funds, \$4,000 (Memorial University of Newfoundland)
Methyldopa metabolism: effect of ferrous sulfate, \$4,000 (Research and Development Committee, Memorial University of Newfoundland)
Methyldopa metabolism: effect of ferrous sulfate, \$3,000 (Memorial University of Newfoundland)

IX. INVITED ADDRESSES

2024

1. Oct 26th: Hypertension Control in Canada, 2024 Annual Scientific Conference of Chinese Hypertension League and 26th International Symposium on Hypertension and Related Diseases. Virtual presentation.

2023

1. Feb 14: Dietary salt reduction: challenges and directions. 28th Joint Annual Convention of the Philippine Society of Hypertension (PSH) and Philippine Lipid and Atherosclerosis Society. Virtual presentation
2. May 17: G20 Co-branded Event for Accelerating the Prevention and management of hypertension and Diabetes (G20, Ministry of Health and Welfare India, World Health Organization India). Panelist: Hypertension and diabetes as tracers for health systems strengthening towards the Global NCD Targets: Public health priorities and actions required. New Delhi, India
3. May 20: A new global online certification course for home blood pressure measurement. For the World Hypertension Day Celebration, Chinese Hypertension League. China. Virtual presentation.
4. Oct 2. Cementing a shared global agenda. Panellist for PAHO/WHO Priorities for CVD risk reduction and hypertension control. At HEARTS in the Americas. World Heart Day Celebration, 29-30 September 2023. Subregional HEARTS Meeting for Andean Countries and Ecuador National Meeting, 2-4 October 2023 Quito, Ecuador.
5. Oct 21, The Canadian Program to Improve Hypertension Control 1999-2019. Plans for 2023 and beyond. Presentation (virtual) to the Chinese Hypertension League.

2022

1. May 21: World Hypertension League, Resolve To Save Lives and International Society Of Hypertension Dietary Sodium (Salt) Global Call To Action. World Hypertension Congress, Macau, China. Virtual taped presentation
2. May 17: Policies to support the implementation of the WHO guideline on treatment of hypertension. Pan American Health Organization Virtual symposia to celebrate World Hypertension Day.
3. Sept 6: The Canadian Program to Improve Hypertension Control 1999-2012 and beyond. Research context. World Health Organization, Resolve to Save Lives, John Hopkins University Webinar.
4. Oct 27: Hypertension control in Canada. Pan American Health Organization Webinar. HEARTS- Economic case for good investment

2021

1. March 1: Hypertension indicators. Webinar. Short presentation and technical advice. Technical meeting on hypertension indicators for improving quality and coverage of services. World Health Organization
2. April 13: The Sao Paulo call and objectives with success stories. World Hypertension League Session. International Society of Hypertension virtual meeting.
3. Nov 26: Worldwide hypertension epidemiology. 7th International Saudi Hypertension Conference 2021. Virtual taped presentation

4. Nov 28: Sodium reduction stakeholder webinar meeting presentation. Inaccuracy of food labels in Canada and introducing the new Resolve to Save Lives Sodium reduction program Framework. Virtual taped presentation to Sodium reduction stakeholders in South Africa
5. Dec 2: Introducing the new Sodium reduction program Framework from Resolve to Save Lives. RTSL links bimonthly global community of practice webinar. Virtual taped presentation

2020

1. Jan 11: Global best practices in hypertension control. Progress seminar for 'National Hypertension Prevention and Control Initiative. National Health Commission, Centre for Disease Control, and National Centre for Cardiovascular Disease Fuwai Hospital. Kunming China.
2. Feb 5: Hypertension control is urgent and important, Representatives from the Sri Lanka Colleges of Cardiology, Endocrinology and Physicians, Heart Foundation and Ministry of Health. Organized by the Ministry of Health, Colombo. Sri Lanka.
3. Feb 5: Global Best Practices in Hypertension Control. Representatives from Cardiology, Endocrinology and Internal Medicine. Organized by the Ministry of Health, Colombo. Sri Lanka.
4. Feb 5: Dietary Salt: Facts and A Call to Action. Representatives from Cardiology, Endocrinology and Internal Medicine. Organized by the Ministry of Health, Colombo. Sri Lanka.
5. Feb 5: Successful programs to reduce dietary salt. Representatives from Cardiology, Endocrinology and Internal Medicine. Organized by the Ministry of Health, Colombo. Sri Lanka.
6. Feb 6: Hypertension and Dietary salt. Chamber of Commerce and Food Processors Association. Organized by the Ministry of Health, Colombo. Sri Lanka.
7. Feb 7: Hypertension and Dietary salt. Sri Lanka Nutrition Association, College of Community Physicians, College of Medical Administrators. Organized by the Ministry of Health, Colombo. Sri Lanka.
8. March 3: Hypertension: magnitude of the problem and key actions for its diagnosis and control. Technical Meeting for HEARTS in the Americas. Meeting on Regulatory Frameworks and Validation of Blood Pressure Measurement Devices. Quito, Ecuador.
9. March 4: WHO's technical specifications for BP devices. Technical Meeting for HEARTS in the Americas. Meeting on Regulatory Frameworks and Validation of Blood Pressure Measurement Devices. Quito, Ecuador.
10. March 6: São Paulo Call to Action for the Prevention and Control of High Blood Pressure. Heart in Ecuador workshop for site implementation, Guayaquil, Ecuador.
11. June 9: Global webinar. LINKS-WHO-Resolve to Save Lives Hypertension control programs. WHO technical specifications for automated non-invasive blood pressure measuring devices with cuff. presentation to Resolve to Save Lives – WHO cardiovascular health partner meeting teleconference.
12. Oct 8; Global webinar. Sodium Reduction Communities of Practice (CoP) LINKS-WHO-Resolve to save Lives. A framework for monitoring and evaluating national population sodium reduction programs.
13. Oct 16; WHO- PAHO Global webinar to Celebrate World Hypertension Day. The relevance of the prevention and control of hypertension and the launch of a new resource to improve practices on blood pressure.

2019

1. Jan 11: Let food be thy medicine. University of Calgary Public Webinar
2. Feb 8: Salt sugar and stroke. International Stroke Conference 2019, American Heart Association. Honolulu Hawaii.
3. Feb 15: Diet (Canada's Food Guide) Salt and Hypertension. Libin Cardiovascular Institute of Alberta Heart Health Day
4. Feb 21: Choosing the best hypertension treatment protocol—does it really matter? Links Webinar (Resolve To Save Lives, WHO, CDC (USA))
5. March 5: Reducing Dietary Salt in Populations. Lessons Learned. Panelist. RESOLVE to save lives partners meetings. New York, New York.
6. May 15. Blood Pressure Assessment in Clinical Practice and Clinical Research. Joint meeting of the Pan American Health Organization and Inter-American Society of Cardiology. Punta Cana, Dominican Republic.
7. May 16. Module S: Systems for Monitoring. Joint meeting of the Pan American Health Organization and Inter-American Society of Cardiology. Punta Cana, Dominican Republic.

8. May 17. Why hypertension is urgent and important? Hearts in the America's. Joint meeting of the Pan American Health Organization and Inter-American Society of Cardiology. Punta Cana, Dominican Republic.
9. May 17. World Hypertension League Resources. Hearts in the America's. Joint meeting of the Pan American Health Organization and Inter-American Society of Cardiology. Punta Cana, Dominican Republic.
10. May 31, Address to graduating classes. Memorial University convocation. St John's Newfoundland.
11. June 13. Global best practices in Hypertension Control. Shandong Hypertension Control Program Launch Meeting. Shandong Health Commission. Qingdao, Shangdong, China.
12. June 14 Hypertension Control in Latin America. Webinar to Graduate Program in Fundamental Nursing, Ribeirão Preto College of Nursing, University of São Paulo, Brazil.
13. June 21 Lessons learned from Canadian Programs to Improve Hypertension Control 1999-2010 and newer hypertension control programs. Webinar to Thames Valley – Oxford conference "It's not Complicated: Improving CVD and Diabetes Care.
14. Aug 6: RESOLVE to save lives. Overview. World Hypertension League, World Health Organization partners forum. Sao Paulo Brazil
15. Aug 7: Sao Paulo Hypertension Facts and call to action. World Hypertension League- Brazilian Society of Hypertension joint session. World Hypertension Congress- Brazilian Society of Hypertension meeting. Sao Paulo Brazil
16. Aug 7: RESOLVE to save lives. Overview. World Hypertension League- Brazilian Society of Hypertension joint session. World Hypertension Congress- Brazilian Society of Hypertension meeting. Sao Paulo Brazil.
17. Aug 8: Hypertension management protocols. World Hypertension League- Brazilian Society of Hypertension joint session. World Hypertension Congress- Brazilian Society of Hypertension meeting. Sao Paulo Brazil.
18. Aug 22: HEARTS, Primary care managers, Better Hearts Better Cities program. Onom Foundation. Ulaanbaatar Mongolia.
19. Aug 22: Empowering primary care to control hypertension. Primary care managers, Better Hearts Better Cities program. Onom Foundation. Ulaanbaatar Mongolia.
20. Aug 22: Performance indicators. Primary care managers, Better Hearts Better Cities program. Onom Foundation. Ulaanbaatar Mongolia
21. Aug 26: HEARTS, District primary care managers, quality managers, public health officers, Heads of primary clinics, Better Hearts Better Cities program. Onom Foundation. Ulaanbaatar Mongolia.
22. Aug 26: Global Best practices in hypertension control. District primary care managers, quality managers, public health officers, Heads of primary clinics, Better Hearts Better Cities program. Onom Foundation. Ulaanbaatar Mongolia
23. Sept 26: Sodium and Health. Colleges and Institutes Canada (CICan) Culinary programs Sodium Reduction Project, (funded by Health Canada) Webinar to Ottawa Ont.
24. Sept 27: Dietary sodium scientific update and call to action. Parallel session. Canadian Hypertension Congress. Edmonton AB

2018

1. Feb 23: Death and disability by food. Libin Cardiovascular Institute of Alberta Heart Health Day. Calgary, Alberta.
2. Feb 23: Hypertension. Libin Cardiovascular Institute of Alberta Heart Health Day. Calgary, Alberta.
3. March 15: Successful national salt reduction programs, Costa Rica food industry representatives. Organized by Unit of Nutrition and Health INCIENSA San Jose Costa Rica.
4. March 15: Dietary salt, and health. Faculty of Medicine, University of Costa Rica. San Jose, Costa Rica.
5. March 16: Optimizing HT Management. Dietary sodium workshop for Unit of Nutrition and Health INCIENSA, Department of Health, University of Costa Rica Faculty of Medicine, San Jose, Costa Rica.
6. March 16: Role of salt in hypertension management. Dietary sodium workshop for Unit of Nutrition and Health INCIENSA, Department of Health, University of Costa Rica Faculty of Medicine, San Jose, Costa Rica.
7. March 16: Successful programs to control HT and to reduce dietary salt. Dietary sodium workshop for Unit of Nutrition and Health INCIENSA, Department of Health, University of Costa Rica Faculty of Medicine, San Jose, Costa Rica.

8. April 17. Empowering primary care to control hypertension, Diverse audience of primary care specialists and the panel creating Mongolian hypertension recommendations. Onom Foundation. Ulaanbaatar, Mongolia.
9. April 17. Improving hypertension medication adherence, lifestyle counselling and performance assessment in primary care. Onom Foundation. Ulaanbaatar, Mongolia.
10. April 24. Monitoring and evaluation of hypertension programs. The PAHO-WHL framework. Hearts Program Pilot Study visit in Matanzas. Matanzas Cuba
11. April 24. ACC AHA 2017 guidelines for the management of hypertension. Implications for the Cuban hypertension program. Hearts Program Pilot Study visit in Matanzas. Matanzas Cuba
12. April 26. Why hypertension control is urgent and important. PAHO-Cuba hypertension symposia. Cuba Health 2018. Havana Cuba
13. April 26. Monitoring and evaluation of hypertension programs. PAHO-Cuba hypertension symposia. Cuba Health 2018, Havana Cuba
14. April 27. Dietary salt and why reduction is important. Hospital Universitario Calixto Garcia, Havana.
15. April 27. ACC AHA 2017 guidelines for the management of hypertension. Implications for the Cuban hypertension program. Hospital Universitario Calixto Garcia, Havana.
16. April 30. ACC AHA 2017 guidelines for the management of hypertension. Implications for the Cuban hypertension program. Cienfuegos Hypertension Pilot Program site visit. Cienfuegos Cuba
17. May 16. The Pan American Health Organization and World Hypertension League Hypertension monitoring and evaluation framework. Global Webinar to celebrate World Hypertension Day. Sponsored by The Pan American Health Organization.
18. June 6. Charleston USA. Video lecture for an online lecture series. Lessons learned from Hypertension Canada Program to Improve Hypertension Control 1999-2010. Sponsored by the South Carolina chapter of the American Society of Hypertension
19. June 7. Video interview for an online lecture series. The evolution of hypertension control programs in Canada. Sponsored by the South Carolina chapter of the American Society of Hypertension. Charleston USA.
20. June 17. Libin Cardiovascular Institute of Alberta and Aga Khan Health Board for the Prairies. Death by Food in Food and Nutrition as Agents of Health. Calgary
21. June 18. A paradigm shift from food as a source of health and wellness to now being the leading risk for death and disability in Canada (and the world) in Canada's Food Guide and a Healthier Canada. Libin Cardiovascular Institute of Alberta and O'Brien Institute for Public Health. Calgary
22. June 25. Global best practices on sodium reduction with focus on food industry engagement" Voluntary target for sodium reduction in packaged food: Public hearing. Department of Health Service Support, Ministry of Public Health. WHO country office. Resolve to save lives. Bangkok Thailand
23. June 27. Global best practices in hypertension control with focus on lessons from Canada in Information exchange meeting on hypertension, WHO country Office, Ministry of public health. Bangkok Thailand
24. Aug 8. Canadian and other programs to reduce dietary salt in the America's. Webinar to United Nations, World Health Organization, Thailand governmental meeting. NCD 2018 in Bangkok
25. Sept 22. Fixed dose combinations and algorithms in Hypertension management. RESOLVE TO SAVE LIVES symposia at the International Society of Hypertension. Beijing China.
26. Oct 31. HEARTs and PAHO-WHL Indicators related to Hypertension control programs. Taped for 'Virtual course on the Implementation of the HEARTs technical package in primary care teams. Charleston USA.
27. Nov 2. Panel discussant and moderator 'Monitoring blood pressure and disease risks. Southern Medical Association. Nov 2, 2018. Charleston USA.
28. Nov 10. Global Population Strategies for High Blood Pressure Control: North America (United States and Canada). RESOLVE to save lives symposia. American Heart Association 2018 meeting. Chicago USA.
29. Dec 1. Experiences in blood pressure control. Chinese Alliance for Hypertension Control. Beijing, China
30. Dec 3. The importance of using simplified treatment algorithms to manage hypertension. RESOLVE to save lives meeting, Provincial experts and policy makers Jinan, Shandong, China
31. Dec 4. The importance of using simplified treatment algorithms to manage hypertension. RESOLVE to save lives meeting, Provincial experts and policy makers, Hefei, Anhui, China

1. Jan 20. Optimizing hypertension control in clinical practices. Medical University of South Carolina. Lecture with questions and answers videotaped for continuing education courses on hypertension.
2. Jan 27. Metrics for monitoring and evaluation of hypertension. Pan American Health Organization, Department of Health, Government of Cuba, Cienfuegos Cuba.
3. Jan 28. Canada. Critical success factors for improving hypertension control. Pan American Health Organization, Department of Health, Government of Cuba, Cienfuegos Cuba.
4. March 16. Hypertension Control by design. Mongolia. Onom Foundation, Novartis Foundation, Better Hearts Better Cities Program Hypertension specialists. Ulaanbaatar Mongolia
5. March 30. Science of dietary salt. In 'The Dangers of excess dietary sugar, fat and salt' Stop marketing to Kids Coalition national webinar series. Canada.
6. April 28. Strategic approaches to hypertension control. XXVI Peruvian Congress of Cardiology, Lima Peru.
7. April 28. Dietary sodium evidence and controversies. XXVI Peruvian Congress of Cardiology, Lima Peru.
8. April 29. Optimizing hypertension control in clinical practice. XXVI Peruvian Congress of Cardiology, Lima Peru.
9. May 16. Draft hypertension indicators for hypertension control programs. Pan American Health Organization- World Health Organization. Regional office Seminar on the Implementation of the Cardiovascular Risk Reduction Project in the Americas. Santiago, Chile.
10. May 17. Canadian Hypertension Control Program. Pan American Health Organization- World Health Organization. Regional Seminar on the Implementation of the Cardiovascular Risk Reduction Project in the Americas. Santiago, Chile. 16 - 18 May 2017
11. May 18. Conceptual bases, building a political commitment and alliances to achieve hypertension control. Pan American Health Organization- World Health Organization. Regional Seminar on the Implementation of the Cardiovascular Risk Reduction Project in the Americas. Santiago, Chile. 16 - 18 May 2017
12. May 18. The role of the World Hypertension League in regional hypertension control activities. Panel discussant. Pan American Health Organization- World Health Organization. Regional Seminar on the Implementation of the Cardiovascular Risk Reduction Project in the Americas. Santiago, Chile. 16 - 18 May 2017
13. Sept 22. Methodological issues and sources of controversy in sodium-based research. Plenary presentation in (World Hypertension League, World Health Organization, Centre for Disease Control and prevention (USA) joint session: Salt-sodium Reduction, World Hypertension Congress, Shanghai China Sept 22-24
14. Sept 22. Who are the partners and how can each partner influence the accelerated adoption and scale-up of HEARTS? Panelist in Plenary session of World Hypertension League, World Health Organization, Centre for Disease Control and prevention (USA) joint session: HEARTS package and implementation. World Hypertension Congress, Shanghai China Sept 22-24
15. Sept 23. Methodological issues as sources of research controversy. In World Hypertension League Mentoring Session 'Research on a Shoestring'. World Hypertension Congress, Shanghai China Sept 22-24
16. Sept 23. Hypertension Control in Canada. Plenary. In World Hypertension League plenary session 'Best practice in primary care for hypertension and CVD control'. World Hypertension Congress, Shanghai China Sept 22-24
17. Nov 7. Diet and hypertension. Panelist and speaker in Panel session in A better food environment. Stakeholder engagement Session. Health Canada Ottawa
18. Nov 21. Hypertension Control and blood pressure screening programs. Video conference to Brazil (Brazilian Hypertension Society)
19. Dec 11. Hypertension Control in Canada. WHO China. Chronic disease and primary care divisions of Central government. RESOLVE. Meeting on hypertension control and selection of management algorithms. Beijing, China
20. Dec 13. Rapid control of hypertension and hypertension indicators. RESOLVE and Provincial government, Hefei, Anhui, China

2016

1. Nov 2. Diet, death disability. Plenary talk, session 1. 8th Annual New Brunswick Health Research Conference. Saint John New Brunswick
2. Oct 12 Sodium and its Relationship to Health. Symposium on Sodium Reduction in Foods, Health Canada,

Ottawa

3. Oct 5 Diet, Death and Disability. Kinesiology course 465, University of Calgary
4. Oct 2 Optimizing Hypertension Prevention and Control. Cardiology for the non-cardiologist. Banff AB.
5. Sept 13 Lessons learned and next steps for Vascular Risk Reduction, a Cardiovascular Health & Stroke Strategic Clinical Network (CvHS SCN) project. Alberta Health. Policy Lunch and learn session. Alberta Health, Edmonton, Alberta
6. July 5. Global Burden of Hypertension. Best Canadian and Global Practices. Onom Foundation and Mongolian Hypertension Experts. Ulaanbaatar, Mongolia
7. Sept 27. Public policies to reduce salt in processed foods: How they may correlate with improvement in blood pressure control and reduced cardiovascular mortality. Plenary invited speaker. International Society of Hypertension, Seoul Korea
8. June 30 Hypertension Control Efforts in Canada. Global Best Practices in CVD Management. World Health Organization Technical Consultation for The Global HEARTS Initiative to Reduce Heart Attacks and Strokes, June 29-30, 2016, Geneva Switzerland
9. June 6 Science of sodium. World Congress of Cardiology. Mexico City, Mexico.
10. June 4 Update on management of hypertension: Review of guidelines. Southern Alberta Cardiology Update. Waterton AB
11. June 1 Surveillance Monitoring and Evaluation (With R Walker). Canadian Hypertension Advisory Committee. Ottawa Canada.
12. June 1 Chair in Hypertension Prevention and Control: The past 10 years. Canadian Hypertension Advisory Committee. Ottawa Canada.
13. May 20 How to manage a local project to improve the control of hypertension. Keys to success. Pan American Health Organization technical meetings with the government of Cuba. Matanzas Cuba
14. May 19 Metrics for monitoring and evaluation hypertension control. Pan American Health Organization technical meetings with the government of Cuba. Havana Cuba
15. May 18 Control of hypertension in Canada. Key for success. Pan American Health Organization technical meetings with the government of Cuba. Havana Cuba
16. May 17 Control of hypertension through salt reduction strategy. Pan American Health Organization technical meetings with the government of Cuba. Havana Cuba
17. May 14 Hypertension recommendations and dietary salt. Alberta, NWT and Nunavut branch of Canadian Council for Cardiovascular Nurses annual meeting. Plenary talk. Calgary AB
18. April 25 Importance of surveillance, evaluation. The Alberta Health Services Strategic Clinical Network. Edmonton AB.
19. April 16 What the World Hypertension League does to fight hypertension, Argentina Arterial Hypertension Society (SAHA) Buenos Aires.
20. April 7 Food for thought. Plenary presentation to Calgary Therapeutic Course. Calgary AB
21. Feb 19 Death by food. Libin Cardiovascular Institute presentation to donors. Calgary AB
22. Feb 19 Hypertension. Libin Cardiovascular Institute presentation to donors. Calgary AB
23. Feb 13 Salt and the effect on population health, 19th Annual Northern Alberta Cardiovascular round table. Jasper AB
24. Feb 13 Salt and the Food industry. Pre dinner talk. 19th Annual Northern Alberta Cardiovascular round table. Jasper AB
25. Feb 3 Death by food: The need for public health policy, In Risky business. A vascular risk reduction program. Alberta Health Services, Medicine Hat, Alberta
26. Feb 3 New hypertension recommendations and clinical approaches to improving BP control, In Risky business. A vascular risk reduction program. Alberta Health Services Medicine Hat Alberta
27. Feb 2 Death by food: The need for public health policy. In Risky business. A vascular risk reduction program. Alberta Health Service, Lethbridge Alberta
28. Feb 2 New hypertension recommendations and clinical approaches to improving BP control, In Risky business. A vascular risk reduction program. Alberta Health Services, Lethbridge Alberta
29. Jan 24 Global Burden of Hypertension. What to do? National collaborative meeting of pharmacists and physicians on hypertension. Surabaya, Indonesia.

2015

1. Dec 5 Hypertension in the America's and the World Hypertension League. What is the WHL doing and what can you do". XXV^o Latino-American Congress and LII^o Chilean Congress of Cardiology and Cardiovascular Surgery, Santiago Chile
2. Dec 5 Key elements for the success of the program for prevention and control of hypertension in Canada. XXV^o Latino-American Congress and LII^o Chilean Congress of Cardiology and Cardiovascular Surgery, Santiago Chile.
3. Dec 3 National Experiences in hypertension control in Canada. How to achieve the 25 x 25 goal in Latin America. Successful strategies in hypertension control in the Americas. Inter-American Society of Cardiology and the Pan American Health Organization/ World Health Organization, Santiago Chile
4. Dec 3 Regional and global plans to improve hypertension control. World Hypertension League. How to achieve the 25 x 25 goal in Latin America. Successful strategies in hypertension control in the Americas. Inter-American Society of Cardiology and the Pan American Health Organization/ World Health Organization, Santiago Chile
5. Dec 2 The case of Canada. Building capacity for CVD management: hypertension control using the health system approach. Santiago Chile
6. Nov 22 Hypertension: Taking Forward the Pharmacists' Role. BC Pharmacy Association Fall Education Event. Coquitlam, B.C
7. Nov 21 Commentary, questions and answers at Marda Loop Justice Film Festival. On 'Sugar coated'. Calgary Alberta
8. Oct 26 The great salt debate. Canadian Cardiovascular Congress. Toronto Canada
9. Oct 23 Hypertension Framework 2015. In HSF CIHR Chair in Hypertension Symposia. Canadian Hypertension Congress. Toronto Canada
10. Oct 22 Addressing the Burden of Hypertension; The Role of Assessing Blood Pressure. Keynote opening presentation. Check, change, control leadership forum, American Heart Association, San Francisco, Ca.
11. Oct 16 Hypertension and cardiovascular disease. Problems and solutions. In Healthcare of the capital: new horizons and search for effective solutions. Moscow Urban forum 2015. Moscow as a dynamic megacity. Moscow, Russia.
12. Sept 30 Diet, Death and Disability. Kinesiology course 465
13. Sept 21 Prevalence and control of hypertension worldwide. Shandong & Ministry of Health Action on Salt and Hypertension Gaomi China
14. Sept 18 Strategic approaches to control hypertension. Opening Plenary talk. 17th International Symposium on Hypertension and Related Diseases. Beijing, China
15. Sept 13 Strategic Approaches to Hypertension Management. Zheng Guang Xing Health Management Group. Chengdu China
16. Sept 12 Canadian programs to improve hypertension control in Hypertension management---international symposium. 17th National conference of Chinese Society of Cardiology, Shanghai China.
17. Sept 3 Recommendations of the Technical Advisory Group going forward. The Technical Advisory Group meeting Cardiovascular Disease Prevention through Population-level Dietary Salt/sodium Reduction of the Pan American Health Organization/World Health Organization. Washington DC
18. Sept 2 Research and publications. The Technical Advisory Group meeting Cardiovascular Disease Prevention through Population-level Dietary Salt/sodium Reduction of the Pan American Health Organization/World Health Organization. Washington DC
19. July 14, Canadian Hypertension Education Program. The first decade. Public Health England/Hypertension Canada webinar.
20. June 17 Hypertension Control in Canada. Teleconference and slide presentation to Cheshire and Merseyside, Champs Public Health Collaborative, UK
21. May 27 Population level dietary salt reduction initiative in the Americas. Canadian Public Health Association annual meeting. Vancouver BC
22. May 13 Reduction of sodium in foods – Experience in Pan-American region. Hong Kong International Symposium on Reduction of Sodium and Sugars in Foods.
23. March 23 Canada, World Hypertension League: Updates on Canada and WHL. Scaling up efforts. Global Standardized Hypertension Treatment Project. Centre for Disease Prevention and Control (USA) and the Pan American Health Organization. Miami FI

24. March 14 Developing innovative careers in Medicine session. Internal Medicine residents retreat, University of Calgary.
25. Feb 23 Canadian Hypertension Prevention, Treatment, and Control. in Successful Global Strategies. Webinar by US Center Centers for Disease Control and Prevention (CDC) and the Pan American Health Organization (PAHO). San Francisco Ca.
26. Feb 27 See this do that. CVD risk assessment workshop (repeated 2 x). Annual Scientific Assembly. Alberta College of Family Physicians. Banff
27. Jan 27 Nutrition and hypertension. At improving the nutrition status of Albertans to prevent chronic diseases and bend the health care cost curve. Edmonton Alberta

2014

1. Dec 13 How to improve blood pressure control. WHL Strategic Approaches. 2014 Annual Scientific Sessions of the Asian Pacific Heart Association and Chinese Cardiologists Congress. Beijing
2. Dec 12 WHL strategic approaches and policy for BP control. World Hypertension League Asia Pacific Regional meeting 2014. Beijing
3. Dec 6 Strategic approaches to salt reduction and the role of NGOs. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
4. Dec 6 World Hypertension League strategic approaches to hypertension prevention and control. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
5. Dec 5 Introduction to hypertension prevention and control in Africa. In WHL sponsored workshop. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
6. Dec 5 World Hypertension League blood pressure screening resources. In WHL sponsored workshop. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
7. Dec 5 Blood pressure in the context of NCD prevention and control. In WHL sponsored workshop. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
8. Dec 5 Health risks of high dietary salt control. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
9. Dec 5 Hypertension. Opening Congress Address. At the Pan African Hypertension Society, Pan African Cardiology Society, 7th Congress of Hypertension in Africa, first World Hypertension League regional meeting, first Congress on Hypertension in Cameroon. Douala, Cameroon
10. Nov 25 Dietary sodium. Canadian progress, challenges and solutions. Championing public health nutrition. 2014 Gatineau Canada.
11. Nov 16 Death by Food. University of Calgary. Main Campus health series
12. Nov 11 Salt and health. The need to act. Hong Kong. Intersectoral meeting Sponsored by the Department of Health and Hygiene, Government of Hong Kong
13. Oct 28 Proposal for setting targets and timelines for the sodium content of foods in the America's. Salt Smart Consortium (Sponsored by the Department of Health Brazil and PAHO). Brasilia, Brazil.
14. Oct 22 Death by Food. Calgary Police Services. Calgary
15. Oct 17 Update on sodium reduction: new evidence, challenges and a way forward. Canadian Hypertension Congress. Gatineau Canada
16. Oct 1 Pathogenic foods. 1 hour Webinar for the Canadian Association of Cardiovascular Prevention and Rehabilitation.
17. Sept 29 Healthy Food Procurement. A call for national policy. A best practice presentation at: "Solutions for Change: Healthy Food Procurement and Nutrition Standards in Public Facilities. Edmonton Alberta

18. Sept 25 Hypertension Prevention and Control. Confederation of Alberta Faculty Associations (CAFA) Distinguished Academic Award Presentation. Edmonton
19. Sept 20 The critical role of the pharmacist in the evolution of the health system. Alberta Health Services, Rxeach Project, Leduc Alberta.
20. Aug 10 Hypertension prevention and control programs in Canada. ACMI (meeting with the 3 local medical schools). Bucaramanga, Colombia
21. Aug 11 Sodium, the evidence and the need to act. Bogota Columbia, Multisectoral meeting of government and civil society on dietary sodium.
22. Aug 8 Canadian hypertension prevention and control programs. Lessons learned. The Association Procongreso of Internal Medicine. Cartagena, Colombia.
23. Aug 8 Hypertension the Global Burden. The Association Procongreso of Internal Medicine. Cartagena, Colombia.
24. July 13 Assessment of blood pressure. Medical University of South Carolina. Talk-video session for American Society of Hypertension. Educational series on Hypertension. Charleston SC
25. June 24 Salt iodization and salt reduction strategies: making policies coherent. WHO guideline development group meeting - nutrition actions, Geneva SZ
26. June 14 The World Hypertension League. International Society of Hypertension International Partners Forum. Athens Greece.
27. June 15 The role of health care professionals and scientists in salt reduction. Symposia on dietary salt. International Society of Hypertension. Athens Greece
28. June 7 Death by food. Council of Cardiovascular Nurses Spring meeting, Calgary
29. June 1 The role of the Pharmacist in hypertension. Canadian Pharmacists Journal Lecture, Canadian Pharmacy Association Annual General meeting, Saskatoon.
30. June 1 Canadian Hypertension Education Program Recommendations. Concurrent session. Canadian Pharmacy Association Annual General meeting, Saskatoon.
31. May 21 Update on salt and health. International Advisory Panel (IAP) on Reduction of Dietary Sodium and Sugars in Hong Kong, Food Safety Agency of Hong Kong
32. May 17 Hypertension and the World Hypertension League. Opening address for World Hypertension Day and opening of the World Hypertension League regional office in Beijing. Chinese Hypertension League and guests.
33. May 7 Case study: The Canadian Hypertension Education Program (CHEP), putting evidence into practice. Iranian Heart Association - Getting high blood pressure under control in low- and middle-income countries. World Congress of Cardiology, 2014, Melbourne Australia.
34. May 6 Role of national and international organizations in prevention and control of hypertension. In a global view of what we need to know. Hypertension. World Congress of Cardiology, 2014, Melbourne Australia.
35. May 5 Hypertension as a model for NCD prevention and control. In Center for Disease Control (CDC-USA) session - The global standardization of hypertension treatment project. World Congress of Cardiology, 2014, Melbourne Australia.
36. May 5 Regional action on salt reduction: Case study from the Americas. National Heart Foundation of Australia- Half the salt, self the sugar, scrap the fat: saving lives through reformulation of food. World Congress of Cardiology, 2014, Melbourne Australia.
37. April 22 Food Policy for the nephrologist. Canadian Society of Nephrology, Vancouver
38. April 21 The development of a public policy and research agenda regarding HTN / salt. Krescent program, (Kidney Foundation and Canadian Society of Nephrology). Vancouver
39. April 3 Task Shifting: Who diagnoses? Who prescribes? 10 minutes + questions Expert Consultation on Population Approaches to Reducing High Blood Pressure, Bloomberg Philanthropies, New York.
40. April 2 Evaluating Salt Policy Impact, 15 minutes + questions. Expert Consultation on Population Approaches to Reducing High Blood Pressure, Bloomberg Philanthropies, New York.
41. March 29 You and the food around you. Genesis Centre (YMCA), Calgary
42. March 18 Death by food. Wellness coordinators, City Hall, City of Calgary.
43. Feb 12 Food Policy and Hypertension. 2nd year nursing class (Community health course), Mount Royal University
44. Feb 11 Food Policy and Hypertension. 2nd year nursing class (Community health course), Mount Royal University

45. Jan 24 Death by food, The Department of Community Health Sciences and the Institute for Public Health. University of Calgary.

2013

1. March 1 Death by Food. Grand Medical Rounds. University of Alberta, Edmonton Alberta
2. March 26 What is the evidence that salt reduction and iodine fortification strategies are compatible? WHO Platform 3 on salt reduction. Coordinating iodine Fortification of salt with salt reduction, Sydney Australia.
3. Apr 5 Hypertension and the Global Burden of Disease. Plenary Speaker World Health Day Symposia, PAHO-WHO Washington DC
4. Apr 9 Hypertension and Public Health. Course 4 Medical School lecture.
5. Apr 24 Three 15-minute public presentations on "What I do for health promotion" HSFC tour of University of Calgary facilities.
6. April Integrating healthy public nutrition policies to prevent and control cardiovascular disease. Keynote speaker. Drug therapeutic day. Schulich Medicine and Dentistry. University of Western Ontario, London Ontario.
7. April Hypertension. Invited short talk on global burden of hypertension. Centre Block Parliament Buildings, Ottawa Canada.
8. April HSFC CIHR Chair Hypertension Prevention and Control. Talk on role of Chair, Hypertension Framework and Hypertension Advisory Committee. Hypertension Canada Partners Forum
9. April 12 Home Blood Pressure Monitoring and Controlling Hypertension. Cardiovascular Summit, Billings, Montana. Montana Department of Public Health and Human Services and the University of Washington School of Medicine.
10. Apr 12 Canadian hypertension prevention and control programs: Past, present and future. Medical Grand Rounds. Billings Clinic, Montana.
11. June 12 Sodium/salt science. World Bank, Washington DC symposia on Improving Nutrition in Food Systems in Latin America and the Caribbean
12. June 28 Hypertension Control: Coalition building for success. Workshop presentation, World Hypertension Congress. Istanbul
13. June 28 Monitoring the nutritional composition of foods to improve the food supply and reduce chronic disease burden in the Americas. Oral abstract presentation, World Hypertension Congress, Istanbul
14. June 28 Dietary salt, water, diuretics, hypotensive drugs, dehydration, and hypotension. Making simple connections. Symposia presentation. World Hypertension Congress, Istanbul
15. June 28 Effectively implementing hypertension recommendations – Lessons from Canada. Symposia presentation. World Hypertension Congress, Istanbul
16. Aug 13 Death by Food. Canadian Association of Hospital Pharmacists. Plenary Speaker. Summer educational session. Calgary
17. Sept 10 Knowledge translation for cardiovascular risk reduction' to the VRR Screening and Prevention in Primary Care Working Group Meeting of Alberta Health Services.
18. Sept 16 Knowledge translation for cardiovascular risk reduction' to the Cardiovascular Strategic Clinical Cardiovascular Network Core meeting of Alberta Health Services
19. Oct 15 Integrating health promotions into clinical practice. Rocky Mountain Internal Medicine Conference. Banff AB. 1 hour plenary talk
20. Oct 17 Reducing dietary sodium is healthy. Debate. Canadian Nurse Practitioners. Montreal

2012

1. Feb 7 Sodium reduction in Canada, a brief review of science, history, recent actions and potential actions nongovernmental organizations can undertake. Canadian Hypertension Advisory Committee. Ottawa
2. Feb 7 Outcomes research, monitoring and evaluation of hypertension in Canada, Canadian Hypertension Advisory Committee. Ottawa
3. Feb 15 Health Policies to support sodium reduction. Ontario Sodium Summit. Toronto
4. March 26 Salt intake, hypertension and stroke in the Americas in Pan American Health Organization PAHO/WHO Webinar Less Salt = lower blood pressure= less stroke
5. Apr 3 10-minute presentation on efforts to prevent and control hypertension in Canada. Libin HSFA public session.

6. Apr 5 Overview of the Pan Canadian Hypertension Framework, Teleconference- 30-minute presentation to the Council of Chief Medical Officers of Health.
7. Apr 12 Hypertension and public health. Renal course (course 4). University of Calgary
8. June 14 Home assessment of Blood Pressure. The Canadian Approach. Hypertension Coalition. Montana Cardiovascular Health Program. Bozeman Mt.
9. June 23 Briefing on Hypertension to Board of HSFA
10. Aug 18 Chronicles of a career. 40th reunion of Dr R Weinshilboum's laboratory. Mayo Foundation, Rochester Minn.
11. Sept 18 Improving Hypertension Control. The Canadian Experience. Annual meeting of Yaroslavl Health Care professionals, regional assistant Governor, Regional Minister of Health and Chiefs of Cardiology, General Practice, Rheumatology, Respiratory Medicine and Endocrinology.
12. Sept 19 The Canadian Hypertension Education Program. Moscow Cardiology Society. Prevention Institute, Moscow.
13. Sept 25 Hypertension: Integrating public health approaches. Grand rounds. Department of Medicine, University of Calgary.
14. Sept 29 International salt reduction efforts-challenges, successes and failures. In Physical activity, nutrition and a pinch of salt. A Satellite symposium to the International Hypertension Society. Sydney Australia, 30 minutes + 90 minutes panel discussion.
15. Oct 3 Canadian Hypertension prevention and control programs, George Institute for International Health. Sydney Australia, 60 minutes
16. Oct 17 Population approach: Sodium reductions policies: What works what doesn't. Health Promotion Plenary Symposia. Canadian Society of Internal Medicine. Quebec City Quebec.
17. Oct 19 Current gaps in screening for hypertension. Short snapper. Canadian Society of Internal Medicine. Quebec City Quebec.
18. Oct 26 Salt reduction a cost-effective public health measure. 30-minute Core curriculum track presentation. 2012 Canadian Hypertension Congress. Toronto Ont.
19. Oct 26 Public Health Approaches. Models for improvement of blood pressure by lifestyle modification. 30-minute presentation in Public Health Plenary session. 2012 Canadian Hypertension Congress. Toronto Ont.
20. Oct 27 Dreaming about hypertension. JG Fodor award presentation. 30 minutes. Canadian Hypertension Congress. Toronto Ont.
21. Oct 30 Integrating healthy food policy to prevent and control hypertension. Grand Medical Rounds. University of Manitoba.
22. Nov 2 Sodium in the food supply. Why is this a public health issue? Plenary presentation at Reducing the sodium intake of Canadians. A provincial and territorial multi sector engagement. Edmonton AB.
23. Dec 11 Review of Evidence of Interventions for Sodium Reduction - What Works and Why it Works. Plenary: Salt Reduction Strategies. Expert Meeting on Population Sodium Reduction Strategies for Prevention and Control of Noncommunicable Diseases in the South-East Asia Region. World Health Organization.
24. Dec 12 Recommended Methods for Measuring Population -Level Sodium Intake. Plenary: Monitoring Salt Intake in the Population. Expert Meeting on Population Sodium Reduction Strategies for Prevention and Control of Noncommunicable Diseases in the South-East Asia Region. World Health Organization.

2011

1. Jan 2 Adverse health effects of high dietary sodium. PAHO salt reduction iodine deficiency disorders prevention collaborative meeting. Washington DC.
2. Jan 10 Canadian experiences. Consultation for Salt reduction strategies for India. 2011. New Delhi
3. Jan 10 Chair roundtable workshop on Tools to assess salt intake and sources of salt in the diet. Consultation for Salt reduction strategies for India. Jan 10, 2011. New Delhi
4. Feb 12 Hypertension Canada. Healthy Public Policy Committee. Talk on Hypertension Framework, Committee activities and workshop for Hypertension Canada Council of Academic Partners.
5. Feb 13 Hypertension Public Health Agency of Canada.
6. March 3 Reducing dietary salt. The Canadian experience. 14th Congress on Public Health Research. Institute of Public Health. Cuernavaca Mexico.

7. March 10 Celebrating Canadian Success. Treating and controlling hypertension. Hypertension and Stroke Prevention and Control Workshop. Sponsored by the Canadian Embassy in Beijing for the Chinese Ministry of Health and Centre for Disease Control China and other Chinese nongovernment organizations.
8. March 11 Treating and controlling hypertension. The Canadian Experience. Beijing Health Research Lecture Series. George Institute- Peking University-University of Sydney (Australia), Beijing China.
9. March 18 Dietary salt and men's health. PAHO webinar for salt awareness week.
10. March 31 Sodium and Health. PAHO joint meeting on salt reduction and Iodine fortification. Washington DC
11. Apr 5 Fire side panel discussant. Maximizing our investment in practice guidelines. CADTH symposia. CADTH annual meeting Vancouver BC
12. Apr 9 Reduction in dietary salt and other dietary interventions to lower blood pressure. International Hypertension Society Lecturer at the World Congress of Nephrology, Vancouver BC
13. Apr 14 Canadian Hypertension Education Program (CHEP): Best practices in hypertension awareness, treatment, and control. McKinsey Health Systems Institute. International webinar to policy makers in Spain, Italy, Australia, Scotland, Singapore and Hong Kong
14. Apr 14 Canadian Hypertension Education Program (CHEP): Best practices in hypertension awareness, treatment, and control. McKinsey Health Systems Institute. International webinar (conducted twice 1.5 hours each). to policy makers in Spain, Italy, Australia, Scotland, Singapore and Hong Kong
15. Apr 21 Blood pressure, hypertension and public health. Class 4; renal course to the U of C Medical School
16. Apr 27 World Economic Forum of Latin America- Pan American Health Organization Health Symposia. Technical expert for group discussion on dietary salt.
17. May 21 Implementation and evaluation of Canadian hypertension programs, American Society of Hypertension, New York.
18. May 25 Canadian efforts to prevent and control hypertension. Presentation to delegation from Qatar at the Libin Cardiovascular Institute.
19. June 9 Global efforts to reduce dietary salt. Plenary session. Toronto International Heart Summit
20. June 10 Assessing outcomes in guidelines processes. The hypertension experience. Parallel session. Toronto International Heart Summit
21. June 13 Hypertension in Diabetes. Cardiology Grand Rounds, Libin Cardiovascular Institute.
22. June 19 Overview of the sodium issue. Public Health Policy mini course, National Specialty Society of Community Medicine. Montreal. 30-minute talk + 3 panel discussions
23. Sept 27 The Canadian Hypertension Education Program. Improvements in awareness, treatment and control over 10 years. Key Lecture. First International congress on prevention, diagnosis and management of hypertension. Isfahan, Iran
24. Sept 28 Adverse health effects of dietary salt and the Canadian experience. Keynote lecture. First International congress on prevention, diagnosis and management of hypertension. Isfahan, Iran
25. Sept 29 National guidelines development and update. Key Lecture. First International congress on prevention, diagnosis and management of hypertension. Isfahan, Iran
26. Sept 29 Implementation of national guidelines. Key Lecture. First International congress on prevention, diagnosis and management of hypertension. Isfahan, Iran
27. Oct 2 Outcomes Research Task Force findings and clinical relevance from 2010-2011. Recommendations Task Force of the Canadian Hypertension Education Task Force.
28. Oct 4 Meet the expert; How can health care professionals get involved in national health policy? Canadian Hypertension Congress.
29. Oct 4 Report from the Chair in Hypertension Prevention and Control. Canadian Hypertension Education Program Symposia. Canadian Hypertension Congress.
30. Oct 4 Nongovernment activities to reduce dietary sodium. Special Public Health Plenary Symposia. Canadian Hypertension Congress.
31. Oct 5 Healthy public policy and building partnerships. Public Health Forum on a Healthy Blood Pressure Framework. A discussion of the way forward. To prevent and control hypertension.
32. Oct 11 Pathophysiology of hypertension and dietary sodium. Association des Médecins Biochimistes du Québec and Canadian Association of Medical Biochemists
33. Oct 12 Hypertension, members of the Quebec Ministry of Health

34. Oct 27 Overview of expert group achievements. Cardiovascular Disease Prevention through Dietary Salt Reduction Meeting of the Regional Expert Group, Countries and Partners convened by the Pan American Health Organization/World Health Organization Washington DC
35. Oct 28 Establishing a Scientific Expert Advisory Committee (Terms of Reference) for phase 2 of Cardiovascular Disease Prevention through Dietary Salt Reduction. Meeting of the Regional Expert Group, Countries and Partners convened by the Pan American Health Organization/World Health Organization. Washington DC
36. Oct 29-30 A series of 9 short talks (approximately 2 hours) to members of the Hypertension Advisory Committee of the HSFC CIHR Chair in Hypertension Prevention and Control. Representatives from Canadian Stroke Network, Canadian Stroke Network, College of Family Physicians of Canada, Canadian Pharmacists Association, Canadian Medical Association, Canadian Public Health Association, The Canadian National Specialty Society for Community Medicine, Canadian Cardiovascular Society, Canadian Society of Internal Medicine, Hypertension Canada, Canadian Institutes of Health Research
37. Nov 14 The United Kingdom Salt Reduction Program, American Heart Association Scientific Sessions 2011, International Congress on Global Cardiovascular Prevention and Health Promotion. Orlando Florida
38. Nov 14 The United States and Canadian Salt Reduction Programs, American Heart Association Scientific Sessions 2011, International Congress on Global Cardiovascular Prevention and Health Promotion. Orlando Florida
39. Nov 25 The role of the Internist in public health. Rocky Mountain Internal Medicine Meeting Banff.

2010

1. Jan 27 Grand rounds St Josephs Hospital, McMaster University. Dietary Sodium
2. Jan 25 Gaps in research and knowledge translation. *Developing a Research Agenda to Support Sodium Reduction in Canada*. CIHR CV-R and Nutrition and DM institutes meeting.
3. Feb 4 Hypertension and dietary salt. Public forum sponsored by Heart and Stroke Foundation of Labrador. St John's.
4. Feb 5 Hypertension and Dietary salt. Grand Medical Round and Community Health Science Rounds. Memorial University.
5. March 1 Hypertension Workshop, Crowfoot Chronic Disease Management Clinic, Calgary.
6. March 6 CHEP 2010 theme + what's new in the CHEP guidelines, Hypertension and Sodium Education Tools CHEP meeting Toronto.
7. March 6 Information on Public Tools – Knowledge Translation, Hypertension and Sodium Education Tools. CHEP meeting Toronto.
8. March 12 The burden of sodium related disease in Canada and Canadian Approaches to reduce the burden. Mexico City. National Health Public Health Institutes of Mexico with video conference to the other National Institutes of Health.
9. March 23 Hypertension and Dietary sodium. The silent and hidden killers. Time to put them in jail. Grand Rounds, University of Calgary.
10. March 26 Hypertension in Canada. Heart and Stroke Foundation of Ontario. Hypertension Collaborative. Train the trainer session. Toronto Ontario.
11. March 26 Panel member for case presentations. Heart and Stroke Foundation of Ontario. Hypertension Collaborative. Train the trainer session. Toronto Ontario.
12. March 27 Plenary Speaker. Dietary Sodium, Hypertension, Heart Disease and Stroke. Heart and Stroke Foundation of Ontario. Hypertension Collaborative. Toronto Ontario.
13. March 29 Plenary Speaker. Hypertension the Big Picture. Hypertension Stakeholders Forum. Nova Scotia Department of Health.
14. March 29 Plenary Speaker - Panel member. Advocacy for national policy changes. Hypertension Stakeholders Forum. Nova Scotia Department of Health.
15. March 30 Lifestyle changes. Plenary Speaker. Hypertension Conference. Heart and Stroke Foundation of PEI.
16. March 30 Hypertension in Canada. Department of Health, Government of PEI.
17. March 31 Hypertension in Canada. Department of Health, Government of New Brunswick.
18. Apr 30 Hypertension: What's new. Plenary speaker. Canadian Council of Cardiovascular Nurses inaugural Annual Spring Meeting.

19. May Hypertension and preventing cardiovascular disease. Libin Cardiovascular Research Institute Research Day
20. May Dietary salt the hidden killer. Time to put it in jail. Can Society of Nephrology Annual meeting.
21. June 9 Prevention and control of hypertension in Canada. CIHR 13th International Heart Summit Toronto Canada.
22. June 9 Chair Hypertension and Prevention Session. CIHR 13th International Heart Summit Toronto Canada.
23. July 1 Pan American Health Organization Expert Group on Salt Reduction. WHO-FSA Platform 1. Creating an enabling environment. London UK.
24. Sept 17 Contemporary Evaluation of Blood Pressure in 2010. New Brunswick 20th Annual Cardiovascular Symposia St John New Brunswick.
25. Sept 18 Investigation and Management of Resistant Hypertension. New Brunswick 20th Annual Cardiovascular Symposia St John New Brunswick
26. Sept 26 Opening remarks for Hypertension Canada. Opening International Hypertension Society. Vancouver.
27. Sept 29 Informing, motivating and improving communication with health care professionals. Challenges, in achieving population blood pressure control. International Hypertension Society. Vancouver.
28. Sept 29 The Pan American Health Organization Salt Reduction Expert Group. Special symposia Global salt reduction initiatives. International Hypertension Society. Vancouver.
29. Sept 29 Report from the CIHR Canada Chair in Hypertension Prevention and Control. Canadian Hypertension Education Program Symposia. International Hypertension Society. Vancouver.
30. Sept 30 Angiotensin receptor blockers cause cancer. Pro: Clinical debate. International Hypertension Society. Vancouver.
31. Oct 8 Hypertension and Dietary sodium. Living well to 100 programs (UofC CME program). Cenovus Energy- Bankers Hall Calgary
32. Oct 18 Pan American Health Organization Expert Group dietary salt surveillance, monitoring and evaluation activities. World Health Organization-Government of Canada Salt Surveillance meeting. Calgary Alberta.
33. Oct 18-20 Opening and closing of the Information exchange and technical meetings of the World Health Organization-Government of Canada Salt Surveillance meeting. Calgary Alberta.
34. Oct 21 Canadian Efforts to prevent and control Hypertension. Lecture Libin Cardiovascular Symposia. Taming the Vascular Disease Epidemic - From Global to Local. Calgary Alberta.
35. Oct 22 Hypertension and Dietary Sodium. Canadian Diabetes Association Edmonton Alberta.
36. Oct 29 Hypertension targets. Canadian Society of Internal Medicine
37. Oct 29 Blood pressure monitoring (automated office, ambulatory and home) workshop. Canadian Society of Internal Medicine.
38. Dec 7 Briefing on Hypertension to the Council of Chief Medical Officers of Health.
39. Dec 10 Keeping it light. Sodium, heart disease and stroke. Plenary at Clinical Update 2010. Heart and Stroke Foundation of Ontario.
40. Dec 10 Advocacy, in Parallel session Saving lives through sodium reduction. Clinical Update 2010. Heart and Stroke Foundation of Ontario.

2009

1. Jan 13 Dietary sodium reduction. Canadian Activities. Pan American Health Organization. Miami.
2. Jan 13 High dietary sodium and health in North America. Pan American Health Organization. Miami.
3. Jan 29 CHEP recommendations and care gaps. Calgary
4. Feb 3 Grand Cardiology Rounds. Hypertension. Libin Cardiovascular Institute.
5. Feb 4 Hypertension, University of Calgary. Telemedicine rounds to Southern Alberta on hypertension.
6. Feb 6/7 Hypertension in Canada to Blood Pressure Canada Sodium work group and to Public Education Task Force.
7. Feb 10 Hypertension. Calgary area Family Physicians.
8. March 10 Hypertension, Calgary area Family Physicians.
9. March 11 Hypertension in People with Diabetes. University of Calgary, GIM journal club.
10. March 18 Hypertension in Canada,. Alberta Hypertension Initiative, Edmonton,

11. March 23 Hypertension in Canada. Tools and Initiatives for preventing and managing hypertension, Nova Scotia Department of Health.
12. Apr 2 Hypertension in Diabetes, Calgary Therapeutics Course,
13. Apr 3 CHEP educational tools for Health Care professionals. CHEP Train the Trainer session. Calgary
14. Apr 18 CHEP 2009 recommendations. Edmonton. RuralRxaction.
15. Apr 18 CHEP 2009 recommendations clinical case scenarios. Edmonton. RuralRxaction
16. Apr 17 CHEP; a model for recommendations processes. Moving forward together: Developing and strengthening partnerships for knowledge translation. 2009 CIHR Partners Forum sponsored by CIHR.
17. Apr 16 Outcomes evaluation in recommendations processes. Moving forward together: Developing and strengthening partnerships for knowledge translation. 2009 CIHR Partners Forum C-Change, sponsored by CIHR.
18. Apr 26 Global risk management in the patient with cardiovascular disease. Heart and Stroke Foundation of Ontario, Niagara on the Lake.
19. Apr 28 CHEP recommendations. C-era, internet lecture.
20. May 20 Hypertension and Dietary Sodium: The Silent and Hidden Killers. Time to put them in jail. Hypertension update on new recommendations. Calgary
21. May 21 Hypertension Update and workshops. Satellite Train the Trainer Session as a satellite to the Tri Council Conference Banff.
22. June 18 Hypertension in Canada. Montana Department of Health, Cardiovascular Health Program, Helena, MT.
23. July 23 GIM fellows, Hypertension training workshop, 3 hours. Calgary
24. August 19 Canadian efforts to reduce dietary sodium. Centre for Disease Control. (+ broadcast to food and drug administration and Depart of Health Services) Atlanta, GA.
25. Sept 9 Sodium and Health issues in the America's. PAHO sodium work group. Washington DC.
26. Sept 23 Sodium and hypertension. The hidden and silent killers. Time to put them in jail. Dept of Community Health Sciences. UofC, Calgary
27. Oct 5 Witness to Parliamentary Standing Committee on Health. Ottawa.
28. Oct 6 Hypertension and the Libin Cardiovascular Institute. Rotary Club. Calgary.
29. Oct 15 What's new in prevention. Canadian Stroke Network Annual General Meeting.
30. Oct 15 Briefing Minister of Health's Policy Advisors and Director Generals of Health Canada Nutrition Divisions re sodium. Ottawa.
31. Oct 19 12 Annual Stroke Collaborative. Dietary Sodium. Toronto.
32. Oct 19 Briefing to the Primary Prevention Subcommittee (HPPPS) of the Ontario Stroke Network Re dietary sodium and what can be done. Toronto.
33. Oct 23 CHEP consensus Symposia, Introduction and overview of hypertension in Canada. Edmonton
34. Oct 24 Hypertension briefing to the Chief Operating Officers of the Heart and Stroke Foundations of Canada. Edmonton.
35. Oct 25 Hypertension, in Canadian Journal of Cardiology symposia, Canadian Cardiovascular Congress, Edmonton.
36. Oct 26 The importance of managing hypertension in people with diabetes, Canadian Hypertension Society, Canadian Cardiovascular Congress (organizer of symposia) Edmonton
37. Oct 26 Chair, opening and closing CHEP symposia, Canadian Hypertension Society, Canadian Cardiovascular Congress, Edmonton
38. Oct 26 Chair, organizer, opening and closing of symposia, Will there be new preventative cardiovascular therapies, Canadian Hypertension Society, Canadian Cardiovascular Congress, Edmonton
39. Oct 27 C-change symposia; hypertension recommendations. Canadian Cardiovascular Congress, Edmonton
40. Oct 27 Distinguished Service Award Lecture. Canadian Hypertension Society, Canadian Cardiovascular Congress, Edmonton.
41. Oct 27 Presidents Report. Blood Pressure Canada, Annual General Meeting, Edmonton
42. Oct 31 Salt Workshop at the World Hypertension Congress. Co-sponsored by World Action of Salt and Health. Organizer, co-chair and presenter of PAHO policy statement on Dietary Salt, Beijing.
43. Nov 1 Canadian Guidelines, Plenary Presentation in symposia on National guidelines. World Hypertension Congress, Beijing.

44. Nov 16 Public health implications of high dietary salt. Symposia. XV Congreso Latinoamericano de Nutricion. Santiago Chile.
45. Nov 26 Update on hypertension and combination treatment. Family Practice Review and Update Course. University of Calgary.
46. Dec 1 Survey of Living with Chronic Disease (hypertension component). Is it useful? Plenary for PHAC Chronic disease surveillance meeting.
47. Dec 2 Grand (Cardiovascular) Rounds. Ottawa Heart Institute. Dietary Sodium and Health.

2008

1. Jan Hypertension in Canada; Canadian Heart Health Strategy Management Committee. (teleconference)
2. Jan Briefing on Hypertension in Canada. Heart and Stroke Foundation of Canada. Ottawa
3. Jan Hypertension and Blood Pressure Canada, Western Canadian Community Program Network. Blood Pressure Canada,
4. Feb 2 Hypertension in the diabetic patient. Calgary (REACH PROGRAM)
5. Feb 26 Hypertension: From management recommendations to outcomes. Grand Rounds Dalhousie University
6. Feb 26 Hypertension cases to internal medicine trainees. Victoria General Hospital, Halifax.
7. Feb 26 Resistant Hypertension. Journal club. General Medicine and Hypertension Clinic. Victoria General Hospital Halifax
8. March 5 Sodium and Health. 2008, Food processors and government, Government of Alberta.
9. Apr 3 Distinguished speaker in Cardiovascular Medicine. Hypertension: From management recommendations to outcomes. Division of Cardiology. University of British Columbia.
10. Apr 3 Case rounds with residents and Fellows in cardiology. Division of Cardiology. University of British Columbia.
11. Apr 16 Journal Club. HYVET and ON TARGET. April 16, 2008. GIM UofC
12. May 2 Briefing on Hypertension in Canada and Alberta, members of Government of Alberta
13. May 15 Canadian Hypertension Recommendations. American Society of Hypertension. Plenary lecture.
14. May 16 Hypertension. Guidelines to Outcomes. Heart and Stroke Foundation of New Brunswick.
15. May 16 Hypertension. To Maritime Heart and Stroke Foundations
16. May 31 Health Risks Associated with High Dietary Sodium. Plenary session. Canadian Society of Clinical Nutrition and Canadian Society of Nutritional Scientists. Toronto.
17. May 31 Health Risks of Dietary Sodium. Debate. Canadian Society of Clinical Nutrition and Canadian Society of Nutritional Scientists. Toronto.
18. June 4 Prevention of cardiovascular disease through improved hypertension prevention and control. The Canadian Experience. Mazankowski Alberta Institute Inaugural Congress. Edmonton Alberta.
19. June 10 From Hypertension recommendations to outcomes. Cera e conference.
20. June 14 Hypertension and sodium. Symposia at Dieticians of Canada national Meeting, Winnipeg MN
21. June 16 International initiatives that work best practices to use in the clinic and as public health initiatives. Symposia at International Society of Hypertension.
22. June 17 Implementing Guidelines. It is working in Canada! Report on behalf of the Canadian Hypertension Education Program. International Society of Hypertension.
23. Aug 18 CME at sea (co-sponsored by UofC) Global CVD risk assessment.
24. Aug 22 CME at sea (co-sponsored by UofC) Hypertension
25. Aug 29 European Cardiovascular Congress: Educational symposia. Know the Score: Best Practices in Cardiovascular Medicine. International success stories 26
26. Sept 3 European Cardiovascular Congress. State of the Art. Stress and blood pressure: What's the connection? Featured oral research session. Relationship between baseline heart rate, allocated treatment and the primary prevention of cardiovascular outcomes in the Anglo Scandinavian cardiac outcomes trial-blood pressure lowering arm.
27. Sept Hypertension research efforts in Canada. Canadian Stroke Network
28. Sept Hypertension Sate of the Union. Canadian Stroke Network
29. Sept 18. CHEP the process and tips on teaching the recommendations. Department of Family Medicine. Dalhousie University.
30. Sep 18 Research Meeting Department of Family Medicine. Dalhousie University.

31. Sept 18 Resistant Hypertension. Department of Family Medicine. Dalhousie University.
32. Sept 18 Hypertension. Public Forum Atlantic Canada Stroke Meeting.
33. Sept 19 Plenary session Sodium and hypertension. Atlantic Canada Stroke Meeting.
34. Sept 19 Hypertension Pharmacotherapy. Concurrent sessions. Atlantic Canada Stroke Meeting.
35. Sept 25 Hypertension recommendations and new clinical trials. Rocky Mountain House Primary Care Network.
36. Oct 1 Sodium and Health. Public Health Agency of Canada.
37. Oct 23 Hypertension in Canada. Federal Provincial expert advisory committee on chronic disease and injury prevention.
38. Oct 24 Overview of CHEP to recommendations Task Force of CHEP.
39. Oct 25 New hypertension educational resources for patient and the public. CHS-CHEP-BPC Multidisciplinary symposia for Health Care Professionals
40. Oct 26 Hypertension educational resources for patient and the public. CHS-CCC annual meeting.
41. Nov 1 Hypertension Management: Does lifestyle change really work. Concurrent sessions. Alberta Stroke Conference.
42. Nov 1 Chair Case studies Panel. Alberta Stroke Conference.
43. Nov 12 Canadian Programs for the prevention, treatment and control of hypertension. Alberta Provincial Stroke Strategy- Hypertension Working Group meeting.
44. Nov 20 TORCH; U of C U of A interdisciplinary talk. Canadian Hypertension guidelines and education program.
45. Dec 2 Hypertension Initiatives in Canada. Heart and Stroke Foundation of Alberta Awards ceremony.

2007

1. Jan 15 Hypertension. Rockview General Hospital Medicine Rounds. Calgary, AB, 20 staff & trainees. 1 hour
2. Jan 24 Hypertension. Kerby Centre, Calgary, AB. 120-150 public attendees. 1.5 hours
3. Jan 27 CHEP Recommendations 2007 Panel member. OPTIM Investigators Los Vegas, NV, USA 50 internists & family physicians. 30 minutes
4. Jan 27 Challenges for Blood Pressure Management, Panel Member. OPTIM Investigators. Las Vegas, NV, USA. 50 internists & family physicians. 30 minutes.
5. Jan 30 CHEP as a model for CME? University of Calgary CME Committee. 10 members 30 minutes.
6. Feb 5 Hypertension in the Elderly. MDCN 412 Aging and the Elderly, University of Calgary Medical School 1 hour
7. Feb 7 White coat hypertension. Family Medicine Evening Program. Calgary, AB. 25 family physicians. 1 hour.
8. Mar 5 Resistant Hypertension. Interdivision General Medicine Rounds, McGill University Internists (25 attendees)
9. Mar 6 Professorial Rounds. Internal Medicine Residents. McGill University – Montreal General Hospital
10. Mar 6 CHEP. Grand Medical Rounds. McGill University – Montreal General Hospital
11. Mar 8 Hypertension and Aging: Treatment Issues. Western Society of Clinical Pharmacology, Banff, AB, Plenary Lecture (100 pharmacologists)
12. Mar 11 CHEP recommendations. Plenary Lecture (10 minutes) & Panel Discussion (30 minutes). Annual Cardiology Conference, Lake Louise AB.
13. Apr 2 The Canadian Effort to Prevent and Control Hypertension. Jiao Tong University School of Public Health. Shanghai, China. 1 hour. 30 attendees (students and faculty)
14. Apr 19 Update on CHEP & OPTIM. Family Physicians. Calgary AB
15. Apr 27 Sodium & Health, Regional Nutrition and Food Service Annual Meeting. Capital Health Region. Edmonton, AB.
16. May 15 Antarctica and global warming; two grade 8 classes at Monsieniuer Doyle School; Attendance 70 students/teachers 2007
17. May 20 Hypertension, A Canadian Perspective. Plenary session at the American Society of Hypertension. Hypertension specialists' audience 500.
18. May Cardiovascular Risk Theme. 10 minutes Canadian Heart Health Strategy. 200 multisectoral and specialty experts.

19. June 6 Canadian Hypertension Education Program Recommendations 2007. 1 hour, Calgary area physicians
20. June 7 Hypertension. Chronic disease and injury prevention alliance (Federal Provincial Committee). 10 minutes,
21. June 7 Canadian Hypertension Education Program Recommendations 2007, Alberta Stroke Network, 1 hour.
22. June 9 Vascular Protection Forum. Workshop repeated twice. Gaps in hypertension management. Toronto. 40 national cardiovascular specialists.
23. June 12, Organizer and co-chair: Workshop on "Research progress and plans in primary prevention. Canadian Stroke Network. Montebello, Quebec
24. June 12 Treatment and control of hypertension, Workshop on "Research progress and plans in primary prevention. 30 attendees. Canadian Stroke Network. Montebello, Quebec
25. June 13 Self management of Hypertension. Workshop in Prevention detection and management of Hypertension. 30 attendees. Canadian Stroke Network. Montebello, Quebec
26. June 13 Canadian Stroke Network progress and plans; panel discussion. Prevention panel. Canadian Stroke Network. 100 members Montebello, Quebec
27. Jun 26 Treat to Goal. Claresholm, Family Physicians AB
28. Sept CHEP overview, challenges and opportunities. CHEP ITF meeting; 20; Montreal 20 minutes. about 25 members
29. Sept CHEP overview. BPC Public Education Task Force meeting; 20; Montreal. 20 minutes about 25 members
30. Sept Hypertension and sodium: Dieticians of Canada; Atlantic Regional meeting. 120 Dieticians. about 3-400 dieticians. Moncton
31. Oct 5 Hypertension in Canada. Community Health Sciences Department Rounds. About 50 community Medicine staff and students
32. Oct 11 Hypertension management to prevent heart failure. Canadian Society of Internal Medicine. 20 minutes talk about 3-400 Internists. St John's
33. Oct 11 Ambulatory Blood Pressure Monitoring Canadian Society of Internal Medicine. Oct 11, 2007, 2 one-hour workshops. Attendance about 60. St John's
34. Oct 11 Advocacy. Canadian Society of Internal Medicine. one hour workshop, attendance 5 internists, St John's
35. Oct 20 Canadian Association of Cardiac Rehabilitation. Hypertension and metabolic syndrome. 30 minutes, Plenary Presentation. 2-300 CACR members, Quebec City.
36. Oct 20 Canadian Hypertension Society. New Hypertension recommendations. 20 minutes. Training Session. 40-50 inter disciplinary attendees, Quebec City
37. Oct 19 Canadian Hypertension Education Program Recommendations Task Force. Overview and Update on CHEP. 20 minutes. 50 CHEP members, Quebec City.
38. Oct 21 Canadian Hypertension Education Program Outcomes Research Task Force. Overview and Update on CHEP. 20 minutes 14 CHEP members, Quebec City.
39. Oct Canadian Hypertension Society- Blood Pressure Canada Symposia. Sodium and hypertension. Plenary Program, 30 minutes. 300 attendees, Quebec City.
40. Oct 20 Canadian Hypertension Society- Heart and Stroke Foundation. Hypertension awareness and control: A Global Perspective. Plenary program presentation 20 minutes. 2-300 attendees, Quebec City
41. Oct 22 Canadian Hypertension Society. Canadian Hypertension Education Program Symposia. Plenary presentation. Overview of CHEP. 10 minutes, 2-300 attendees. Quebec City
42. Oct 22 Overview of hypertension in Canada, Hypertension Clinic Network Workshop. 20 attendees, Quebec City
43. Oct Canadian Hypertension Society. Canadian Hypertension Education Program Symposia. Plenary presentation. Report from the Canadian Hypertension Chair. 2-300 attendees, Quebec City
44. Oct 23 Canadian Hypertension Education Program Sponsors Roundtable. Overview, Update on CHEP and report for the Outcomes Research Task Force. 30 minutes. 20 attendees, Quebec City
45. Oct 23 Blood Pressure Canada, Report from the President, Report from the Canada Hypertension Chair, Report on the Public Education Task Force. 3-40 attendees. Quebec City

46. Nov 8 Guidelines that work. 30 minutes + 30 minutes discussion. Tripartite Committee Society of Obstetrics and Gynecologists of Canada, Assisted Human Reproduction Canada, and Canadian Fertility and Andrology Society. Attendance 16. Ottawa.
47. Nov 18 Hypertension Prevention and Control in Canada. Concurrent Symposia. Asian Pacific Conference on hypertension, 20 minutes, 100 in attendance Beijing China.
48. Nov Hypertension Prevention and Control in Canada. World Hypertension League, 5 minutes, 30 in attendance Beijing China
49. Nov 22 Hypertension. New Guidelines. Family Practice Review and Update Conference. University of Calgary. 20 minutes 150 in attendance.

2006

1. Jan 17 Hypertension guidelines: CHEP 2006. Calgary, Alberta
2. Feb 1 Lecture, Hypertension, University of Calgary, Calgary, Alberta
3. Feb 1 Lecture, Pharmacology, University of Calgary, Calgary, Alberta
4. Mar 4 Hypertension Guidelines and CHEP: Diovanage Investigators Meeting. Banff, AB, 100 family physicians
5. Mar 8 Hypertension and Surveillance. Statistics Canada CHMS Colloquium Series. Ottawa, ON, 80 Statistics Canada, Health Canada & Public Health Agency Staff
6. Mar 26 But the blood pressure won't come down. Emerald Lake, Alberta, 15 family physicians (Alberta) 45 minutes x 2
7. Apr 28 CHEP Hypertension Recommendations. Cardiac Update Calgary. 50 family doctors and internists. Canadian Heart Research Centre/Libin Institute. Accredited by U of C and CFPC. 20 minutes
8. Apr 29 CHEP Hypertension Recommendations. Cardiac Update Vancouver. 200 family physicians and internists. Canadian Heart Research Centre/Libin Institute. Accredited by U of C and CFPC. 20 minutes
9. May 7 Assessment of Blood Pressure. Crowfoot Medical Clinic, Calgary, AB. 15 physicians and staff. 30 minutes.
10. May 25 CHEP: Strengths, weaknesses, opportunities, threats and an environmental scan. CHEP Executive Strategic Planning Session, 9 attendees. 1.5 hours
11. May 26 CHEP and Nephrology. Plenary Session. Canadian Society of Nephrology. 400 attendees. 25 minutes.
12. Jun Hypertension Surveillance. Canadian Stroke Network. Prevention Theme breakout. 40 attendees, 20 minutes. St. John's, NF
13. Sept 29 CHEP Overview of 2006. Recommendations Task Force, Canadian Hypertension Education Program. 54 scientists and clinicians. 30 minutes. Toronto.
14. Sept 30 CHEP Overview of 2006. Implementation Task Force, Canadian Hypertension Education Program. 12 clinicians & medical educators. 30 minutes. Toronto
15. Oct 4 Cardiovascular Risk Assessment. Collaborative Program for Service Integration. Vancouver Island Health Authority. Victoria, BC, 100 physicians and staff
16. Oct 10 Hypertension. Faculty of Medicine, Mini Med School, University of Calgary. 300 attendees
17. Oct 16 Decreases in Death from Stroke, Acute Myocardial Infarction and Congestive Heart Failure in Relationship to Increases in Total Antihypertensive Drug Prescriptions in Regions of Canada between 1998 and 2003. Oral abstract. International Society of Hypertension. 200 hypertension specialists. Fukuoka Japan 15 minutes
18. Oct 21 The need for public education on hypertension. Canadian Cardiovascular Congress, Canadian Hypertension Society. 100 physicians and nurses. Vancouver, BC, 10 minutes
19. Oct 23 CHEP Introduction and Reducing Bias in Recommendations. Symposium Canadian Hypertension Society, Canadian Cardiovascular Congress. Vancouver, BC 350 attendees 10 minutes
20. Oct 23 Outcomes Research Task Force Report. Symposium, Canadian Hypertension Society, Canadian Cardiovascular Congress Vancouver, BC. 300 attendees. 15 minutes.
21. Oct 29 Diagnosis of Hypertension: Recommendations and Evidence. Novartis Clinical Trial Meeting, Vancouver, BC. 50 family physicians. 45 minutes.
22. Oct 29 Treatment of Hypertension: Recommendation and Evidence. Novartis Clinical Trial Meeting, Vancouver, BC. 50 family physicians. 45 minutes.

23. Nov 4 Sodium as a health risk. Canadian Society for Internal Medicine Short Snapper. Canadian Society of Internal Medicine Annual General Meeting, Calgary, AB, 300 internists. 10 minutes.
24. Nov 8 Journal Club. University of Calgary, Calgary, AB. 20 internists. 30 minutes.
25. Nov 30 TORCH Presentation on CHEP
26. Dec 6 Hypertension Update. PEI Medical Society. Charlottetown, PEI. 60 physicians. 45 minutes.
27. Dec 6 Resistant Hypertension. PEI Medical Society. Charlottetown, PEI. 60 physicians. 45 minutes.
28. Dec 6 What's your blood pressure. Public education session. Heart and Stroke Foundation of PEI. Summerside, PEI. 100 attendees. 2 hours.
29. Dec 7 Hypertension Update. Heart and Stroke Foundation of PEI. Charlottetown, PEI. 70 Multidisciplinary attendees. 2.5 hours.

2005

1. Jan 31 Heart and Stroke Foundation of Alberta – Calgary Annual meeting. Hypertension. Calgary Alberta
2. Feb 25 Alberta Northwest Territory Council of Cardiovascular Nurses Annual Meeting, Plenary lecture. New hypertension recommendations Calgary
3. March Public Health Agency of Canada Prediabetes meeting Panel discussant on Pharmacotherapy. Ottawa Ont.
4. Apr 15 Canadian Society for Clinical Pharmacology -2nd Canadian Therapeutics Congress. Plenary Lecture. The Canadian Hypertension Education Program. A knowledge translation program intended to improve the treatment and control of hypertension in Canada. Vancouver BC
5. May 5 Family Physicians on hypertension, CV Course, Calgary
6. May 25 Family Physicians White coat hypertension (accredited workshop), Pincher Creek
7. Sept Family doctors ASCOT and CHEP hypertension recommendations: Edmonton
8. Sept Canadian Stroke Network. Plenary Lecture Prevention of Stroke, Quebec City.
9. Oct 5 Family Physicians White coat hypertension module: accredited workshop Medicine Hat
10. Oct 12 Winnipeg Fire department training session at the CFD, Hypertension: Calgary
11. Oct 24 Satellite to the Canadian Cardiovascular Congress ASCOT-BPLA trial. The Canadian Perspective, Montreal.
12. Nov Canadian Society for Internal Medicine. Plenary lecture. Canadian Hypertension Education Program. Toronto
13. Nov 30 White coat hypertension module, College of Family Physicians of Canada accredited course 12 physicians. Taber, AB, 2 hours
14. Dec Hypertension guidelines: Maximizing control, University of Calgary, CME Course 30-40 family physicians, Calgary, AB, 1 hour.

2004

1. Jan 19 Hypertension; FHH Hospitalist program 1 hour
2. Jan Hypertension: Evening Course program U of C CME 1.5 hours
3. Jan 24 Canadian Hypertension Education Program. Satellite symposia "Barriers to hypertension prevention and control" of the Canadian Cardiovascular Society "Gap conference", Cancun Mexico
4. Jan 28 Hypertension management in Metabolic Syndrome, Satellite symposia "Metabolic Syndrome" of the Canadian Cardiovascular Society "Gap conference", Cancun Mexico
5. Jan 29/30 Hypertension is exciting (not really). Main session 2-hour workshop (repeated on January 30th) of the Canadian Cardiovascular Society "Gap conference", Cancun Mexico
6. Feb. 3 CHEP and Europa. Saskatoon Family Doctors and Specialists
7. Feb 5 Resistant hypertension and systolic hypertension, Family Docs Calgary Alberta: Noon workshop
8. Mar 4 Hypertension and the 2004 CHEP recommendations, Accredited 1.25 hours Pharmacy CME, -60 pharmacists, Calgary Alberta
9. Mar 6 Office assessment of hypertension, adherence to therapy, and home measurement of hypertension, 3 talks +1 workshop. Southern Alberta Family Physicians
10. Apr 20 Hypertension recommendations. Calgary Regional Family Doctors- 1 hour lecture
11. Apr 21 Hypertension recommendations and management of elderly hypertensive patients. Intercare Chinook.
12. Apr 26 Hypertension: To the Calgary Fire Department National Training Program on blood pressure

assessment program

13. May 12 Hypertension recommendations. GIM Journal Club
14. May 14 Hypertension recommendations. Department of Medicine Noon teaching rounds
15. Jun 2 CHEP and the 2004 hypertension recommendations Family Physicians and Internists Regina
16. Jun 3 CHEP and the 2004 hypertension recommendations Family Physicians and Internists Winnipeg
17. Jul 13 Meeting/consultation with Family Physicians in Victoria (chronic disease management program) Re assessment of hypertension. 2 hours
18. Jul 21 Disability Appeals Board Judges Annual meeting, Oak Island Nova Scotia. Hypertension.
19. Sept 15 Hypertension case studies. Content expert. Calgary Family Physicians
20. Sept 21 Treatment and Control of Hypertension in Canada: The CHEP program. Centre for Chronic Disease Prevention and Control. Health Canada, Ottawa
21. Oct 15 The CHEP program. CCOHTA-COMPU National meeting. Ottawa
22. Oct Clinical Science Workshop. Should ABPM be used in the routine diagnosis of hypertension? Canadian Hypertension Society Annual Meeting/ Canadian Cardiovascular Congress. Organized by N Campbell and jointly presented with Dr Martin Myers
23. Oct 26 Workshop 'Outcomes from the CHEP Program'. Canadian Cardiac Rehabilitation Society Annual meeting / Canadian Cardiovascular Congress workshop on 'Encouraging best practices'.
24. Oct 25 Outcomes from the CHEP Program. Canadian Hypertension Society Annual meeting Symposia, Canadian Hypertension Recommendations Symposia.
25. Oct 22 Presentation 'Healthy choices. The individual vs. the environment'. Canadian Hypertension Society Annual Meeting Symposia. Prevention and Control of Hypertension- Calgary to Canada: Bench to Bedside
26. Oct 22 Organizer and Co-Chair Prevention and Control of Hypertension- Calgary to Canada: Bench to Bedside Symposia Canadian Hypertension Society Annual Meeting.
27. Oct 22 Presentation 'Awareness Treatment and Control of Hypertension'. Hypertension Specialist Clinical Hypertension Symposia. Canadian Hypertension Society Annual Meeting.
28. Nov 2 Hypertension Management recommendations and management of resistant hypertension. IMPACT Investigators. Calgary Alberta

2003

1. Jan 14 General Internal Medicine Journal club. ALLHAT trial
2. Jan 15 National Teleconference re Hypertension control, adherence and combination drugs
3. Jan 22 National Teleconference re Hypertension control, adherence and combination drugs
4. Jan 22 Hypertension: To the coordinators of the Fire Department Blood Pressure Assessment Program rollout to Edmonton and Lethbridge.
5. Jan 30 Hypertension new trials and evidence. Calgary Area Medical Specialists
6. Feb 1 Quebec City. National Hypertension Education Program. Train the trainer Roll Out-Novartis. New Hypertension Trials and potential new recommendations
7. Feb 2 Workshop; Quebec City. National Hypertension Education Program. Train the trainer Case presentation of hypertension in Diabetes, 3 hours
8. Feb 6 University of Calgary Family Practice teleconference rounds. Calgary Hypertension recommendations and ABPM.
9. Feb 6 Drug-Drug interactions. Lethbridge family doctors and specialists
10. Feb 7 Hypertension new trials and evidence. Lethbridge ICU rounds
11. Feb 7 Hypertension new trials and potential new recommendations. Taber Family Practice Clinic
12. Feb 11 Evolution of Hypertension Recommendations. Calgary Area specialists and Family Doctors
13. Mar 7 Update in Hypertension recommendations. Banff Alberta College of Family Physicians- Plenary talk
14. Mar 7 Workshop on hypertension. 2 workshops. Alberta College of Family Physicians
15. Mar 14 Hypertension new evidence and recommendations. Cardiology Rounds, St Paul's Hospital, Vancouver
16. Mar 14 Resistant hypertension, Cardiology Fellows Academic Half Day University of British Columbia, talk/workshop
17. Mar 14 Hypertension new evidence and recommendations, Community Medical Specialists and Cardiologists. Vancouver
18. Mar 15 Hypertension new evidence and recommendations. Cardiology Rounds, Vancouver General

Hospital

19. Mar 15 Hypertension new evidence and recommendations. Cardiology Rounds, Surrey General Hospital, Vancouver
20. Apr 15 Drug-drug interactions: Calgary Family Doctors
21. Apr 28 Family Medicine/ UofC Rural Audio Rounds. Hypertension Update. Two 1-hour sessions
22. May 14 Hypertension and new recommendations. Health Plus Calgary
23. May 15 Drug-drug interactions. Medicine Hat Family Physicians
24. May 22 Hypertension trials and the 2003 CHEP hypertension management recommendations. Calgary Region specialists
25. Jun 3 Hypertension recommendations. Willow Park Family Practice Clinic (Calgary)
26. Jun 4 Hypertension recommendations: Family Physicians, Edmonton
27. Jun 5 Medical Grand Rounds: Royal Alexander Hospital, Edmonton
28. Jun 23 Family Physicians Calgary. Hypertension recommendations
29. Jun 25 Family Physicians Calgary. Hypertension recommendations
30. Jun 26 Stroke Rounds, Hypertension management, Calgary Health Region
31. Jul 3 Medial Specialists Calgary. Hypertension recommendations and new evidence
32. July 17 World Heart Foundation Clinical Epidemiology Course. Victoria BC. The Canadian Hypertension Education program.
33. July 16-19 World Heart Foundation Clinical Epidemiology Course: Critical appraisal small group workshop faculty.
34. Aug 12 White coat hypertension-pilot workshop for national rollout (Mainpro-C U of C/Laval). 2 hours U of C- Family doctors
35. Aug 30 Vienna Austria: Canadian Hypertension Education Program. Outline. Aventis Advisory Board meeting
36. Sept 6 White coat hypertension. Montreal Quebec. National train the trainer session of U of C CME approved course/. Lecture and 3 45-minute workshops.
37. Sept 13 Hypertension management in the secondary prevention of Cardiovascular and renal disease. Department of Medicine Retreat, Sault St Marie
38. Sept 29 Blood pressure measurement: Nurses from Health Promotion and Disease Prevention Division, Healthy Communities, CHR
39. Sept 30 Hypertension Management, Rocky Mountain House Family Physicians
40. Oct 7 Hypertension management. Chinese Medical Society, Edmonton Alberta
41. Oct 8 Hypertension management. Family Physicians, Edmonton
42. Oct 9 Cardiology Rounds. Secondary Prevention In hypertension. Royal Alexander Hospital Edmonton
43. Oct 9 Isolated systolic Hypertension: Treat to target Program. Red Deer Alberta, Family Doctors
44. Oct 16 Hospital Hypertension 2.5 hours- Nurse practitioner course, Calgary Health Region, Calgary.
45. Oct 23 Management of hypertension. College of Family Physicians National meeting. 1 hour lecture/questions, Calgary Alberta
46. Oct 26 Canadian Hypertension Education Program. Outcomes research report. Canadian Cardiovascular Congress. Toronto
47. Oct 27 Canadian Hypertension Education Program. Recommendations for risk assessment and treatment targets. Meet the expert session of the Canadian Cardiovascular Congress. Toronto
48. Oct 29 Europa. Calgary area medical specialists
49. Nov 1 The PROFILE trial, Investigators meeting, Lake Louise. Epidemiology of hypertension
50. Nov 1 The PROFILE trial, Investigators meeting, Lake Louise; The PROFILE trial.
51. Nov 1 The PROFILE trial, Investigators meeting, Lake Louise, Workshop on how to improve recruitment.
52. Nov 2 The PROFILE trial, Investigators meeting, Lake Louise, Workshop on PROFILE and how to improve recruitment.

2002

1. Jan 26 Regina: Family Physicians. Small group workshops on the management of isolated systolic hypertension-4 hours
2. Feb 1 Advances in Cardiovascular Medicine Phoenix AZ. Talk: CHS recommendations where do all the medications fit. 35 minutes. Sponsored by Bioval and by the CCS (course accredited for 6.5 group learning

hours)

3. Feb 1 Advances in Cardiovascular Medicine, Phoenix AZ. Workshop: Controversies in Hypertension recommendations: 45 minutes. Sponsored by Bioval and by the CCS (course accredited for 6.5 group learning hours)
4. Feb 4 Hypertension recommendations and new clinical trials. Calgary Area Family Doctors, Lecture 1 hour.
5. Feb 9 Chair and Facilitator, Hypertension-drug interaction workshop, Cardio active program, Montreal Quebec
6. Feb 9 Calgary Fire Department blood pressure measurement program. Presentation + group discussion to the Canadian Stroke Network, London Ontario
7. Mar 16 Systolic hypertension, American College of Cardiology satellite meeting, Atlanta GA,
8. Mar 16 Canadian recommendations for the management of hypertension. American College of Cardiology satellite meeting, Atlanta GA,
9. May 3 McKiden conference, Calgary. Canadian hypertension recommendations 1 hour repeated.
10. May 4 New Clinical trials and recommendations. Ontario Hypertension Society, Alison Ontario
11. May 5 Canadian Hypertension Society recommendations. Ontario Hypertension Society. What's new and what's important. Alison Ontario
12. Jun 4 Drug-Drug interactions. Calgary Area Family Doctors. 1.5 hours didactic + workshop
13. Jun 4 Cardiovascular risk assessment and management: a national internet session to *Family Doctors*. 1.5 hours
14. Jun 6 Calgary Fire Department Blood Pressure Assessment Program. Canadian Stroke Network annual meeting.
15. Jun 12 Cardiovascular risk assessment and management: a national internet session to Family Doctors. 2 hours
16. Jun 13 The Southern Alberta Cardiovascular Institute, An opportunity for Cardiovascular Disease Prevention and Control. Presented with at the Calgary Cardiovascular Network annual meeting. ½ hour.
17. Jun 18 Cardiovascular risk assessment and management: a national internet session to Family Doctors. 1.5 hours
18. Jul 29 Invited Presentation on Ministers expert committee to the Ministers Expert Panel on Health Services. 1 hour
19. Aug 1 Hypertension management. Family Practice academic half day 1.5 hours
20. Aug 26 Meeting of Medical specialists and family physicians' CV at Goal program: Office measurement of hypertension, Kananaskis
21. Aug 26 Meeting of Medical specialists and family physicians' CV at Goal program: Self-measurement of blood pressure. Kananaskis
22. Aug 26 Meeting of Medical specialists and family physicians' CV at Goal program: Treat to target (Canadian Hypertension recommendations) Lecture and workshop. Kananaskis
23. Sept 12 Drug-Drug Interactions-Academic half day for Internal Medicine residents 1.5 hours
24. Sept 14 Chair Meeting of Medical specialists and family physicians' CV at Goal program. Speaker on office measurement of hypertension (30 minutes), Workshop 1 hour. Self measurement of blood pressure (30 minutes), Treat to target (Canadian Hypertension recommendations) 15 minutes, workshop 1 hour. CV at goal 1 hour. Winnipeg.
25. Sept 26 3 hours of teaching 1 didactic and 2 workshop on the management of hypertension to the nurse practitioner training course.
26. Sept 28 Meeting of Medical specialists and family physicians' CV at Goal program. Office measurement of hypertension (30 minutes), Workshop 1 hour. Treat to target (Canadian Hypertension recommendations) 15 minutes, workshop 1 hour. CV at goal 1 hour. Mannitou, Ontario.
27. Sept 27 1 hour didactic/workshop. Drug-Drug interactions – MTU trainees
28. Oct 24 1 hour lecture on high blood pressure to the first roll out of the Calgary Fire Department Blood Pressure measurement program to other communities (Yellowknife, Crossfields), Calgary
29. Oct 27 Hypokalemia is it overrated? Canadian Cardiovascular Congress Satellite meeting
30. Oct 28 Patient compliance and combination therapy. Canadian Cardiovascular Congress Satellite meeting
31. Oct 28 Canadian Hypertension recommendations 2002: What's new and what's important? Plenary symposia of the Canadian Hypertension Society and the Canadian Cardiovascular Society at the Canadian Cardiovascular Congress

32. Oct 30 Hypertension trials: Plenary symposia of the Canadian Cardiovascular Society at the Canadian Cardiovascular Congress
33. Nov 15 Diagnosis of renovascular hypertension. 10-minute talk Rocky Mountain Internal Medicine/CSIM/ACP/ASIM Regional meeting
34. Nov 16 Burden of illness, new and old clinical trials and the ALLHAT trial. 1 hour didactic and 2 hours of workshop. Pfizer Canada Advisory Board. Chicago Illinois.
35. Nov 18 Hypertension Management, 1 hour workshop repeated once, Family Practice Update, University of Calgary
36. Nov 27 Drug-Drug Interactions. 1 hr talk/workshop. Calgary area family doctors.

2001

1. Jan 20 The hype in hypertension, Calgary area Family Physicians Lecture and Case based hypertension workshop.
2. Feb 3 Hypertension: Implementing and Implications of Guidelines. 15-minute talk with 45-minute open discussion. Calgary area Internists
3. Feb 15 Journal Club Division of General Internal Medicine
4. Feb 21 Western Canada Investigators teleconference. Lecture, Avapromise trial results and implications.
5. Mar 14 Hypertension recommendations lecture and workshop. Train the trainer sessions in the Canadian Hypertension Recommendations, American College of Cardiology, Orlando Florida
6. Mar 24 Hypertension the latest and greatest. Family physicians Calgary.
7. Apr 6 What's the hype in hypertension? University of Saskatchewan CME "Collaborative management of hypertension and heart failure. 1-hour
8. Apr 6 Nonpharmacological treatment strategies Workshop 1 hour repeated once. University of Saskatchewan CME "Collaborative management of hypertension and heart failure.
9. Apr 6 Revelations from new clinical trials Workshop 1 hour repeated once. University of Saskatchewan CME "Collaborative management of hypertension and heart failure".
10. May 2 Blood pressure measurement in-service. Foothills hospital outpatient staff.
11. May 23 Hypertension in the elderly, talk/workshop- 1 hour Family Doctors Carbonear NFLD
12. May 24 New clinical trials and public health issues in hypertension, Division of Nephrology, Memorial University of Newfoundland, St John's NFLD
13. May 24 Hypertension Issues and management recommendations, Department of medicine, St. Clares hospital St John's NFLD.
14. May 24 Hypertension in the elderly, talk/workshop- 1 hour Family Doctors St John's NFLD
15. Jun Achievements of the Western Canadian Cardiovascular forum. Campbell River BC
16. Jul 14 Hypertension recommendations and new trial evidence. Specialists Calgary Alberta
17. Sept 6-7 Hypertension recommendations, Toronto. Specialists and Family Physicians
18. Oct 2 Medical Grand Rounds FHH, Hypertension case, philosophy, recommendations and new trials
19. Oct 4 St Paul's Hospital Vancouver-Cardiology Rounds Hypertension recommendations and new trials
20. Oct 4 St Paul's Hospital Vancouver-Renal Rounds Hypertension recommendations and new trials
21. Oct 5 Vancouver General Hospital Cardiology Rounds Hypertension recommendations and new trials
22. Oct 15 Progress trial Background and rational Calgary Area specialists
23. Oct 19 Canadian Hypertension recommendations process. Methods for 2001 and outcomes from 2000. Halifax NS
24. Oct 21 Aldosterone as a risk factor in hypertension. Lecture and panel discussion, CCC satellite symposium Halifax NS
25. Oct 22 Chair Canadian Hypertension recommendations CHS symposia Lecturer Process and overview of methods
26. Oct 23 Progress trial, CCC lecture satellite symposia
27. Nov 5 Blood pressure measurement- Field trainers Calgary Fire Department
28. Nov 7 New clinical trials and hypertension recommendations. Calgary area specialists.
29. Nov 16 Canadian Coalition for High Blood Pressure Prevention and Control. Report on the Calgary cardiovascular network, and the Canadian hypertension recommendations process.
30. Dec Hypertension Grand rounds St Boniface Hospital Winnipeg
31. Dec Clinical rounds-case presentations. St Boniface Hospital Winnipeg

2000

1. Jan 22 Canadian hypertension recommendations. An overview. Internal medicine and cardiologists. Palm Springs Calif.
2. Jan 22 Workshop on educating family physicians to treat hypertension according to Canadian recommendations Internal medicine and cardiologists. Palm Springs Calif.
3. Jan 29 Hypertension: An overview. Canadian Hypertension Recommendations Committee, Ottawa
4. Jan 29 Process for the development of new hypertension recommendations. Canadian Hypertension Recommendations Committee, Ottawa
5. Mar 11 Canadian hypertension recommendations. An overview. Internal medicine and cardiologists. Satellite to American College of Cardiology meeting. Anaheim
6. Mar 11 Workshop on educating family physicians to treat hypertension according to Canadian recommendations Satellite to American College of Cardiology meeting Anaheim.
7. Mar 26 Canadian hypertension recommendations. An overview. Internal medicine and cardiologists. Satellite to American College of Cardiology meeting. Lake Louise
8. Mar 26 Workshop on educating family physicians to treat hypertension according to Canadian recommendations Satellite to American College of Cardiology meeting Lake Louise
9. Apr 5 11th Annual Therapeutics Course, Queens University
10. Apr 6 Does office diagnosis of hypertension require 24-hour blood pressure monitoring? Is lifestyle modification worth it for BP control? New BP targets replace 140/90? Issues and challenges in the management of hypertension. Queens University/ Kingston General Hospital, Grand medical Rounds.
11. Apr 6 House staff intake rounds. An interesting case of hypertension. Kingston General Hospital,
12. May 6 Canadian hypertension recommendations Vancouver, cardiologists
13. May 6 Workshop on Hypertension in Elderly Vancouver, cardiologists
14. May 9 Causes and consequences of blood pressure control in Canada, Victoria BC Family Physician CME session
15. May 9 Measurement of Blood pressure (office. Self and ambulatory), Victoria BC Family Physician CME session
16. Jun 8, 1999, Canadian recommendations for the treatment of hypertension. Family physicians Vancouver Canada
17. Jun 8, 1999, Canadian recommendations for the treatment of hypertension (2). Family physicians. Vancouver Canada
18. Jun 15 Hypertension in Canada recommendations and new clinical trials. Specialists in Calgary.
19. Jul 29 Hypertension recommendations and new trials. Internists from Calgary and Edmonton. Calgary
20. Aug 26 Unmet needs in hypertension. Internists Western Canada. CV symposia.
21. Aug 31 North American Stroke Conference. Hypertension workshop. Toronto 1.5 hours
22. Sept 9 Importance of systolic blood pressure and barriers to control. Value trial investigators. Toronto
23. Sept 27 Hypertension in the Elderly, Treatment recommendations and new clinical trials. Calgary Area physicians Imax Theatre
24. Oct 14 Optimum management of hypertension. The new Canadian guidelines. St John New Brunswick. The 10th annual cardiovascular symposium.
25. Oct 22 Current recommendations for clinical management of high blood pressure. Canadian Coalition for High Blood pressure Prevention and Control- Canadian Public Health Association annual meetings. Part of a symposia Hypertension Public enemy # 1.
26. Oct 28 Hypertension recommendations and new clinical trials. Satellite symposia to the Canadian Cardiovascular Congress
27. Nov 3 The Burden of Disease. Presentation at the Public forum on cardiovascular disease, Libin Theatre.
28. Nov 17 Edmonton Therapeutics course. Update in Clinical Pharmacology.
29. Nov 21 Public Forum on Hypertension, 2 hours Libin Theatre, Calgary
30. Nov 23 The P-450 System. Family Practice Update. Libin Theatre,
31. Nov 25 Update in Hypertension, Rocky Mountain General Internal Medicine Meeting
32. Dec 6 New Clinical Trials in Hypertension, Division of Nephrology

1999

1. Jan 21 Canadian Guidelines for treatment of hypertension, Internists Calgary
2. Mar 18 Calgary Therapeutics Course. Old vs. new antihypertensive agents.
3. Mar 25 Canadian Hypertension Society Recommendations, Calgary Internists and Family Physicians,
4. Apr Canadian recommendations for diagnosis and treatment of hypertension. The Avapromise trial. Emerald Lake, Family Physicians.
5. Apr 10 CHF treatment-patient issues. Cardiologists and Internists Mont. Tremblay Quebec
6. May 7 Chair, Treatment of risk factors in the elderly. World Hypertension League/ Inter American Hypertension Society. Buenos Aires,
7. May 14 Production of Canadian Hypertension Guidelines. Canadian Coalition for High Blood pressure prevention and Control Annual Meeting
8. May 28 Cardiovascular Risk factors. Internists, Lake Louise,
9. Aug 7 Issues and challenges in the Hypertension. Kananaskis-Cardiologists- Internists.
10. Aug 7 Office Measurement and Self-Measurement of Blood Pressure, 2 one-hour workshops Kananaskis-Cardiologists-Internists.
11. Oct 1 Canadian Council of Cardiovascular nurses Nova Scotia Regional Meeting Hypertension Guidelines for the next millennium. 1 hour,
12. Oct 1 Canadian Council of Cardiovascular Nurses Nova Scotia Regional Meeting. Lifestyle modification to prevent and control hypertension 45 minutes.
13. Oct 2 Family Physicians, Digby Nova Scotia. Canadian Guidelines for the treatment of Hypertension.
14. Oct 21 Canadian Council of Cardiovascular nurses- National meeting. Quebec City. Hypertension workshop. Issues challenges and new hypertension guidelines
15. Nov 18 General Medicine Journal Club, the CAPPP trial.
16. Nov 18 Resistant Hypertension, Family Physicians Foothills Hospital
17. Dec 2 Hypertension challenges and guidelines. University of Calgary Residents and Internists
18. Dec 9 Hypertension challenges and guidelines. Family Doctors, Calgary

1998

1. May 1 Unmet needs in Hypertension. Irbesartan Advisory Board meeting. NAPA California
2. May The role of the Pharmaceutical Industry in Patient Education. Prairie Cardiovascular Forum, Banff Alberta
3. Jun From Hypertension to Heart Failure. Trochu/Three Hills. Family Physicians
4. Jul 23 Reducing the risk of end organ damage: the importance of 24-hour blood pressure control. Family Doctors, Calgary Alberta.
5. Sept 2 Pharmacotherapy of Hypertension, Third International Heart Health Conference Singapore
6. Sept 4 Hypertension and Benefits of Treatment Sponsored by All India Institute for Medical Sciences and the Congress of Indian Industry, National Workshop on Corporate Commitment to Heart Health, New Delhi
7. Sept 7 Workshop on Hypertension Management. Alla Gappa, Karacudi, India,
8. Sept 8 Management of High Blood Pressure Maduri Medical College, Maduri, India,
9. Sept 8 Management of Hypertension. Maduri Branch of the India Medical Association, Maduri, India
10. Sept Management of Hypertension, Omayal Achi College of Nursing and Sundaram Medical Foundation, Chennai (Madras) India,
11. Sept 15-16 Management of Hypertension Omania Medical College, Hyderabad, India, Medicentre, Hyderabad, India,
12. Sept 18 Modern Trends in Hypertension Management Bombay, India
13. Oct 17 Unmet needs in Hypertension. Family Physicians. Emerald Lake.
14. Oct 23 Secondary Prevention: Closing the gap between guidelines and practice. Hypertension post myocardial infarction. Canadian Association of Cardiac Rehabilitation. Ottawa Canada
15. Oct 23 Blood pressure variability, 24-hour ambulatory monitoring, and monitoring guidelines. Zeneca Pharmaceuticals/ Cardiovascular specialist meeting, Ottawa Canada
16. Oct 24 Canadian Guidelines for Diagnosis and Follow-up of Hypertension. Canadian Hypertension Society, Ottawa Canada.
17. Nov 7 Differences in blood pressure when measured by physicians' usual technique and a standardized technique. Rocky Mountain Internal Medicine Conference

1997

1. Jan 3 Nonpharmacological therapy for the prevention and control of hypertension. Presentation on purpose and process. 1 hour Ottawa, To the Canadian Working group on Nonpharmacological therapy to prevent and control hypertension.
2. Jan 4 Alcohol and hypertension: The evidence. Speaker to Canadian Working group on Nonpharmacological therapy to prevent and control hypertension.
3. Jan 5 Alcohol and hypertension; Recommendations for prevention and control of hypertension. Speaker to Canadian Working Group on Nonpharmacological therapy to prevent and control hypertension.
4. Jan 24 Management of Hypertension; Health Plus, Calgary Alberta; Family Physicians Workshop 1.5 hours
5. Feb 28 Safety of Folic acid fortification. Health Canada, LCDC Ottawa Ontario
6. Apr 11 Calgary Therapeutics Course, Therapeutics in the Elderly.
7. Apr 21 Hypertension work-up and assessment of end organ damage, University of Calgary CME session Innisfail Alberta.
8. May 4 Commonalties and differences in guidelines for hypertension treatment in the Pacific Rim (Canada). Panel discussant. 2nd Pacific Rim Hypertension Conference. Manila Philippines
9. May 5 Epidemiology of hypertension in Pacific Rim Countries (Canada). Panel discussant 2nd Pacific Rim Hypertension Conference Manila Philippines
10. May 13 Hypertension Update, Foothills Hospital Nursing In-service
11. Jun 30 Epidemiology of congestive heart failure in Canada. World Hypertension League Annual Meeting. Montreal Canada
12. Jul 3 Alcohol and Hypertension. Satellite symposia on Nonpharmacological Therapy for Hypertension of the 4th International Conference on Preventive Cardiology
13. Sept 3 Individualization of Drug Therapy. Lessons learned from Heparin. Medical Rounds. University of Calgary Foothills Hospital.

1996

1. Feb 23 Calcium Channel Blockers in hypertension. The controversy. National teleconference
2. Mar 13 Calcium Channel Blockers in hypertension. The controversy. National teleconference
3. Mar 25 Lethbridge Alberta, Angiotensin receptor blockers. A new class of antihypertensive agent.
4. Apr 1 The future of diuretics in hypertension treatment in Canada. Panel discussant moderator. The University of Calgary,
5. May 19 Unique features of hypertension in the elderly. Lecture Alberta Internal Medicine Meeting Kananaskis
6. May 19 Hypertension in the elderly. Workshop, Alberta Internal Medicine Meeting Kananaskis
7. Jun 13 Individualization of Drug Therapy. Lessons learned from Heparin. Medical Rounds. Memorial University.
8. Jun 20 Measurement of blood pressure; causes and consequences of error. Calgary Public Health Nurses, 1.5 hours
9. Sept Accuracy of self-measured blood pressure. Royal College of Physicians & Surgeons, Halifax,
10. Sept Ferrous sulfate-captopril interaction. Royal College of Physicians & Surgeons, Halifax,
11. Oct Angiotensin receptor blockers. Second Annual Rocky Mountain General Internal Medicine Conference. Banff, Alberta.
12. Oct 21 Clinical Medicine Rounds; Health Science Centre University of Manitoba,
13. Oct 22 Grand Medical Rounds; Treatment of Patients with White Coat Hypertension Health Science Centre University of Manitoba,
14. Nov 12 24-hour ambulatory blood pressure monitoring. Division of Nephrology. University of Calgary.

1995

1. Mar Calgary District Hospital Group, Grand Medical Rounds, Evolving Concepts in Hypertension,
2. Mar National Workshop on the Primary Prevention of Neural Tube Defects. Safety of folic acid supplementation. Ottawa,
3. Jun World Conference on Blood Pressure Control; Plenary Symposia on blood pressure measurement: Self-measurement of blood pressure. Ottawa
4. Jun 27 American College of Physicians Regional Meeting. Banff Alberta, Issues in Hypertension.

5. Jun 27 American College of Physicians Regional Meeting. Banff Alberta, Hypertension Workshop.
6. Aug 30 Regina, Medical specialists, Renal Excretion of Cardiovascular Drugs,
7. Sept Montreal, Patient factors relating to adherence to blood pressure lowering therapy. National consensus panel.
8. Sept 28 Brandon Manitoba, Renal excretion of cardiovascular drugs. Medical specialists.
9. Sept 28 Winnipeg, Manitoba, Renal excretion of cardiovascular drugs. Pharmacists.
10. Sept 30 Calgary, When and how to select an ACE Inhibitor; Family physicians,
11. Oct 14 Western Canadian Internal Medicine Specialists Conference, Banff All patients with an elevated office blood pressure should be investigated with 24 Hr ABPM and treated accordingly [debate]
12. Oct 15 Western Canadian Internal Medicine Specialists Conference, Banff Workshop on 24-hour ambulatory BP monitoring.
13. Nov 2 St. John's Newfoundland. Controversies in hypertension. Medical specialists
14. Nov 3 St. Clares Mercy Hospital, St John's Newfoundland, Medical Grand Rounds. Angiotensin II receptor blockers: a new class of antihypertensive medication.
15. Nov 3 Memorial University. Angiotensin II receptor blockers: a new class of antihypertensive medication. Grand Medical Rounds.
16. Nov 23 University of Calgary. Family Practice Update. Angiotensin II receptor blockers: a new class of antihypertensive medication.
17. Dec 20 University of Calgary. Division of General Internal Medicine. Angiotensin II receptor blockers: a new class of antihypertensive medication.

1994

1. Jan Calgary, Western Canadian Merck Frosst representatives. Renal effects of ACE inhibitors
2. Jan Faculty of Medicine, University of Calgary, Family Practice CME, Teleconference, Multiple medical problems and polypharmacy
3. Jan Faculty of Medicine, University of Calgary, Clinical Trials Course, Lecturer and Tutor
4. Mar Faculty of Medicine, Calgary Therapeutics Course, Treatment of systemic hypertension
5. Apr Moosejaw, Saskatchewan, Internist/Anesthetists, Perioperative hypertension
6. Jun Canadian Coalition for High Blood Pressure Prevention, Annual Meeting, Workshop on blood pressure measurement. Edmonton
7. Jun Canadian Coalition for High Blood Pressure Prevention, Annual Meeting, Panelist on the Coalitions recommendations. Edmonton
8. Jun Canadian Coalition for High Blood Pressure Prevention, Annual Meeting, Measurement of Blood Pressure in the Elderly. Edmonton
9. Jun Southern Alberta Geriatric Program. Pre-operative assessment of the geriatric patient with hip fracture
10. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Age and gender effects on heparin levels and apt response in patients with proximal deep vein thrombosis. Toronto
11. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Changes in methyldopa renal clearance and absorption following eight weeks of ingestion. Toronto
12. Oct Drumheller, Public Forum on Cardiovascular Disease, Alberta Cardiovascular Society, Hypertension
13. Oct Southern Alberta Geriatric Program. NSAIDS and Cardiovascular Disease
14. Nov Faculty of Medicine, University of Calgary, Family Practice CME course, Hypertension treatment: the old Vs the new. Calgary,
15. Dec Calgary Pharmacists, Treatment of systemic hypertension.

1993

1. Jan University of Alberta. 'Regulation of drug transport.' Journal Club, Faculty of Pharmacy
2. Jan Faculty of Medicine, University of Calgary, Family Practice CME, Hypertension. Teleconference,
3. Mar Teleconference to New Brunswick. Use of ACE inhibitors in hypertension
4. Apr Brooks Alberta, Family Physicians, Hypertension Update
5. Apr Faculty of Medicine, Calgary Therapeutics Course, Drug interactions in the Elderly
6. Apr Calgary Family Physicians, Hypertension.

7. Apr Calgary Family Physicians, Measurement of blood pressure/Treatment of systemic hypertension.
8. Jun Calgary Family Physicians, Treatment of systemic hypertension and the role of other cardiovascular risk factors.
9. Jul Calgary, Intravenous Enalaprilat, Western Canadian Merck Frosst representatives
10. Aug The International Society of Cardiovascular Pharmacotherapy. Minneapolis Minn. The effect of acute furosemide and fasting on serum lipid and lipoprotein levels.

1992

1. Mar Calgary General Hospital, Family Practice Grand Rounds, Hypertension
2. Apr Calgary Therapeutics' Course, Hypertension.
3. Apr Calgary Therapeutics' Course, Preoperative assessment of drug therapy
4. Sept Foothills Hospital Calgary, Iron interactions with thyroxine. Endocrinology Laboratory Rounds
5. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Ferrous sulfate reduces cimetidine absorption.
6. Oct Medicine Hat, Family Physicians, Hypertension update
7. Oct Faculty of Medicine, Family Practice Update, Adverse effects and withdrawal of corticosteroids
8. Oct Calgary Family Physicians, Thyroid Disorders in Pregnancy
9. Nov Faculty of Medicine, University of Calgary, Family Practice Update. Adverse effects and withdrawal of corticosteroids.
10. Nov Lethbridge; Family Physicians, Hypertension update,
11. Nov Western Canadian Geriatric Conference, Lake Louis, The SHEP study,

1991

1. Jan Calgary Family Physicians. Assessment of blood pressure
2. Jan Calgary Family Physicians. Pitfalls in the measurement of blood pressure
3. Jan Calgary Family Physicians. Safe use of drugs in renal impairment.
4. Feb Calgary Family Physicians Update in Internal Medicine. Assessment of high blood pressure. CME. Calgary Alberta
5. Feb Foothills Hospital/University of Calgary. Medical Grand Rounds. Iron-drug interactions
6. Apr Calgary Therapeutics' Course. Hypertension in the Elderly.
7. Apr Calgary Pharmacists. Iron-drug interactions
8. Apr Calgary Therapeutics' Course. Sustained release preparations: The good and the bad.
9. May 9 Red Deer Hospital Grand Rounds, Medical Misadventure in measurement: The assessment of high blood pressure.
10. Jun American College of Physicians Region Meeting Banff, Hypertension Workshop,
11. Jun American College of Physicians Region Meeting Banff, Workshop on Geriatric Clinical Pharmacology.

1990

1. Apr Faculty of Medicine, Memorial University of Newfoundland. Renal Rounds. Iron-drug interactions.
2. Sept Faculty of Medicine, University of Calgary, Renal Research Rounds. A potential Iron-captopril interaction
3. Sept Faculty of Medicine, Gastrointestinal Research Rounds, Iron-drug interactions that reduce drug absorption.
4. Sept Faculty of Medicine, University of Calgary, Family Practice Rounds Banff, Calcium Channel Blockers in hypertension.
5. Nov Faculty of Medicine, University of Calgary, Hypertension Study Group Rounds. Blood pressure measurement.

1989

1. Feb Faculty of Medicine, Memorial University of Newfoundland. Family Practice teleconference. Antihypertensives: one as good as another?
2. Feb Faculty of Medicine, Memorial University of Newfoundland. Family Practice teleconference. Referral for hypertension
3. Sept Mayo Clinic, Department of Pharmacology, Iron-drug interactions

4. Sept Stanford University, Research Seminar, Human Phenol Sulfotransferases in drug metabolism
5. Nov Newfoundland Pharmacy Association. Drug interactions with antihypertensives
6. Dec McMaster University, Iron interactions with drugs which reduce drug absorption,

1988

1. Mar American Society for Clinical Pharmacology and Therapeutics'. Reduction in levodopa bioavailability associated with ferrous sulfate administration.
2. Apr Memorial University, Surgical Grand Rounds, Update on the Pharmacological Therapy of Hypertension
3. Apr The University of Manitoba, Faculty of Medicine Research Rounds, The Role of Human Phenol Sulfotransferases in Drug Metabolism
4. Apr The University of Manitoba, Faculty of Medicine, Clinical Research Rounds, Newer Interactions between Iron and Other Drugs
5. May The University of Texas at San Antonio, Pharmacology Research Seminar, Human Phenol Sulfotransferases in Drug Metabolism
6. Aug Memorial University, Medical Grand Rounds, Ferrous Sulfate-Drug Interactions: Something for Everyone.
7. Sept Drug Directorate, Department of Health and Welfare, Ottawa. Iron interactions with drugs.
8. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Ferrous sulfate reduces levodopa bioavailability.

1987

1. May Grand Falls, Family Physicians, Diuretics and Hypertension
2. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Methyldopa: Effects of ferrous sulfate and ferrous gluconate on absorption and metabolism.
3. Oct Clarenville Section of the Newfoundland Medical Association, Hypertension Update,

1986

1. Feb Memorial University, Anesthesia Grand Rounds, Hypertension for the Anesthetist
2. Feb Memorial University, Medical Grand Rounds, Conns Syndrome
3. Apr Memorial University, Surgical Grand Rounds, Surgical Hypertension
4. Aug Labrador City, Family Physicians, Resistant Hypertension
5. Sept The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Human Phenol Sulfotransferase (PST): Correlation of liver and platelet activities.

1985

1. Aug Memorial University, Medical Grand Rounds, Hypertension
2. Sept Memorial University, Update in Nephrology, Essential Hypertension Management
3. Nov Memorial University, Medical Grand Rounds, Polyarteritis and Hypertension,
4. Nov Faculty of Medicine, Memorial University of Newfoundland. Family Practice teleconference. Hypertension Update.

1984

1. Federation of the American Societies of Biological Sciences. Human liver phenol sulfotransferase (PST): Partial purification of the "TS" form. 1984.
2. The Royal College of Physicians and Surgeons of Canada, Canadian Society for Clinical Investigation. Methyldopa metabolism: Importance of sulfate availability.

1983

1. II World Conference in Clinical Pharmacology and Therapeutics'. Catechol-o-methyltransferase, phenol sulfotransferase and methyldopa metabolism in man.

1982

1. Western Society for Clinical Investigation. Potassium conservation in thiazide induced hypokalemia in uncomplicated essential hypertension.

X PUBLICATIONS:

i. **MANUSCRIPTS AND COMMUNICATIONS IN PEER REVIEWED JOURNALS: (original research in bold)**

571. Song J, Wang C, Pombo-Rodrigues, MacGregor GA, Campbell NRC, He FJ. **Formulas to estimate dietary sodium intake from spot urine lead to misleading associations with cardiovascular disease risk and mortality** J Hypertension. In Press

570. Campbell NRC. Inappropriate design, methods and literature review with predictably unreliable results and conclusions. JAMA Open. Comment on 2024;7(7):e2421589. doi:10.1001/jamanetworkopen.2024.21589.

569. Clapham E, Picone D, Carmichael S, Stergiou G, Campbell N, Stevens J, Batt C, Schutte A, Chapman N. Home blood pressure measurements are not performed according to guidelines and standardized education is urgently needed. Hypertension. In Press

568. Jefferies B, Campbell NRC. Re-calculation of sodium risks needs better reconciliation with consumption levels and risk parameters. J Hypertension. [letter] 2025;43:177

567. Mclean RM, Song J, Wang C, He FJ, Cappuccio FC, Campbell NRC, MacGregor GA. Formula-led methods using first morning fasting spot urine to assess usual salt intake: a secondary analysis of PURE study data. J Hypertension. 2024;42:2003-10.

567. Cloutier L, Tsuyuki R, Campbell NRC, Gelfer M. Canadian groups help develop free online certification course for home measurement of blood pressure. Canadian Nurse. 2024 May

566. Hutchinson B, Walter A, Campbell N, Whelton PK, Varghese C, Husain MJ, Nugent R, Kostova D, Honeycutt A. Scaling hypertension treatment in 24 low- and middle-income countries: economic evaluation of treatment decisions at three blood pressure cut points. BMJ Open. 2024 Apr 15;14(4):e071036. doi: 10.1136/bmjopen-2022-071036.

564. Owolabi M, Olowoyo P, Dzudie A, Okekunle A, Obiako R, Mocunbi A, Beheiry H, Parati G, Lackland D, Sarfo F, Odili A, Agyemang C, Campbell N et al. ACHIEVE Conference Proceedings: Implementing Action Plans to Reduce and Control Hypertension Burden in Africa. J Hum Hypertens. 2024; <https://doi.org/10.1038/s41371-024-00903-8>.

563. Olowoyo P, Barango P, Moran A, Williams B, Whelton PK, Owolabi M, on behalf of ACHIEVE (N Campbell, ACHIEVE member) Priorities to reduce the burden of hypertension in Africa through ACHIEVE. The Lancet Global Health 2024;12: e192-e193

562. Campbell NRC, He FJ, McLean RM, MacGregor GM. Is there a safe level for adding sodium to food versus is it safe to reduce dietary sodium intake? J Hypertens. 2024;42(4):607-608. doi: 10.1097/HJH.0000000000003678.

561. Campbell NRC, McKay DW, Petrella R, Kaczorowski J. The urgent need to reestablish a health coalition focused on hypertension prevention and control in Canada. CJC. CJC. 2024;40:610-12

560. Ordunez P, Campbell NRC, DiPette D, Jaffe MG, Rosende A, Martinez R, Gamarra A, Lombardi C, Parra N, Rodriguez L, Rodriguez Y, Brettler J. HEARTS in the Americas. Targeting health system change to improve population hypertension control. Current Hypertension Reports. 2023: <https://doi.org/10.1007/s11906-023-01286-w>

559. Campbell NRC. The associations between dietary sodium and atherosclerosis. Are the methods used accurate and reproducible? 2023 EHJ Open. [letter] DOI:10.1093/ehjopen/oead110
558. Campbell NRC, He FJ, McLean RM, Cappuccio FP, MacGregor GM. Less sodium and more potassium to reduce cardiovascular risk and the PURE study. EHJ Open. 2023;3:1-2 [letter] DOI:10.1093/ehjopen/oead096.
557. Charchar FJ, Prestes PR, Mills C, Mooi CS, Neupane D, Marques FZ, Sharman JE, Vogt L, Burrell L, Korostovtseva L, Zec M, Patil M, Schultz MG, Wallen MP, Renna NF, Islam SMS, Hiremath S, Gyeltshen T, Chia Y-C, Gupta A, Schutte AE, Klein B, Borghi C, Browning CJ, Lee H-Y, Itoh H, Miura, K, Brunström M, Campbell NRC et al. New Directions in Lifestyle Management of Hypertension and Cardiovascular Disease: International Society of Hypertension Position Paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42(1):23-4910. DOI: 10.1097/HJH.0000000000003563
556. Tsuyuki RT, Cloutier L, Gelfer M, Campbell N. The Pharmacist's Role in Facilitating the Accurate Measurement of Home Blood Pressure. Can Pharmac J 2023 Jul 7;156(4):175-176. doi: 10.1177/17151635231178252.
555. Campbell NRC, MacGregor GA, He FJ. Dietary counseling to reduce moderate sodium intake. Concerns about the methods, evidence and feasibility of lowering sodium intake. eClinicalMedicine. [letter]. 2023;57: 101856. <https://doi.org/10.1016/j.eclinm.2023.101856>.
554. Moran AE, Gupta R for the Global Hearts Initiative Collaborators (N Campbell is an initiative collaborator). National programs to control hypertension in over eight million patients in 31 low- or middle-income countries: the Global Hearts experience 2017-2022. JACC JACC 2023, <https://doi.org/10.1016/j.jacc.2023.08.043>
553. Owolabi M, Olowoyo P, Mocumbi A, Ogah OS, Odili A, Wahab K, Ojji D, Adeoye MA, Akinyemi R, Akpalu R, Obiako R, Sarfo Fs, Bavuma C, Beheiry HM, Ibrahim M, Aroussy WE, Parati G, Dzudie A, Singh S, Akpa O, Kengne AP, Okekunle AP, Aikins ADG, Agyemang C, Ogedegbe G, Ovbiagele B, Garg R, Campbell NRC, Lackland DT, Barango P, Slama S, Varghese CV, Whelton PK, Zhang X-H on behalf of the World Hypertension League. African Control of Hypertension through Innovative Epidemiology and a Vibrant Ecosystem (ACHIEVE): Novel Strategies for Accelerating Hypertension Control in Africa. J Hum Hypertens. 2023; <https://doi.org/10.1038/s41371-023-00828-8>.
552. Campbell NRC, Martinez R, Ordunez P. The estimated impact of changes in population hypertension control on cardiovascular disease in Canada between 2000 and 2017. Can J Cardiol 2023: DOI: <https://doi.org/10.1016/j.cjca.2023.03.011>
551. Campbell NRC, Cook NR, Whelton PK. Weak research on dietary sodium should not generate strong conclusions on a major public health policy. J Hum Hypertens. 2023; 37:507–508. <https://doi.org/10.1038/s41371-023-00819-9>
550. Campbell NRC, Whelton PK, Orias M, Cobb LK, Jones ESW, Garg R, Williams B, Khan N, Yook Chin C, Jafar TH, Ide N for the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals' sodium (salt) intake in association with health outcomes. A policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. J Hypertension. 2023;41: 683-686 DOI: 10.1097/HJH.0000000000003385
549. Valdés González Y, Morejón Giraldoni A, Pérez Perea L, Jiménez Chiquet A, López Lima C, Campbell N, Giraldo G. La Iniciativa HEARTS en Cuba: experiencias tras 5 años de implementación [The HEARTS Initiative in Cuba: experience of five years of implementation]. Rev Panam Salud Publica. 2022 Oct 17;46:e176. Spanish. <https://doi.org/10.26633/RPSP.2022.176>. PMID: PMC9578651.

548. Sharman JE, Ordunez P, Brady T, Parati G, Stergiou G, Whelton P, Padwal R, Olsen MH, Delles C, Schutte A, Benjamin I, McGowan S, Zhang X-H, Lackland D, Moran A, Tomaszewski M, Rakotz MK, Campbell NRC on Behalf of The Lancet Commission On Hypertension Group. The Critical Need to Regulate Validation of Automated Blood Pressure Measuring Devices: A Policy Statement from the World Hypertension League. J Hum Hypertens. (2022). <https://doi.org/10.1038/s41371-022-00747-0>
547. Abdel-Gawad N, Campbell N, Ide N, Cobb L, Garg R. A sodium reduction framework to address the rising global burden of hypertension and cardiovascular disease. J Hum Hypertens. 2022; 36:880–881
546. Campbell NRC, Padwal R, Tsuyuki RT, Leung AA, Bell A, Kaczorowski J, Tobe SW. Ups and downs of hypertension control in Canada. Critical factors and lessons learned. Revista Panamericana de Salud Pública/Pan American Journal of Public Health. 2022;46: e141. <https://doi.org/10.26633/RPSP.2022.141>
- 545. Martinez R, Soliz P, Campbell NRC, Lackland D, Whelton P, Ordunez P. Association between ischemic heart disease and stroke mortality and population hypertension control in 35 countries of the Americas, 1990-2019. An ecological study. Revista Panamericana de Salud Pública/Pan American Journal of Public Health. 2022 Sep 16;46:e143. doi: 10.26633/RPSP.2022.143. eCollection 202**
544. Jaffe MG, DiPette DJ, Campbell NRC, Angell S, Ordunez P. Developing population-based hypertension control programs. Panamericana de Salud Pública/Pan American Journal of Public Health. 2022;46: e153. <https://doi.org/10.26633/RPSP.2022.153>
- 543. Ordunez P, Campbell NRC, Giraldo Arcila GP, Angell SY, Lombardi C, Brettler JW, Rodriguez Morales YA, DiPette DJ, Gamarra A, Jaffe MG, Rosende A, Piñeiro DJ, Rodriguez L, Sharman JE, Martinez R. HEARTS in the Americas: Innovations for improving hypertension and cardiovascular disease risk management in primary care. Revista Panamericana de Salud Pública/Pan American Journal of Public Health. 2022;46: e96. <https://doi.org/10.26633/RPSP.2022.96>**
542. Parati G, Lackland D, Campbell N, Owolabi M, Bavuma C, Beheiry H, Dzudie A, Ibrahim M, El-Aroussy W, Singh S, Varghese C, Whelton P, Zhang X-H on behalf of the World Hypertension league. How to improve awareness, treatment and control of hypertension in Africa, and how to reduce its consequences. A call to action from the World Hypertension League. Hypertension. 2022;79:00–00. DOI: 10.1161/HYPERTENSIONAHA.121.18884
- 541. Wang NX, Arcand J, Campbell NRC, Johnson C, Malta D, Petersen K, Rae S, Santos JA, Sivakumar B, Thout SR, McLean R. The World Hypertension League Science of Salt: A regularly updated systematic review of salt and health outcomes studies (Sept 2019 to Dec 2020). J Hum Hypertens. 2022. <https://doi.org/10.1038/s41371-022-00710-z>**
540. Campbell NRC, Whelton PK, Orias M, et al. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension Dietary Sodium (Salt) Global Call To Action. J Hum Hypertens. 2022; <https://doi.org/10.1038/s41371-022-00690-0>
- 539. Picone DS, Peterson G, Jackson S, Campbell N, Delles C, Olsen MH, Padwal R, Schutte AE, Sharman JE. Perceptions of pharmacists on the quality of automated blood pressure devices: a national survey. J Hum Hypertens 2022. <https://doi.org/10.1038/s41371-022-00670-4>.**
538. Brettler JW, Giraldo Arcila GP, Aumala T, Best A, Campbell N, Cyr S, Gamarra A, Jaffe MG, Jimenez M, Maldonado J, Mukhtar Q, Neira C, Haughton M, Malcolm T, Perez V, Rodriguez G, Rosende A, Valdez Y, Wood P, Zuniga E, Ordunez P. Drivers and scorecards to improve hypertension control in primary care practice: Recommendations from HEARTS in the Americas Innovation Group. The Lancet Regional Health – Americas. 2022;9: 100223. <https://doi.org/10.1016/j.lana.2022.100223>.

537. Campbell NRC, Paccot Burnens M, Whelton PK, Angell SY, Jaffe MG, Cohn J, Brito AE, Irazola V, Brettler JW, Roccella EJ, Maldonado Figueredo JI, Rosende A, Ordunez P. The 2021 World Health Organization hypertension pharmacological treatment recommendations. Policy implications for the Region of the Americas. *The Lancet Regional Health – Americas*. 2022;9: 100219. <https://doi.org/10.1016/j.lana.2022.100219>.
536. Whelton PK, Picone DS, Padwal R, Campbell NRC, Drawz P, Rakotz MK, Parati G, Zhang X-H, Sharman JE. Global proliferation and clinical consequences of non-validated automated BP devices. *J Hum Hypertens* (2022). <https://doi.org/10.1038/s41371-022-00667-z>
535. Arcand J, Campbell NRC. Dietary sodium reduction in Canada: More action is needed to reach the 2025 global targets. *CMAJ [commentary]*. 2022. 194 (10) E387-E388; DOI: <https://doi.org/10.1503/cmaj.211787>.
534. Ordunez P, Lombardi C, Picone D, Brady T, Campbell N, Moran A, Padwal R, Rosende A, Whelton P, Sharman J. HEARTS in the Americas: A global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. *J Hum Hypertens*. 2022 doi.org/10.1038/s41371-022-00659-z.
- 533. Picone DS, Campbell NRC, Padwal R, Schutte AE, Olsen MH, Ordunez P, Whelton PK, Sharman JE. Global consumer availability of blood pressure measuring devices validated for accuracy. *JAMA [research letter]* 2022;327(7):680-681. doi:10.1001/jama.2021.24464**
532. Cappuccio FP, Campbell NR, He FJ, Jacobson MF, MacGregor GA, Antman E, Appel LJ, Arcand J, Blanco-Metzler A, Cook NR, Guichon JR, L'Abbe MR, Lackland DT, Lang T, McLean RM, Miglinas M, Mitchell I, Sacks FM, Sever PS, Stampfer M, Strazzullo P, Sunman W, Webster J, Whelton PK, Willett W. Sodium and health: old myths, a new dogma based on denial? *Current Nutrition Reports*. <https://doi.org/10.1007/s13668-021-00383-z>.
- 531. Ma Y, He FJ, Yuan C, Kieneker LM, Curhan GC, MacGregor GA, Bakker SJL, Campbell NRC, Rimm EB, Willet WC, Hofman A, Gansevoort RT, Sun Q, Cook NR, Hu FB. Sodium intake and risk of cardiovascular disease: An individual-participant data meta-analysis of cohort studies with multiple 24-hour urine collections. *NEJM*. 2022; 386:252-263. DOI: 10.1056/NEJMoa2109794**
- 530. Song J, Brown M, Tan M, MacGregor G, Webster J, Campbell NRC, Trieu K, Mhurchu C, Cobb L, He FJ. Impact of color-coded and warning nutrition labelling schemes: a systematic review and network meta-analysis. *PLOS 1* 2021: 18(10): e1003765. <https://doi.org/10.1371/journal.pmed.1003765>**
- 529. Jeemon P, Séverin T, Balabanova D, Campbell N, Celso A, Gaita D, Kario K, Khan T, Melifonwu R, Moran A, Ogola E, Ordunez P, Perel P, Piñero D, Schutte A, Wyss F, Yan L, Poulter N, Prabhakaran D. World Heart Federation Roadmap for Hypertension – a 2020 Update. *Global Heart* 2021;16(1):63. DOI: <http://doi.org/10.5334/gh.1066>**
- 528. Leung AA, Bell A, Tsuyuki RT, Campbell NRC. Hypertension control, commercial support and the way forward. *CMAJ [response to letter]*. 2021: <https://www.cmaj.ca/content/193/23/E854/tab-e-letters>**
527. Campbell NRC, Cappuccio FP, McLean RM, He FJ, MacGregor GA. Comment on Hogas et al. Salt, Not Always a Cardiovascular Enemy? A Mini-Review and Modern Perspective. *Medicina [letter]* 2022, 58, 1175. <https://doi.org/10.3390/medicina59010051>
- 526. Hasan S, Naugler C, Decker J, Fung M, Morrin L, Campbell NRC, Anderson TJ. Laboratory reporting of Framingham Risk Score increases Statin prescriptions in at-risk patients *Clinical Biochemistry*. 2021; 96: 1-7. <https://doi.org/10.1016/j.clinbiochem.2021.06.004>.**

525. Campbell NR, He FJ, Cappuccio FP, MacGregor GA, McLean. Atheromatosis. Concerns about the evidence review and methods. [letter]. Hellenic Journal of Cardiology. 2022;63:92-93.
524. Myanganbayar M, Boldbaatar K, Tuvdendarjaa K, Beaney T, Partington G, Baatarsuren U, Bayarsaikhan N-E, Davaadamdin O, Bungert A, Campbell NRC, Poulter NR, Dashdorj N. May Measurement Month 2019: an analysis of blood pressure screening results from Ulaanbaatar, Mongolia. European Heart Journal Supplements (2021) 23 (Supplement B), B107–B109. doi:10.1093/eurheartj/suab052
523. He FJ, Campbell NRC, Woodward M, MacGregor GA. Salt reduction to prevent hypertension: the reasons of the controversy. European Heart Journal. 2021. doi:10.1093/eurheartj/ehab274
522. Campbell NRC, He FJ, Cappuccio FP, MacGregor GA. Sources of controversy relating to dietary sodium. Issues and potential solutions. Curr Nutr Rep 2021. <https://doi.org/10.1007/s13668-021-00357-1>
521. Leung AA, Bell A, Tsuyuki RT, Campbell NRC. Missing the Target for Hypertension Control in Canada: Refocusing on the Goal. CMAJ. 2021 193 (23) E854-E855; DOI: <https://doi.org/10.1503/cmaj.210140>
520. Campbell NRC, Feng HJ, McLean RM, Cappuccio FP, Woodward M, McGregor GA. Dietary sodium and cardiovascular disease in China. Concerns about the methods, conclusions, and evidence review. J Hypertension. [letter] 2021; 39:1466-1467.
519. McLean R, Campbell N. Spot urine is a poor predictor of dietary sodium intake in individuals. Am J Hypertens. 2021 (correspondence) hpab045, <https://doi.org/10.1093/ajh/hpab045>
- 518. Naser AM, He FJ, Rahman M, Campbell NRC. Spot-urine formulas to estimate 24-hour urinary sodium excretion alter the dietary sodium and blood pressure relationship. Hypertension. 2021; 77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16651**
- 517. Huang L, Neal B, Wu J, Huang Y, Marklund M, Campbell NRC, He FJ, Yoshimura S, Chalmers J, Trieu K. The impact of baseline potassium intake on the dose-response relation between sodium reduction and blood pressure change: Systematic review and meta-analysis of randomised trials. J Hum Hypertens. 2021 <https://doi.org/10.1038/s41371-021-00510-x>.**
516. Tsuyuki RT, Gelfer M, Bell A, Petrella R, Campbell NRC, Cloutier L, Lindsay P, Leung AA, Morris D, McLean D, Dattani S, Kaczorowski J. [Letter], Response to letter. Canadian Family Physician. 2021, 67 (3) 157; DOI: <https://doi.org/10.46747/cfp.6703157>
- 515. Santos JA, Tekle D, Rosewarne E, Flexner N, Cobb L, Al-Jawaldeh A, Kim WJ, Breda J, Whiting S, Campbell N, Neal B, Webster J, Trieu K. A systematic review of salt reduction initiatives around the world – a midterm evaluation of progress towards the 2025 global non-communicable diseases salt reduction target. Advances in Nutrition. 2021 <https://doi.org/10.1093/advances/nmab008>**
- 514. Fan W, Wang W-Y, Meng Y, Sharman JE, Parati G, Campbell NRC, Su H. Intra visit and between visit intra-individual blood pressure variability in an unselected adult population from rural China. J Hypertension. 2021;38; DOI:10.1097/HJH.0000000000002810.**
513. John O, Campbell NRC, Brady TM, Farrell M, Varghese C, Velazquez Berumen A, Velez Ruiz Gaitan LA, Toffelmire N, Ameal M, Mideksa M, Jaffe MG, Schutte AE, Khan T, Lopez Meneses LP. The 2020 WHO technical specifications for automated non-invasive blood pressure measuring devices with a cuff. Hypertension. 2021; 77:806–812. DOI: 10.1161/HYPERTENSIONAHA.120.16625
512. Campbell NRC. Estimated salt intake and risk of atrial fibrillation in a prospective community-based cohort. J Intern Med. [letter] 2020; <https://doi.org/10.1111/joim.13221>

511. Giraldo GP, Joseph K, Campbell NRC, Angell SY, Connell K, DiPette D, Escobar MC, Gonzalez-Valdez Y, Jaffe MJ, Malcolm T, Maldonado J, Lopez-Jaramillo P, Hecht Olsen M, Ordunez P. Mapping stages, barriers and facilitators to the implementation of HEARTS in the Americas initiative in 12 countries: a qualitative study. *J Clin Hypertens*. 2021. DOI: 10.1111/jch.14157
510. Campbell NRC, Ordunez P, Giraldo G, Rodriguez Morales YA, Lombardi C, Khan T, Padwal R, Tsuyuki RT, Varghese C. WHO HEARTS, a global program to reduce cardiovascular disease burden: Experience implementing in the America's and opportunities in Canada. *Can J Cardiol*. 2021; 37:744-55. doi: 10.1016/j.cjca.2020.12.004
509. Tobe SW, Campbell NRC, Padwal RS, Khan NA, Singer J. Change of education strategy associated with slippage in Canadian hypertension awareness treatment and control rates. *J Hum Hypertens*. 2021; 35:1045-56. <https://doi.org/10.1038/s41371-021-00519-2>
508. Gelfer M, Bell A, Petrella R, Campbell NRC, Cloutier L, Lindsay P, Leung A, Morris D, McLean D, Tsuyuki, Dattani S, Kaczorowski J. Urgent need to increase the rates of diagnosing, treating and controlling hypertension in older women. A call for all levels of government, health professional associations, health charities and clinicians to reengage and to take action. *Can Family Physician*. 2020;66:726-731 (note the similar topic publication in *Can Pharm J*)
507. DiPette DJ, Goughnour K, Skeete J, Ridley E, Zuniga E, Angel S, Brettler JW, Campbell N, Coca A, Connell K, Doon R, Jaffe M, Lopez-Jaramillo PJ, Moran A, Pineiro D, Rosende A, Valdez-Gonzalez Y, Ordunez P. Towards Standardized Treatment to Improve Hypertension Control in Primary Health Care: The HEARTS in the Americas Initiative Pathway. *J Clin Hypertens*. 2020; 22:2285–2295; <https://doi.org/10.1111/jch.14072>.
506. Naser AM, He FJ, Rahman M, Unicomb L, Zaman M, Narayan KMV, Campbell NRC. Urinary sodium excretion and blood pressure relationship across methods of evaluating the completeness of 24-hour urine collections. *Nutrients*. 2020;12: doi:10.3390/nu12092772.
505. Picone D, Padwal R, Campbell NRC, Boutouyrie P, Brady T, Olsen MH, Delles C, Lombardi C, Mahmud A, Meng Y, Mokwatsi GG, Ordunez P, Phan H, Pucci G, Schutte AE, Sung K-C, Zhang X-H, Sharman JE for the Accuracy in Measurement of Blood Pressure (AIM-BP) Collaborative. How to check if a blood pressure monitor has been properly tested for accuracy. *J Clin Hypertens*. 2020; DOI:10.1111/jch.14065
504. Lombardi C, Sharman JE, Padwal R, Picone D, Eng A, Ayala Eng R, Gittens A, Lawrence-Williams P, Malcolm T, Neira C Perez V, Rosende A, Tesser J, Villacres N, Campbell NRC, Ordunez P. Weak and fragmented regulatory frameworks on the accuracy of blood pressure measuring devices pose a major impediment for the implementation of HEARTS in the Americas. *J Clin Hypertens*. 2020; DOI: 10.1111/jch.14058
503. Quan S, Chen G, Tran K, Liang Z, Padwal RS, McAlister FA, Rabi DM, Campbell NRC, Feng Y, Leung AA on behalf of Hypertension Canada's Research and Evaluation Committee. Frequency of Laboratory Testing and Associated Abnormalities in Patients with Hypertension. *J Clin Hypertens*. 2020: doi.org/10.1111/jch.14040
502. Campbell NRC, Khalsa T, Ordunez P, Zhang X-H, Parati G, Padwal R, Tsuyuki RT, Sharman JE. Short online certification course for measuring blood pressure with an automated blood pressure device. A new resource to support a (deferred) World Hypertension Day Oct 17th, 2020. *J Clin Hypertens*. 2020; <https://doi.org/10.1111/jch.14017>

501. Overwyk KJ, Pfeiffer C, Storandt R, Zhao L, Zhang Z, Campbell NR, Wiltz JL, Merritt RK, Cogswell ME. Distribution and characteristics related to serum sodium and potassium among the US population, NHANES 2009-2016. *Journal of Applied Laboratory Medicine*. 2020; <https://doi.org/10.1093/jalm/jfaa127>
500. Martinez R, Soliz P, Mujica OJ, Reveiz L, Moran A, Campbell N, Ordunez P. The slowdown in the reduction rate of premature mortality from cardiovascular diseases puts the Americas at risk of achieving SDG 3.4: a population trend analysis of 37 countries from 1990 to 2017. *J Clin Hypertens*. 2020; 22:1297-1308. DOI: 10.1111/jch.13922
499. Campbell NRC, Tsuyuki, Dattani S, Bell A, Gelfer M, Cloutier L, Petrella R, Lindsay P, Morris D, Leung A, McLean D, Kaczorowski J. Urgent need to increase the rates of diagnosing, treating and controlling hypertension in older women. A call for all levels of government, health professional associations, health charities and clinicians to reengage and to take action. *Can Pharm J*. 2020: DOI: 10.1177/1715163520947006
498. Dodd R, Santos JA, Tan M, Jacobson M, Campbell NRC, Mhurchu CN, He F, Trieu K, Cobb L, Webster J. Theory and Practice of Salt Taxation: a systematic review of the evidence R. *Advances in Nutrition*. 2020; 11:1616–1630. <https://doi.org/10.1093/advances/nmaa067>
497. Ordunez P, Campbell NRC. Smoking cigarettes drive the most death and disability combined in Cuba. Commentary. *Lancet. Global Health*. 2020;8: e752-753.
496. Campbell NRC, Padwal R, Picone DS, Su H, Sharman JE for the Accuracy in Measurement of BP (AIM-BP) Collaborative. The impact of small to moderate inaccuracies in assessing blood pressure on hypertension prevalence and control rates. *J Clin Hypertens*. 2020; 6:939-42
495. Petersen KS, Malta D, Rae S, Dash S, McLean R, Raj TS, Campbell NRC, Arcand J. Further evidence that methods based on spot urine samples should not be used to examine sodium-disease relationships from the Science of Salt: A regularly updated systematic review of salt and health outcomes (November 2018 to August 2019) *J Clin Hypertens*. 2020; 2020;00: e13958 DOI:10.1111/jch.13958.
494. Park HK, Lee Y, Kang BW, Kwon K-i, Kim J-W, Kwon OS, Cobb LK, Campbell NRC, Blakeman DE, Kim CI. Progress on sodium reduction in South Korea. *BMJ Global Health* 2020;5: e002028. doi:10.1136/bmjgh-2019-002028
493. Sharman JE, Padwal R, Campbell NRC on behalf of the co-authors and endorsing partners. Global marketing and sale of accurate cuff measured blood pressure devices. [Commentary] *Circulation* 2020; 142:321–323 <https://doi.org/10.1161/CIRCULATIONAHA.120.046205>.
492. Picone DS, Deshpande R, Schultz MG, Fonseca R, Campbell NRC, Delles C, Hecht-Olsen M, Schutte AE, Stergiou G, Angell SY, Padwal R, Sharman JE. Non-validated home blood pressure devices dominate the online marketplace: major implications for cardiovascular clinical practice. *Hypertension*. 2020; 75:00-00. DOI: 10.1161/HYPERTENSIONAHA.120.14719
491. Leung AA, Williams GVA, McAlister FA, Campbell NRC, Padwal RS for Hypertension Canada's Research and Evaluation Committee. Worsening Hypertension Awareness, Treatment, and Control Rates in Canadian Women between 2007 and 2017. *Can J Cardiol*. 2020 <https://doi.org/10.1016/j.cjca.2020.02.092>
490. Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, Li Q, Lackland D, Leung AA, Anderson CAM, MacGregor G, He FJ for the TRUE Consortium. Impact of Dose and Duration of Dietary Sodium Reduction on Blood Pressure Levels: Systematic Review and Meta-analysis of Randomised Trials. *BMJ* 2020;368:m315 <http://dx.doi.org/10.1136/bmj.m315>.

489. Valdés González Y, Campbell NRC, Pons Barrera E, Calderón Martínez M, Pérez Carrera A, Morales Rigau JM, Afonso de León JA, Pérez Jiménez V, Landrove Rodríguez O, DiPette DJ, Giraldo G, Orduñez P. Implementation of a community-based hypertension control program in Matanzas, Cuba. J Clin Hypertension. J Clin Hypertens. 2020; 22:142-149. DOI:10.1111/jch.138144.

488. Potts H, Baatarsuren U, Myanganbayar M, Purevdorj B, Lkhagvadorj B-U, Ganbat N, Dorjpalam A, Boldbaatar D, Tuvdendarjaa K, Sampilnorov D, Boldbaatar K, Dashtseren M, Batsukh B, Tserengombo N, Unurjargal T, Palam E, Bosurgi R, So G, Campbell NRC, Bungert A, Dashdorj N, Dashdorj ND. Hypertension prevalence and control in Ulaanbaatar, Mongolia 2020. J Clin Hypertension 2019. 2020; DOI:10.1111/jch.13784.

487. Fan W-G, Xie F, Wan YR, Campbell NRC, Su H. The impact of changes in population blood pressure on hypertension prevalence, and control in China. J Clin Hypertension 2020; 22:150-156. DOI: 10.1111/jch.13820

486. Whelton PK, Campbell NRC, Lackland DT, Parati G, Ram CVS, Weber MA, Zhang X-H. Strategies for prevention of cardiovascular disease in adults with hypertension. J Clin Hypertension 2020; 22:132-134 DOI: 10.1111/jch.13797

485. Campbell NRC, Flores G, Blanco-Metzler A, Webster J. Argentina regulates a warning label on packages of salt. J Clin Hypertension [letter] 2019 DOI:10.1111/jch.13776.

484. Padwal R, Campbell NRC, Weber M, Lackland D, Sharman J for the Accuracy in Measurement of Blood Pressure Collaborative. The Accuracy in Measurement of Blood Pressure (AIM-BP) Collaborative: Background and Rationale. J Clin Hypertens. 2019; 21:1780–1783 doi. org/10.1111/jch.13735.

483. McLean R, Cameron C, Butcher E, Otley N, Cook NR, Woodward M, Campbell NRC. 24-hour urine and 24-hour diet recall for estimating dietary sodium intake in populations: Systematic Review and Meta-analysis. J Clin Hypertens. 2019; 21:1753–1762. doi. org/10.1111/jch.13729.

482. Nowson CA, Lim K, Campbell NRC, O'Connell SL, He FJ, Daly RM. Impact of fractional excretion of sodium on a single morning void urine collection as an estimate of 24-hour urine sodium. Clin Hypertens. 2019; 21:1763–1770. DOI: 10.1111/jch.13725

481. Campbell NRC, Schutte AE, Varghese CV, Ordunez P, Zhang X-H, Khan T, Sharman JE, Whelton PK, Parati G, Weber MA, Orias M, Jaffe MG, Moran AE, Plavnik FL, Ram CVS, Brainin M, Ramirez AJ, Barbosa E, Bortolotto LA, Lackland DT, São Paulo Call to Action for the Prevention and Control of High Blood Pressure: 2019. J Clin Hypertens. 2019; 21:1744–1752 DOI: 10.1111/jch.13741.

480. Campbell NRC, Webster J, Blanco-Metzler A, He FJ, Tan M, MacGregor GA, Cappuccino FP, Arcand J, Trieu K, Farrand C, Jones A, Whelton PK, Zhang XH. Packages of Sodium (Salt) sold for consumption and salt dispensers should be required to have a front of package health warning label. A position statement of the World Hypertension League, national and international health and scientific organizations. J Clin Hypertension. 2019 DOI: 10.1111/jch.13698

479. Campbell NRC, Greene Raine N. Child Health Protection Act, a missed opportunity. CMAJ. 2019;191: E1040-1041 <https://doi.org/10.1503/cmaj.190857>

478. Sharman JE, O'Brien E, Alpert B, Schutte AE, Delles C, Olsen MH, Asmar R, Atkins N, Calhoun D, Campbell NRC, Chalmers J, Jennings G, Laurent S, Lopez-Jaramillo P, McManus R, Mihailidou A, Padwal R, Palatini P, Parati G, Poulter N, Rakotz MK, Rosendorff C, Saladini F, Scuteri A, Barroso WS, Townsend R, Wang J, Willum-Hansen T, Wozniak G and Stergiou G on behalf of the Lancet Commission on Hypertension Group. Lancet Commission on Hypertension Group Position Statement on Improving the Accuracy Standards

for Devices that Measure Blood Pressure J Hypertension. 2020, 38:21–29:
DOI:10.1097/HJH.0000000000002246.

477. Campbell NRC. A step in the global effort to control hypertension: Fixed dose combination antihypertensive drugs. J Clin Hypertension. 2019. DOI:10.1111/jch.13683

476. Frieden TR, Varghese CV, Kishore SP, Campbell NRC, Moran A, Padwal R, Jaffe MG. Scaling Up Effective Treatment of Hypertension Is Essential for Universal Health Coverage. J Clin Hypertension 2019 DOI:10.1111/jch.13655.

475. Khan N, Bell A, Berg A, Campbell N, Kacorowski J, Rabi D, Schiffrin EL, Tsuyuki RT. A Call to Action to Implement Prescribing Authority to Pharmacists for Hypertension Management. CPJ 2019: DOI: 10.1177/1715163519866144

474. Jakobson M, Campbell NRC. Potassium Labeling of Foods: Potential Benefit for Blood Pressure. J Clin Hypertension 2019 DOI: 10.1111/jch.13651

473. Santos JA, Sparks E, Thout SR, McKenzie B, Trieu K, Hoek A, Johnson C, McLean R, Arcand J, Campbell NRC, Webster J. The Science of Salt: A global review on changes in sodium levels in foods. J Clin Hypertens 2019. DOI: 10.1111/jch.13628

472. Mohammadifard N, Marateb H, Mansourian M, Khosravi A, Abdollahi Z, Campbell NRC, Webster J, Petersen K, Sarrafzadegan N. Can methods based on spot urine samples be used to estimate average population 24-hour sodium excretion? Results from Isfahan Salt Study. Public Health Nutrition. 2019 DOI: <https://doi.org/10.1017/S136898001900257X>.

471. McLean R, Petersen K, Arcand J, Malta D, Rae S, Trieu K, Campbell NRC. Science of Salt: A regularly updated systematic review of salt and health outcomes studies (April to October 2018). J Clin Hypertension. 2019 Jun 27. doi: 10.1111/jch.13611

470. Jakobson M, Campbell NRC. Shaking Out the Truth About Salt. J Clin Hypertension 2019 10.1111/jch.13595

469. Feldman RD, Campbell NRC. Believing in the Impossible: Achieving Universal Blood Pressure Awareness on a Global Basis. Eur Heart J. 2019 DOI:[10.1093/eurheartj/ehz413](https://doi.org/10.1093/eurheartj/ehz413)

468. Myanganbayar M, Baatarsuren U, Chen G, Campbell NRC, Bosurgi R, So G, Unurjargal T, Dashtseren M, Tserengombo N, Batsukh B, Bungert A, Dashdorj N, Dashdorj N. Hypertension Knowledge, Attitudes and Practices of Nurses and Physicians in Primary Care in Ulaanbaatar Mongolia. J Clin Hypertension 2019 DOI: 10.1111/jch.13592

467. He FJ, Ma Y, Campbell NRC, MacGregor GA, Cogswell ME, Cook NR. Formulas to estimate sodium intake from spot urine alter sodium-mortality relationship. Hypertension. 2019; 74:00-00. DOI: 10.1161/HYPERTENSIONAHA.119.13117.

466. Campbell NRC, He FJ, Tan M, Cappuccio FP, Neal B, Woodward M, Cogswell ME, McLean R, Arcand J, MacGregor G, Whelton P, Jula A, L'Abbe MR, Cobb LK, Lackland D. The International Consortium for Quality Research on Dietary Sodium/Salt (TRUE) position statement on the use of 24-hour, spot and short duration (less than 24-hours) timed urine collections to assess dietary sodium intake. J Clin Hypertension 2019; DOI: 10.1111/jch.13551

- 465. Thout SR, Santos JA, McKenzie B, Trieu K, McLean R, Arcand J, Campbell NRC. The Science of Salt: updating the evidence on global estimates of salt intake J Clin Hypertension 2019 DOI: 10.1111/jch.13546**
464. Bacon S, Campbell NRC, Raine K, Kaczorowski J. Canada's New Healthy Eating Strategy: Implications for Healthcare Professionals and a call to Action. Canadian Pharmacists Journal (also published in Can Family Physician and Canadian Journal of General Internal Medicine 2019; 14:6-13) 2019 DOI:10.1177
463. Padwal R, Campbell NRC, Schutte AE, Olsen HM, Delles C, Etyang A et al. Optimizing Observer Performance of Clinic Blood Pressure Measurement: A Position Statement from the Lancet Commission on Hypertension Group. J Hypertension 2019;37:1737-45. DOI:10.1097/HJH.0000000000002112.
462. He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Errors in application of the Kawasaki formula to estimate sodium intake and false interpretation of data misclassify the relationship of sodium intake with mortality. [letter] International Journal of Epidemiology, [letter] 2019, 1–2. DOI: 10.1093/ije/dyz030
- 461. Zack R, Okunade O, Olson E, Salt M, Amodeo C, Anchala R, Berwanger O, Campbell N, Chia YC, Damasceno A, Phuong Do TN, Tamdja Dzudie A, Fiuza M, Mirza F, Nitsch D, Ogedegbe G, Podpalov V, Schiffrin EL, Vaz Carmeiro A, Lamptey P. Improving Hypertension Outcome Measurement in Low- and Middle-Income Countries. Hypertension. 2019; 73:990–997 doi: 10.1161/HYPERTENSIONAHA.118.11916.**
460. Campbell NRC, Bacon S, Tsuyki R, Arango M, Raine K, Kaczorowski J. Dietary sodium and the health of Canadians. [letter] Can Journal of Cardiol 2019;35;671 DOI.org/10.1016/j.cjca.2019.01.020
459. Farrand C, Macgregor G, Campbell N, Webster J. Potential use of salt substitutes to reduce blood pressure. J Clin Hypertension. 2019; 21:35-354. DOI:10.1111/jch.13482
- 458. Barsky J, Hunter R, McAllister C, Yeates K, Campbell N, Liu P, Perkins N, Hua-Stewart D, Maar MA, Tobe S. Evaluation of Implementation, User Perspectives and Feedback from DREAM-GLOBAL, a mobile Health Intervention in Canadian Indigenous and Tanzanian Communities for Individuals living with Hypertension. JMIR mHealth and uHealth. 2019;7(12): e12639https://mhealth.jmir.org/2019/12/e12639**
- 457. Petersen KS, Rae S, Venos E, Malta D, Johnson C, Trieu K, Jefferson K, Santos JA, Wong MMY, Thout SR, Webster J, Campbell NRC, Arcand J. Paucity of High-Quality Studies Reporting on Salt and Health Outcomes from The Science of Salt: A regularly updated systematic review of salt and health outcomes (April 2017 to March 2018). J Clin Hypertension 2018. DOI:10.1111/jch.13450**
456. Olstad DL, Campbell NRC, Raine KD Diet quality in Canada: Toward policy solutions for equity. CMAJ January 28, 2019, 191 (4) E100-E102; DOI: DOI.org/10.1503/cmaj.180938
455. Campbell NRC, Valdes Gonzalez Y, Ordunez P. The Burden of Hypertension in Cuba. Lancet Public Health. 2019; DOI.org/10.1016
- 454. Tobe SW, Yeates K, Campbell NRC, Maar MA, Perkins N, Liu P, Sleeth J, McAllister P, Hua-Stewart D, Wells G, Bernick J. Diagnosing Hypertension in Indigenous Canada (DREAM-GLOBAL): A Randomized Controlled Trial to Compare the Effectiveness of SMS Messaging for Management of Hypertension: Main Results. J Clin Hypertension. 2018 DOI 10.1111/jch.13434**
- 453. Malta D, Petersen K, Santos J, Johnson C, Trieu K, Rae S, Jefferson K, Wong M, Raj T, Webster J, Campbell N, Arcand J. High sodium intake increases blood pressure and risk of kidney disease from the**

Science of Salt: A regularly updated systematic review of salt and health outcomes (August 2016 to March 2017. J Clin Hypertension 2018 10.1111/jch.13408.

452. DiPette JD, Skeete J, Ridley E, Campbell NRC, Lopez-Jaramillo P, Kishore SP, Jaffe MG, Coca A, Ordunez P. Fixed-Dose Combination Pharmacologic Therapy to Improve Hypertension Control Worldwide: Clinical perspective and policy implications. J Clin Hypertension 2018 10.1111/jch.13426

451. McLean R, Farmer V, Nettleton A, Cameron C, Cook N, Woodward M, Campbell N. Twenty-four-hour diet recall and diet records compared with 24-hour urinary excretion to predict an individual's sodium consumption: a systematic review. J Clin Hypertension. 2018; 20:1360–1376. DOI: 10.1111/jch.1339

450. Lucko A, Doktorchik CTA, Woodward M, Rabi D, Anderson C, Neal B, MacGregor G, Cogswell M, L'Abbe M, He F, Arcand J, Whelton PK, Campbell NRC for the TRUE Consortium. How much dietary sodium is excreted in 24-hour urine collections: A systematic review and meta-analysis. J Clin Hypertension. 2018; 20:1220-1229 DOI: 10.1111/jch.13353

449. He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Effect of measurement error on the relationship between sodium intake and mortality in cohort studies. International J Epidemiology. 2018; 47(6):1784-1795 DOI.org/10.1093/ije/dyy114

448. Myanganbayar M, Baatarsuren U, Chen G, Bosurgi R, So G, Campbell NRC, Erdenebileg N, Ganbaatar K, Magsarjav P, Batsukh M, Munkherdene T, Unurjargal T, Dashtseren M, Tserengombo N, Batsukh B, Bungert A, Dashdorj N, Dashdorj N. Knowledge, Attitudes, and Practices of Primary Care Physicians in Ulaanbaatar. J Clin Hypertension 18 DOI: 10.1111/jch.13320.

447. Lackland DT, Beilin LJ, Campbell NRC, Jaffe MG, Orias M, Ram CV, Weber MA, Zhang X-H for the World Hypertension League. The Global Implications of Blood Pressure Thresholds and Targets: Guideline Conversations from the World Hypertension League. Hypertension. 2018;71: 985-7. <https://doi.org/10.1161/HYPERTENSIONAHA.118.11280>

446. Campbell NRC, Ordunez P, DiPette DJ, Giraldo G, Angell S, Jaffe M, Lackland D, Martinez R, Maldonado J, Paccot M, Santana M, Valdez Y, Whelton PK. A new Pan American Health Organization (PAHO) – World Hypertension League (WHL) Hypertension Monitoring and Evaluation Framework to aid Hypertension Control Programs. J Clin Hypertension. 2018; 20:984–990. DOI: 10.1111/jch.13307

445. Jaffe MG, Frieden TR, Campbell NRC, Matsushita K, Appel LJ, Lackland DT, Zhang X-H, Muruganathan A, Whelton PK. Improving Management of Hypertension Globally: Resolve to Save Lives-World Hypertension League Recommended Treatment Protocols. J Clin Hypertension. 2018. DOI: 10.1111/jch.13280

444. Nerenberg K, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe G, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, et al for Hypertension Canada. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018 DOI: 10.1016/j.cjca.2018.02.022

443. Campbell NRC, Zhang X-H. Hypertension in China. Time to transition from knowing the problem to implementing the solution. Circulation. 2018; 137:2357–2359. DOI: 10.1161/CIRCULATIONAHA.118.034028

442. Lucko A, Doktorchik CTA, Campbell NRC. Impact of quality of research on patient outcomes in the Institute of Medicine 2013 report on dietary sodium. J Clin Hypertension. 2018 10.1111/jch.13168
441. Peng M, Chen G, Tang K, Quan H, Smith E, Faris P, Hachinski V, Campbell N. Blood pressure at age 60-65 versus age 70-75 and vascular dementia: a population based observational study, BMC Geriatrics. 2017; 17:252. DOI 10.1186/s12877-017-0649-3.
440. Raine K, Atkey K, Beaulieu D, Buhler S, Campbell NRC, Cook B, Ferdinands A, L'Abbé M, Lederer A, Maharaj J, McKellar L, Mowatt D, Nykiforuk C, Lee Olstad D, Stree J. Healthy Food Procurement and Nutrition Standards in Public Facilities: Evidence Synthesis and Consensus Policy Recommendations. Health Promotion and Chronic Disease Prevention in Canada 2018;38: <https://doi.org/10.24095/hpcdp.38.1.03>
439. McLean R, Farmer VL, Nettleton A, Cameron CM, Cook NR, Campbell NRC. True Consortium, (inTernational consoRtium for qUality resEarch on dietary sodium/salt). Assessment of dietary sodium intake using Food Frequency Questionnaire and 24h urinary sodium excretion: A Systematic Literature Review. J Clin Hypertension. 2017; 19:1214-30.
438. Yeates K, Campbell N, Maar M, Perkins N, Liu P, Sleeth J, McAllister C, Hua D, Wells G, Tobe SW. The Effectiveness of Text Messaging for Detection and Management of Hypertension in Indigenous People in Canada: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2017;6(12): e244 DOI: 10.2196/resprot.7139
437. Campbell NRC. More on Dissidents and Dietary Sodium. International J Epidemiology. Letter. 2018, 670–673. doi: 10.1093/ije/dyy003
436. Johnson C, Santos J, McKenzie B, Raj T, Trieu K, McLean R, Petersen K, Campbell N, Webster, J. The Science of Salt: A regularly updated systematic review of the implementation of salt reduction interventions (September 2016 to February 2017). J Clin Hypertension. 2017 DOI: 10.1111/jch.13099
435. Campbell N, Dashdorj N, Baatarsuren U, Myanganbayar M, Dashtseren M, Unurjargal T, Zhang X-H, Velludo Veiga E, Beheiry HM, Mohan S, Almustafa B, Niebylski M, Lackland D. Assessing health care professional knowledge, attitudes, and practices on hypertension management. Announcing a new World Hypertension League resource. J Clin Hypertension. 2017 10.1111/jch.13079.
434. Campbell NRC, Train EJ. A systematic review of fatalities related to ingestion of salt. A need for warning labels? Nutrients. 2017, 9(7), 648; DOI: 10.3390/nu9070648
433. Walker R, Ghali WA, Chen G, Khalsa TK, Mangat BK, Campbell NRC, Dixon E, Rabi D, Jette N, Dhanoa R, Hude Quan. ACSC indicator: Testing reliability for hypertension. BMC Medical Informatics and Decision Making. 2017; 17:90. DOI 10.1186/s12911-017-0487-4
432. Arcand J, Wong MMY, Santos JA, Leung AA, Trieu K, Raj TS, Webster J, Campbell NRC. More evidence that salt increases blood pressure and risk of kidney disease from the Science of Salt: A regularly updated systematic review of salt and health outcomes (April to July 2016). J Clin Hypertension. 2017; 19:813-823.
431. Padwal R, Rashead M, Snider J, Morrin L, Lehman A, Campbell NRC. Worksite-Based Cardiovascular Risk Screening and Management: A Feasibility Study. Vascular Health and Risk Management. 2017;13 209–213
430. Nilson EAF, Spaniol MA, Santos Gonçalves VS, Campbell NRC, Oliveira ML, Constante Jaime P. The Impact of Voluntary Targets on the Sodium Content of Processed Foods in Brazil, 2011-2013. J Clin Hypertension 2017;1-7; DOI:10.1111/jch.13044

429. Castronuovo L, Allemandi L, Tiscornia V, Champagne B, Campbell N, Schoj V. Análise de uma iniciativa voluntária para reduzir o sódio em produtos e processador ultra-processados na Argentina: perspectivas das partes interessadas (Sodium reduction policies in Argentina: Strength and Weaknesses of a voluntary initiative). Reports in Public Health/ Cad Saude Publica. 2017 Jul 3;33(6): e00014316. doi: 10.1590/0102-311X00014316.
428. Webster J, Waqanivalu T, Arcand J, Trieu K, Cappuccio F, Appel LJ, Woodward M, Campbell NRC, McLean R. Understanding the science that supports population-wide salt reduction programs. J Clin Hypertension. 2017; 19:569-76. DOI: 10.1111/jch.12994
427. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Pasad R, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ,⁵ Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC. et al. Hypertension Canada's 2017 Guidelines. Can J Cardiol 2017. <http://dx.doi.org/10.1016/j.cjca.2017.03.005>
- 426. Naugler C, Cook C, Morrin L, Wesenberg J, Venner A, Campbell N, Anderson T. Statin prescriptions for high-risk patients are increased by laboratory-initiated Framingham Risk Scores: results of a quality improvement initiative. Can J Cardiol. DOI: <http://dx.doi.org/10.1016/j.cjca.2017.02.005>**
425. Campbell NRC. Volunteerism, and alignment, are needed for a major paradigm shift in approaches to hypertension control. 2016 World Hypertension League Excellence Award in Hypertension Prevention and Control and the Distinguished Service Award. J Clin Hypertension. 2017; 19:740-742. <https://doi.org/10.1111/jch.13003>
424. Campbell N, Ordunez P, Jaffe MG, Orias M, DiPette DJ, Patel P, Khan N, Onuma O, Lackland DT. Implementing standardized performance indicators to improve hypertension control at both population and at healthcare organizations level. J Clin Hypertension. 13 FEB 2017 | DOI: 10.1111/jch.12980
- 423. Wong MMY, Arcand J, Leung AA, Raj TS, Campbell NRC. The science of salt: A regularly updated systematic review of salt and health outcomes (December 2015 to March 2016). J Clin Hypertension. 2017; 19: 322–332**
- 422. Barberio AM, Sumar N, Trieu K, Lorenzetti DL, Tarasuk V, Webster J, Campbell NRC, McLaren L. Population-level interventions in government jurisdictions for dietary sodium reduction: Cochrane Review. Int J Epidemiol. 2017 doi: 10.1093/ije/dyw361**
421. Padwal R, Campbell NRC. Blood Pressure Control in Canada: Through the Looking-Glass into a Glass Half Empty? Am J Hypertension. 2017; doi:10.1093/ajh/hpw152
420. Myers M, Campbell NRC. Unfounded Concerns about the Use of Automated Office Blood Pressure Measurement in SPRINT J Am Soc Hypertens. 2016;10:903-905.
419. TRUE Consortium. Recommended Standards for Assessing Blood Pressure in Human Research Where Blood Pressure or Hypertension is a Major Focus. (N Campbell, Chair of TRUE Consortium steering and expert committees) J Clin Hypertension. 2016. DOI: 10.1111/jch.12948 also published in *Journal of Human Hypertension* **31**, 487–490 2017 doi:10.1038/jhh.2017.10, *Journal of Hypertension and Cardiology* 2017 10.14302/issn.2329-9487.jhc-16-1338, *Hypertension Journal* 2017;(3) 1-6, *Kidney International Reports* 10.1016/j.ekir.2017.02.009, *Clinical and Experimental Hypertension*, DOI: [10.1080/10641963.2017.1281939](https://doi.org/10.1080/10641963.2017.1281939)
- 418. Houle SKD, Charrois TL, Kolber MR, McAlister FA⁵, Rosenthal MM, Lewanczuk R, Campbell NRC,**

Tsuyuki RT Pay-for-performance remuneration for pharmacist prescribers' management of hypertension: A pre-specified sub-study of the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Canadian Pharmacists Journal. 2016; 149:345-351. doi:10.1177/1715163516671745

417. Cappuccio FP, Campbell NRC. Population Dietary Salt Reduction and the Risk of Cardiovascular Disease: A commentary on recent evidence. J Clin Hypertension. 2016. DOI: 10.1111/jch.12917

416. Trieu K, McLean R, Johnson C, Santos JA, Raj TS, Campbell NRC, Webster J. The Science of Salt: A regularly updated systematic review of the implementation of salt reduction interventions (November 2015 to February 2016). J Clin Hypertension. 2016. DOI: 10.1111/jch.12909

415. Huang L, Crino M, Wu JHY, Woodward M, Land M-A, McLean R, Webster J, Enkhtungalag B, Nowson C, Elliott P, Cogswell M, Toft U, Mill JG, Furlanetto T, Ilich JZ, Hong YH, Cohall D, Luzardo L, Noboa O, Holm E, Gerbes A, Senousy B, Kara SP, Brewster LM, Ueshima H, Subramanian S, Wee TB, Allen N, Choudhury SR, Polonia J, Yasuda Y, Campbell NRC, Neal B, Petersen KS. Protocol for a systematic review and meta-analysis to reliably quantify the potential for equations based upon spot urine samples to estimate population salt intake. JMIR Research Protocols. 2016;5: e1-10.

414. Campbell NRC. Dissidents and dietary sodium. Concerns about the commentary by O'Donnell et al. Letter. International Journal of Epidemiology. Letter. 2016:1-5doi:10.1093/ije/dyw292.

412. Grace SL, Turk-Adawi K, Contractor A, Atrey A, Campbell N, Derman W, Ghisi GMG, Sarkar B, Yeo TJ, Lopez F, Buckley J, Hu D, Sarrafzadegan N. Cardiac rehabilitation delivery model for low-resource settings: An International Council of Cardiovascular Prevention and Rehabilitation consensus statement. Progress in Cardiovascular Diseases (2016), doi: 10.1016/j.pcad.2016.08.004

412. Wong MMY, Arcand J, Leung AA, Raj TS, Trieu K, Santos JA, Campbell NRC. The Science of Salt: A regularly updated systematic review of salt and health outcomes (August to November 2015). J Clin Hypertension 26 JUL 2016 | DOI: 10.1111/jch.12874.

411. Campbell NR, Khalsa T, Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang X-H (World Hypertension League), Burrell L, Horiuchi M, Poulter NR, Prabhakaran M, Ramirez AJ, Schiffrin EL, Touyz RM, Wang J-G, Weber MA (International Society of Hypertension), International Council of Cardiovascular Prevention and Rehabilitation 2016 Dietary Salt Fact Sheet. J Clin Hypertension. 2016. DOI: 10.1111/jch.12894

410. Chen G, Lisa L, Tu K, Hemmelgarn B, Campbell NRC, McAlister F, Quan H for the Hypertension Outcome and Surveillance Team. Influence of using different databases and 'look back' intervals to define comorbidity profiles for patients with newly diagnosed hypertension: Implications for health services researchers. PLOS ONE. 2016;11(9): e0162074. doi: 10.1371/journal.pone.0162074.

409. Mozheyko M, Eregina S, Danilenko N, Vigdorchik A, Tobe S, Campbell N, McLean D, Baskakova Z, Klimovskaia I, Ramanathan K, Hughes D. Hypertension in Russia: Changes observed after 4 years of a Comprehensive Health System Improvement Program in Yaroslavl Region. J Clin Hypertension. 2016. DOI: 10.1111/jch.12885.

408. Campbell NR, Khalsa T, World Hypertension League Executive (Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang X-H), (International Society of Hypertension executive (Burrell L, Horiuchi M, Poulter NR, Prabhakaran M, Ramirez AJ, Schiffrin EL, Touyz RM, Wang J-G, Weber MA), World Stroke Organization, International Diabetes Federation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. High Blood Pressure 2016: Why Prevention and Control are Urgent and Important. J Clin Hypertension. 2016 DOI: 10.1111/jch.12840.

407. Campbell NRC, Cappuccio FP. Dietary Salt and Blood Pressure: verdict is clear, so why any debate? *Hypertension Journal*. 2016; 2:57-59.
- 406. Johnson C, Raj TS, Trieu K, Arcand J, Wong MK, McLean R, Leung A, Campbell NRC, Webster J. The Science of Salt: A Systematic Review of Quality Clinical Salt Studies May 2014 to June 2015. *J Clin Hypertension*. 2016 DOI: 10.1111/jch.12877.**
405. Grace SL, Turk-Adawi K., Contractor A, Atrey A., Campbell N., Derman W, Ghisi GLM, Oldridge N, Sarkar BK, Yeo TJ, Lopez F, Mendis S, Oh P, Hu D, Sarrafzadegan N. Cardiac rehabilitation delivery model for low-resource settings: A consensus statement. *Heart* 2016; 0:1–7. doi:10.1136/heartjnl-2015-309209.
404. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, et al for the Canadian Hypertension Education Program Hypertension Canada's 2016 CHEP Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension. *Can J Cardiol* 2016 DOI: <http://dx.doi.org/10.1016/j.cjca.2016.02.066>
- 403. Sadeghirad B, Duhaney T, Motaghipisheh S, Campbell NRC, Johnston BC. Influence of unhealthy food and beverage marketing on children's dietary intake and preference: a systematic review and meta-analysis of randomized trials. *Obesity Reviews*. 2016. 2016 DOI: 10.1111/obr.12445.**
- 402. McLaren L, Sumar N, Barberio AM, Trieu K, Lorenzetti DL, Tarasuk V, Webster J, Campbell NRC. Population-level interventions in government jurisdictions for dietary sodium reduction (Review). *Cochrane Database of Systematic Reviews* 2016, Issue 9. Art. No.: CD010166. DOI: 10.1002/14651858.CD010166.pub2.**
401. Campbell N, Sauvé M. Reducing deaths by diet: A call for public policy to prevent chronic disease. *Canadian Journal of Internal Medicine*. 2016;11;7-9.
- 400. Trieu K, McLean R, Johnson C, Santos JA, Angell B, Arcand J, Raj TS, Campbell NRC, Wong MMY, Leung AA, Neal B, Webster J. The Science of Salt: A regularly updated systematic review of the implementation of salt reduction interventions (June to October 2015). *J Clin Hypertension*. 2016; 18:487-94. DOI: 10.1111/jch.12806/jch.12806**
399. Campbell NRC, Gelfer M, Stergiou GS, Alpert BS, Myers MG, Padwal R, Rakotz M, Schutte AE, O'Brien E for the World Hypertension League and International Society of Hypertension. A call to regulate manufacture and marketing of blood pressure devices and cuffs. A position statement from the World Hypertension League, International Society of Hypertension and supporting hypertension organizations. *J Clin Hypertension*. 2016; 18:378-380 DOI: 10.1111/jch.12782
398. Kaczorowski J, Campbell NRC, Duhaney T, Mang E, Gelfer M. Reducing Deaths by Diet: A Call to Action for a Public Policy Agenda for Chronic Disease Prevention. *Canadian Family Physician* 2016; 62:469-70.
397. Schiffrin EL, Campbell NRC, Feldman RD, Kaczorowski J, Lewanczuk R, Padwal R, Tobe S, Hypertension in Canada: Past, Present and Future, *Annals of Global Health* 2016, doi: 10.1016/j.aogh.2016.02.006.
- 396. Arcand J, Wong MMY, Trieu K, Leung AA, Campbell NRC, Webster J, Johnson C, Raj TS, McLean R, Neal B. The Science of Salt: A regularly updated systematic review of salt and health outcomes. (June and July 2015). *J Clin Hypertension*. 2016; 18:371-377.**

395. Ordunez P, Campbell NR. Beyond the opportunities of SDG 3: the risk for the NCDs agenda. *Lancet Diabetes & Endocrinology* 2015 doi.org/10.1016/S2213-8587(15)00488-X
- 394. McLaren L, Sumar N, Barberio AM, Trieu K, Lorenzetti DL, Tarasuk V, Webster J, Campbell NRC. Population-level interventions in government jurisdictions for dietary sodium reduction (Protocol). *Cochrane Database of Systematic Reviews* 2015, Issue 10. Art. No.: CD010166. DOI: 10.1002/14651858.CD010166.pub2**
393. Zhang X-H, Liu L, Campbell NRC, Lackland DT, Niebylski ML, Nilsson P, for the World Hypertension League Implementation of WHO Package of Essential Non-Communicable Disease Interventions (WHO PEN) for Primary Care in Low-Resource Settings: A policy statement from the World Hypertension League. *J Clin Hypertension*. 2015 DOI: 10.1111/jch.12749
392. Campbell NRC. Questionable scientific basis for relaxed dietary sodium recommendations. *Can J Cardiol.* (letter) 2016 DOI: <http://dx.doi.org/10.1016/j.cjca.2015.10.027>
- 391. John KA, Cogswell ME Campbell NRC, Nowson C, Legetic B, Hennis A, Patel SM. The accuracy and usefulness of select methods for assessing complete collection of 24h urine, a systematic review. *J Clin Hypertension*. 2016;18: 456-467 DOI: 10.1111/jch.12763. 1-12**
390. Campbell NRC, Redburn KA, Niebylski ML, Drouin D, Zhang X-H, Liu L, Nilsson P, Lackland DT. Restructuring hypertension congresses and scientific meetings for improved hypertension prevention and control. *J Clin Hypertension*. 2016 DOI: 10.1111/jch.12748
389. Arcand J, Webster J, Johnson C, Raj TS, Neal B, McLean R, Trieu K, Wong MMY, Leung AA, Campbell NRC. Announcing 'Up to Date in the Science of Sodium'. *J Clin Hypertension*. 2016;18;85-88 DOI: 10.1111/jch.12732.
388. Campbell NRC Feldman RF. Hypertension in Canada and the Global Context. The wine is vintage, and the glass is two thirds full but is the bottle empty? *Can J Cardiol*.2015 DOI: <http://dx.doi.org/10.1016/j.cjca.2015.07.014>
- 387. Wielgosz A, Robinson C, Mao Y, Jiang Y, Campbell N, Muthuri S, Morrison H. The impact of using different methods to assess completeness of 24-hour urine collection on estimating dietary sodium. *J Clin Hypertension*. 2016; 18:581-4. DOI: 10.1111/jch.12716**
386. Campbell NRC, Lemongoum D. Hypertension in Sub Sahara Africa. A massive and increasing health disaster awaiting solution. *Cardiovascular Journal of Africa*. 2015;26;202-4
385. Ordunez P, Campbell N. Global health metrics and NCDs: the case of hypertension. *Lancet Diabetes and Endocrinology*. 2015; 3(8):763.
384. Campbell NRC, Niebylski ML, Redburn KA, Lisheng L, Nilsson P, Zhang XH, Lackland DT: Executive members for the World Hypertension League. World Hypertension League Position on Public Use of Blood Pressure Kiosks. *J Clin Hypertension*. 2015; 17:913 DOI: 10.1111/jch.12671
383. Velludo Veiga E, Daniel ACQG, Bortolloto LA, Machado CA, Plavinik FL, CláudiaIrigoyen A, Campbell N, Kenerson J, Cloutier L. Some Problems and Solutions in implementing the World Hypertension League recommendations for automated office assessment of blood pressure. *J Clin Hypertension*. 2016; 18:7-9. DOI: 10.1111/jch.12676
- 382. Peng, M, Chen G, Lix LM, McAlister, Tu, K, Campbell NR, Hemmelgarn, Svenson LW, Quan H;**

Hypertension Outcome and Surveillance Team. Methods of defining hypertension in electronic medical records-validation against national survey data, *Journal of Public Health*. 2016 Sep;38(3): e392-e399. Epub 2015 Nov 6.

381. Padwal RS, Bienek A, McAlister FA, Campbell NRC for the Outcomes Research Task Force of the Canadian Hypertension Education Program. *Epidemiology of Hypertension in Canada: An Update*. *Can J Cardiol*. 2015 DOI: <http://dx.doi.org/10.1016/j.cjca.2015.07.734>

380. Downs S, Christoforou A, Snowdon W, Dunford E, Hoesjov P, Legetic B, Campbell N, Webster J. Setting targets for salt levels in foods: a five-step approach for low- and middle-income countries. *Food Policy* 55 (2015) 101–108

379. Weaver CG, Clement F, Campbell N, James MT, Klarenbach S, Hemmelgarn BR, Tonelli M, McBrien KA, for the Alberta Kidney Disease Network (AKDN) and the Interdisciplinary Chronic Disease Collaboration (ICDC). *Health Care Costs Attributable to Hypertension: A Canadian Population-Based Cohort Study*. *Hypertension*. 2015; 66:00-00. DOI: 10.1161/HYPERTENSIONAHA.115.05702.

378. Khalsa T, Campbell NRC, Redburn KA, Lemongoun D, Niebylski ML. A Needs Assessment of Sub Sahara African National Hypertension Organizations for Hypertension Prevention and Control Programs. *J Clin Hypertension*. DOI: 10.1111/jch.12632 2015;17:756-9.

377. Campbell N, Gelfer M, Cloutier L, Lamarre-Cliche M, McLean D, Padwal R. Expediting the diagnosis of hypertension. The Canadian Hypertension Education Program 2015 recommendations. *Canadian Journal of Internal Medicine*. 2015; 10:16-17

376. Trieu K, Hawkes C, Dunford E, Campbell N, Rodriguez-Fernandez R, Legetic B, McLaren L, Barberio A, Neal B, Webster J. Salt reduction initiatives around the world - a systematic review of progress towards the global target. *PLoS ONE* 10(7): e0130247. doi: 10.1371/journal.pone.0130247

375. Al Hamarneh Y, Tsuyuki R, Campbell N. Death by Food: Why Pharmacists Should Care Canadian Pharmacists Journal. *Canadian Pharmacists Journal*. 2015;148(5):232-3. doi: 10.1177/1715163515596759.

374. Tsuyuki RT, Houle SKD, Charrois, TL, Kolber MR; Rosenthal MM, Lewanczuk R; Campbell NRC, Cooney D, McAlister FA. A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: The Alberta clinical trial in optimizing hypertension (RxACTION). *Circulation*. 2015; 132:93-100. DOI: 10.1161/CIRCULATIONAHA.115.015464

373. Campbell NRC, Bovet P, Schutte A, Lemogoum D, Nkwescheu AS. High Blood Pressure in Sub-Saharan Africa: Why Prevention and Control are Urgent and Important. *J Clin Hypertension*. 2015; DOI: 10.1111/jch.12599

372. Campbell N, Touyz R, Lackland D, Redburn K, Niebylski M. Celebrate World Hypertension Day (WHD) on May 17, 2015, and Contribute to Improving Awareness of Hypertension. *J Clin Hypertension*: 23 MAR 2015 | DOI: 10.1111/jch.1254

371. Ji C, Lu T, Dary O, Legetic B, Campbell NRC, Cappuccio F. Systematic Review of Studies Comparing 24-hour versus Spot Urine Collections for Estimating Population Iodine Intake. *Revista Panamericana de Salud Pública/Pan American Journal of Public Health*. 2015;38(1):73–81.

370. Campbell NRC, Lackland, DT, Lisheng L, Zhang X-H, Nilsson PM, Niebylski MI for the World Hypertension League Executive: Where now and where to in salt reduction. *Cardiovascular Diagnosis and Therapy*. 2015; 5:238-42. doi: 10.3978/j.issn.2223-3652.2015.04.08

369. Campbell N, Legowski B, Legetic B, Nilson, E, L'Abbé M. Inaugural maximum values for sodium in processed food products in the Americas. *J Clin Hypertension*. 2015; 17:611- DOI: 10.1111/jch.12553
374. Campbell NC, Lackland, DT, Lisheng L, Zhang X-H, Nilsson PM, Redburn KA, Niebylski ML. The World Hypertension League Challenges Hypertension and Cardiovascular Organizations to Develop Strategic Plans for the Prevention and Control of Hypertension. *J Clin Hypertension*. 2015; 17:325-7 DOI: 10.1111/jch.12557
- 367. Peng M, Chen G, Lix L, McAlister F, Tu K, Campbell N. Hemmelgarn B, Svenson L Quan H. Chen G, Hude. Refining hypertension surveillance to account for potentially misclassified cases. *PLOS One*. March 24. 2015 DOI: 10.1371/journal.pone.0119186**
366. Cloutier L, Gelfer M, Padwal R, Daskalopoulou SS, Lamarre-Cliché M, Bolli P, McLean D, Milot A, Tobe SW, Tremblay G, McKay DW, Townsend R, Myers M, Campbell N. A new algorithm for the diagnosis of hypertension in Canada. *Can J Cardiol*. 2015, doi: 10.1016/j.cjca.2015.02.014.
365. Daskalopoulou SS, Rabi DM, Nerenberg K, Zarnke KB, Dasgupta K, Herman RJ, Bacon SL, Cloutier L, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, WilsonTW, Feldman RD, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, McLean D, Campbell NRC, et al for the Canadian Hypertension Education ProgramThe 2015 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension. *Can J Cardiol*. 2015; 31:549-68.
- 364. Johnson C, Raj ST, Trudeau L, Bacon SL, Padwal R, Webster J, Campbell N. The Science of Salt: A systematic review of clinical salt studies 2013-2014. *J Clin Hypertension*. 2015; 17:401-11 DOI: 10.1111/jch.12529.**
363. Ordunez P; Martinez R, Niebylski ML, Campbell NR. Hypertension Prevention and Control in Latin America and the Caribbean. *J Clin Hypertension*. 2015;17: 499-502. DOI: 10.1111/jch.12518.
362. Campbell N, Lackland D, Lisheng L, Niebylski M, Nilsson PM, Zhang X-H. Using the Global Burden of Disease Study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: A resource from the World Hypertension League. *J Clin Hypertension*. 2014; 17:5-6. DOI: 10.1111/jch.12469
- 361. Niebylski M, Redburn KA, Duhaney T, Campbell NRC. Healthy Food Subsidies and Unhealthy Food Taxation: A Systematic Review of the Evidence. *Nutrition*. DOI: <http://dx.doi.org/10.1016/j.nut.2014.12.010>**
360. Campbell NRC, Lackland DT, Lisheng L, Zhang X-H, Nilsson P, Redburn, KA; Niebylski ML. The World Hypertension League: A Look Back and a Vision Forward. *J Clin Hypertension*. 2015;17;5-6 DOI: 10.1111/jch.12469
359. Mangat BK, Campbell N, Berbari A, Cloutier L, Kenerson J, Khalsa JK, Lemogoum D, Mohan S, Niebylski ML, Orias M, Veiga E, Zhang XH. Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide from the World Hypertension League. *J Clin Hypertension*. *J Clin Hypertension*. 2015; 17:418-20 DOI: 10.1111/jch.12499
358. Campbell NRC, L'Abbe M. Controversial sodium guidelines or too much focus on low quality science? Response to Stuart M. MacLeod and John A. Cairns. Controversial sodium guidelines: Scientific solution or perpetual debate? (letter) *CMAJ cmaj*.141011; published ahead of print November 10, 2014, doi:10.1503/cmaj.141011

357. Cheung C, Martyn A, Campbell N, Frost S, Gilbert K; Michota F, Seal D, Ghali W, Khan N. Predictors of Intraoperative Hypotension and Bradycardia, American Journal of Medicine. DOI: <http://dx.doi.org/10.1016/j.amjmed.2014.11.030>.
356. Blom K, Farina S, Gomez Y-D, Campbell NRC, Hemmelgarn B, Cloutier L, Mackay DW, Dawes M, Tobe SW, Bolli P, Gelfer M, Mclean D, Bartlett G, Joseph L, Featherstone R, Schiffrin EL, Daskalopoulou SS. MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): a Study Protocol. Current Hypertension Reports. 2015 Apr;17(4):533. doi: 10.1007/s11906-015-0533-5.
355. Walker RL, Chen G, McAlister FA, Campbell NRC, Hemmelgarn BR, Dixon E, Ghali W, Rabi D, Tu K, Jette N, Quan H for Hypertension Outcome and Surveillance Team. The relationship between primary care physician utilization and hospitalizations or ED visits for uncomplicated hypertension, an ambulatory care sensitive condition. Can J Cardiol 2014; 30(12):1640-1648. doi:10.1016/j.cjca.2014.09.035
354. Gelfer M, Mang E, Duhaney T, Campbell N. Calls for Restricting the Marketing of Unhealthy food to children: Health Care and Scientific Community is ignored by policy makers. What can we do? Canadian Family Physician. 2014; 69:969-71.
353. Campbell N, Lackland D, Niebylski M, Nilsson PM. Is reducing dietary sodium controversial? Is it the conduct of studies with flawed research methods that is controversial? A Perspective from the World Hypertension League Executive. J Clin Hypertension 2014; DOI: 10.1111/jch.12437
352. Campbell NRC. Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. Letter. J Hypertension 2014; 32:2499-50.
351. Khalsa TK, Campbell NRC, Lackland DT, Lisheng, L, Niebylski ML, Zhang ZH, A Needs Assessment of National Hypertension Organizations for Hypertension Prevention and Control Programs. J Clin Hypertension. 2014 DOI: 10.1111/jch.12432
350. Duhaney T, Campbell N, Niebylski ML, Kaczorowski J, Tsuyuki RT, Willis K, Mang E, Arango M, Morris D, Ashley L. Death by diet: The role of food pricing interventions as a public policy response and health advocacy opportunity. Can J Cardiol. 2014; 30:1-5, doi.org/10.1016/j.cjca.2014.09.005.
349. Webster J, Lan MA, Christoforou A, Eastman CJ, Zimmerman M, Campbell N, Neal B. Reducing dietary salt and preventing iodine deficiency: a common agenda for public health. Med J Aust 2014; 201 (9): 507-508. DOI: 10.5694/mja14.00818
348. Fitzpatrick L, Arcand J, L'Abbe M, Deng M, Duhaney T, Campbell N. Accuracy of the Canadian food labels for the sodium content of food. *Nutrients* 2014, 6(8), 3326-3335; DOI: 10.3390/nu6083326.
347. Campbell N, Legowski B, Legetic B, Ferrante D, Nilson E, Campbell C, L'Abbé M. Targets and timelines for reducing salt in processed food in the PAHO-WHO region. J Clin Hypertension 2014 DOI: 10.1111/jch.12379.
346. Gee ME, Campbell N, Sarrafzadegan N, Jafar T, Khalsa TK, Mangat B, Poulter N, Prabhakaran D, Sonkodi S, Whelton PK, Woodward M, Zhang X-H. Standards for the uniform reporting of hypertension in adults using population survey data: Recommendations from the World Hypertension League Expert Committee. J Clin Hypertension. DOI: 10.1111/jch.12387

345. Campbell N, Correa-Rotter R, Cappuccio F, Webster J, Lackland DT, Neal B, MacGregor GA. Proposed nomenclature for salt intake and for reductions in dietary salt. J Clin Hypertension. 2014 DOI: 10.1111/jch.12442.
344. Campbell NRC, Duhaney T, Arango M, Ashley L, Bacon SL, Gelfer M, Kaczorowski J, Mang E, Morris D, Nagpal S, Tsuyuki R, Willis K. Healthy Food Procurement Policy: An Important Intervention to Aid the Reduction in Chronic Noncommunicable Diseases. Can J Cardiol. 2014; 30:1456-1459. DOI: 10.1016/j.cjca.2014.06.021
- 343. Cunningham CT, Sykes L, Metcalfe A, Cheng A, Riaz M, Lin K, Schorr E, Metcalfe Campbell NRC, Quan H. Ethnicity and health literacy: A survey on hypertension knowledge among Canadian ethnic populations. Ethnicity & Disease. 2014; 24(3) 276-282**
- 342. McLaren L, Heidinger S, Dutton DJ, Tarasuk V, Campbell NR. Socio-economic inequities in dietary sodium consumption among Canadian adults: Implications for national sodium reduction strategies. International Journal for Equity in Health.2014, 13:44 DOI: 10.1186/1475-9276-13-44**
341. Campbell N, Appel L, Cappuccio F, Correa-Rotter R, Hankey G, Lackland D, MacGregor G, Neal B, Niebylski M, Webster J, Willis K, Woodward M. A call for quality research on salt intake and health: From the World Hypertension League and Supporting Organizations" J Clin Hypertension. 2014; 16:469-71DOI: 10.1111/jch.12364
340. Weber MA, Campbell NRC, Lackland DT. The Journal of Clinical Hypertension Has Become the Official Journal of the World Hypertension League. J Clin Hypertension. 2014; 16:319.
339. Campbell N, Niebylski M, Lackland D et al. High Blood Pressure: Why Prevention and Control are Urgent and Important. A 2014 Fact Sheet from the World Hypertension League and the International Society of Hypertension. J Clin Hypertension. 2014 16; 551-553 DOI: 10.1111/jch.12372
338. Campbell N, Niebylski M, Lackland D. 2014 Dietary salt fact sheet of the World Hypertension League, International Society of Hypertension, Pan American Health Organization Technical Advisory Group on Cardiovascular Disease Prevention through Dietary Salt Reduction, WHO Coordinating Centre on Population Centre Salt Reduction, and World Action on Salt and Health. J Clin Hypertension. 2014 DOI: 10.1111/jch.12402.
337. Campbell NRC, Berbari AE, Cloutier L, Gelfer M, Kenerson JG, Khalsa TK, Lackland DT, Lemogoum D, Mangat BK, Mohan S, Myers MG, Niebylski ML, O'Brien E, Stergiou GS, Velludo Veiga E, Zhang X-H. Policy Statement of the World Hypertension League on non-invasive blood pressure measurement devices and blood pressure measurement in the clinical or community setting. J Clin Hypertension. 2014; 16:320-322.
336. Houle SKD, Rosenthal M, Campbell N, Duhaney T, Tsuyuki RT, Why pharmacists should care about the marketing of unhealthy foods – A call to action for an increased role for pharmacists in public health policy. Can Pharmacists Journal. 2014 147: 4 DOI: 10.1177/1715163513515833
- 325. Clement FM, Chen G, Khan N, Tu K, Campbell NRC M, Quan H, Hemmelgran B, McAlister FA, for the Hypertension Outcome and Surveillance Team. Primary care physician visits by patients with incident hypertension. Can J Cardiol. 2014;30: e653-660.**
- 324. Tu K, Anderson LN, Butt DA, Quan H, Hemmelgarn BR, Campbell NR, McAlister FA, on behalf of the Hypertension Outcome and Surveillance Team Antihypertensive drug prescribing and persistence among new elderly users in Ontario, Canada. Can J Cardiol 2014; 30:647-52.**

323. Campbell NR, Niebylski ML, World Hypertension League Executive. Prevention and Control of Hypertension. Developing a global agenda. *Curr Opin Cardiol*. 2014; *Current Opinion Cardiol*. 2014, 29:000–000, DOI:10.1097/HCO.0000000000000067
- 322. Niebylski M, Lu T, Campbell NRC, Arcand J, Schermel A, Hua D, Yeates K, Tobe S, Twohig P, L'Abbé M, Liu P. Healthy Food Procurement Policies and their Impact. *Int. J. Environ. Res. Public Health* 2014, 11, 2608-2627; DOI:10.3390/ijerph110302608.**
321. Campbell N, Pipe A, Duhaney T. Calls for Restricting the Marketing Unhealthy food to children: Canadian Cardiovascular, Health Care and Scientific Community get ignored by policy makers. What can they do? *Can J Cardiol*. 2014;30:479-81.
320. The Executive Board of the World Hypertension League (Campbell NRC, Lackland D, Chockalingam A and Lisheng L), and the Executive Committee of the International Society of Hypertension (Schiffrin EL, Harrap S, Touyz RM, Burrell L, Ramírez A, Schmieder R, Schutte A, Prabhakaran D). The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. *J Hypertension* 2014; Feb;32(2):446-7 and *J Clin Hypertension*. 2014;16(2):99-100.
- 319. Mozheyko M, Eregim S, Vigdorchik A, Chazova I, Tobe S, Campbell N, Riahi F, Hughes D. Changes in Hypertension Treatment in the Yaroslavl Region of Russia: Improvements Observed Between 2 Cross-sectional Surveys. *J Clin Hypertension*. 2013; Dec;15(12):918-24.**
- 318. Campbell N, Willis KJ, Arthur G, Jeffery B, Robertson HL, Lorenzetti DL. Federal government food policy committees and the financial interests of the food sector. *Open Medicine*. 2013; 4:107-11.**
- 317. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, McAlister FA, Johansen H, Baclic O, Campbell N. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. *Br Med J Open*. 2013;3(8): e003423 DOI:10.1136/bmjopen-2013-003423.**
- 316. Gee ME, Pickett W, Janssen I, Campbell NRC, Birtwhistle R. Validity of self-reported blood pressure control in people with and without diabetes attending a primary care centre. *Blood Pressure Monitoring*. 2014; 19:19-25**
315. Campbell NRC, Lackland DT, MacGregor GA. Dietary Sodium. A perspective on recent sodium evidence, its interpretation and controversies. *J Clin Hypertension*. 2013 Nov;15(11):765-8.
- 314. Gee ME, Pickett W, Janssen I, Johnson JA, Campbell NR. Health Behaviors for Hypertension Management in People with and without coexisting Diabetes *J Clin Hypertension*. 2013;15(6):389-96.**
- 313. Walker RL, Chen G, McAlister FA, Campbell NR, Hemmelgarn BR, Dixon E, Ghali W, Rabi D, Tu K, Jette N, Quan H; Hypertension Outcome and Surveillance Team. Hospitalization for uncomplicated hypertension: an ambulatory care sensitive condition. *Can J Cardiol*. 2013 Nov;29(11):1462-9.**
312. Cloutier L, Morris D, Bruneau J, McLean D, Campbell N. World Health Organization Celebrates World Health Day, April 7, 2013—Focusing on Hypertension. *Can J Cardiovascular Nursing*, 2013; 23(2), 9– 11.
311. The Food Monitoring Group (N Campbell, Contributor). Progress with a global branded food composition database. *Food Chemistry*. 2013; 140:451–457.

310. Morris D, Cloutier L, Bruneau J, McLean D, Campbell N. Bringing focus to hypertension. Canadian Nurse (feedback). April 2013.

309. Campbell N, Tsuyuki RT. Hypertension: Silent and/or ignored. Can Pharmacists Journal. 2013; 146:61-62.

308. Gelfer M, Drouin D, Dawes M, Campbell N. World Health Day. Focusing on hypertension in 2013. Canadian Family Physician. 2013; 59:341-2.

307. Mohan S, Campbell N, Chockalingam A. World Health Day: Time to Effectively Address Hypertension in India. Indian J Med Res. 2013; 137:1-5.

306. Jones CA, Nanji A, Mawani S, Davachi S, Ross L, Vollman A, Aggarwal S, King-Shier K, Campbell N. Feasibility of community-based screening for cardiovascular disease risk in an ethnic community: The South Asian Cardiovascular Health Assessment and Management Program (SA-CHAMP). BMC Public Health. 2013;13:160.

305. Quan H, Chen G, Walker RL, Wielgosz A, Dai S, Tu K, Campbell NRC, Hemmelgarn BR, Hill MD, Johansen H, McAlister FA, Khan N for Hypertension Outcome and Surveillance Team. Incidence, cardiovascular complications and mortality of hypertension by sex and ethnicity. Heart. 2013;99:10 715-721.

304. Campbell NRC, Feldman R, Kaczorowski J, Larochelle P. High blood pressure selected as the theme for World Health Day April 7, 2013: Cup half full or half empty? Can J Cardiol. 2013;29:415-17.

303. Quan H, Chen G, Tu K, Bartlett G, Butt DA, Campbell N, Hemmelgarn BR, Hill MD, Johansen H, Khan N, Lix LM, Smith M, Svenson L, Walker RL, Wielgosz A, McAlister FA for Hypertension Outcome and Surveillance Team Outcomes among 3.5 million newly diagnosed hypertensive Canadians. Can J Cardiol. 2013;29:592-97.

302. McAlister FA, Robitaille C, Rao D, Gillespie C, Yuan K, Loustalot F, Grover S, Joffres M, Campbell N. The Impact of Cardiovascular Risk-Factor Profiles on Blood Pressure Control Rates in Adults from Canada and the United States. Can J Cardiol. 2013; 29:593-605.

301. Bienek AS, Gee ME, Nolan RP, Kaczorowski J, Campbell NRC, Bancej C, Gwadry-Sridhar F, Robitaille C, Walker RL, Dai S. Methodology of the 2009 Survey on Living with Chronic Diseases in Canada – hypertension component. Chronic Diseases and Injuries in Canada. 2013; 33:267-76.

300. Chen J, Sykes L, Paul C, Dary O, Campbell N, Cappuccio FP on behalf of the Sub-Group for Research & Surveillance of the PAHO/WHO Regional Expert Group for Cardiovascular Disease Prevention through population-wide Dietary Salt Reduction. Systematic review of studies comparing 24-h vs spot urine collections for estimating population salt intake. Revista Panamericana de Salud Pública/Pan American Journal of Public Health. 2012;32(4):307–15.

299. Whelton PK, Appel LJ, Sacco RL, Anderson CMA, Antman EM, Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR, MacGregor GA, Sacks FM, Stamler J, Vafiadis DK, Van Horn LV. Sodium, Blood Pressure and Cardiovascular Disease: Further Evidence Supporting the American Heart Association Sodium Reduction Recommendations, A Presidential Advisory from the American Heart Association. Circulation. 2012; 126:2880-2889.

298. Campbell NRC, Dary O, Cappuccio FP, Neufeld LM, Harding KB, Zimmermann MB. A call for action to coordinate programs to improve global health by optimizing salt and iodine intake. Revista Panamericana de Salud Pública/Pan American Journal of Public Health. 2012;32(4):281-6.

- 297. Claro RM, Linders H, Zancheta C, Correa-Rotter R, Legetic B, Campbell NRC. Consumers' attitudes, knowledge and behaviors related to salt consumption in sentinel countries of the Americas. *Revista Panamericana de Salud Pública/Pan American Journal of Public Health*. 2012;32(4):265-73.**
296. Campbell N, Correa-Rotter R, Legowski B, Legetic B. Efforts to reduce dietary salt in the Americas. *Revista Panamericana de Salud Pública/Pan American Journal of Public Health*. 2012;32(4):257-8.
- 295. McLaren L, Sumar N, Lorenzetti D, Campbell NRC, McIntyre L, Tarasuk V. Population-level interventions in government jurisdictions for dietary sodium reduction: differential effects by social and economic indicators on health outcomes related to high sodium intake (protocol). *The Cochrane Library*, Issue 10, October 2012.**
294. Tobe SW, Poirier L, Tremblay G, Lindsay P, Reid D, Campbell NRC; Canadian Hypertension Education Program. Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program. *Open Med* 2012;6(4): e127–e133.
- 293. The Food Monitoring Group (N Campbell a contributor to group). International collaborative project to compare and track the nutritional composition of fast foods. *BMC Public Health*. 2012; 12:559 DOI:10.1186/1471-2458-12-559.**
292. He FJ, Campbell NRC, MacGregor GA. Reducing Salt Intake to Prevent Hypertension and Cardiovascular Disease. *Revista Panamericana de Salud Pública/Pan American Journal of Public Health*. 2012;32(4):293-300.
291. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris S. Response to letter from Jacky Siu et al on Hypertension in People with Type 2 Diabetes: An Update on Pharmacological Management. *Can Family Physician*. 2012; 58:634-636
- 290. Wilkins K, Gee M, Campbell NRC. The difference in hypertension control between older men and women. *Health Reports*. 2012; 23:3-10.**
289. Campbell NRC, McAlister FA, Quan H, for the Hypertension Outcomes Research Task Force. Monitoring and evaluating efforts to control hypertension in Canada. Why, how and what it tells us about current care gaps? *Can J Cardiol*. 2013;29:564-70.
- 288. McBrien K, Rabi D, Campbell N, Barnieh L, Clement F, Hemmelgarn B, Tonelli M, Leiter L, Klarenbach S, Manns B. Systematic review and meta-analysis of intensive blood pressure targets in type 2 diabetes. *Arch Intern Med*. 2012;172(17):1296-1303.**
287. Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin LE, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad RVR, Lebel M, McLean D, Arnold JMO, Moe GW, Howlett JG, Boulanger J-M, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NRC, Reid D, Poirier L, and Tobe SW, for the Canadian Hypertension Education Program. The 2012 Canadian Hypertension Education Program (CHEP) Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk and Therapy. *Can J Cardiol*. 2012; 28:270-287.
286. Campbell NRC. Re US tops salty fast food league table. Response to letter from Morton Satin. *BMJ* 2012 <http://www.bmj.com/content/344/bmj.e2769/rr/582338>, Re: Desk-bound authors do not understand food industry. Response to letter from Morton Satin. *CMAJ*, published online May 2, 2012.

285. Dunford E, Webster J, Woodward M, Czernichow S, Lun Yuan W, Jenner K, Ni Mhurchu C, Jacobson M, Campbell N, Neal B. The variability of reported salt levels in fast foods across six countries-opportunities for salt reduction. *CMAJ*. 2012; June 12;184(9):1023-8.
284. Gee ME, Campbell NRC, Gwadry-Sridhar F, Nolan RP, Kaczorowski J, Bienek A, Robitaille C, Joffres M, Dai S, Walker RL for the Outcomes Research Task Force of the Canadian Hypertension Education Program. Antihypertensive medication use, adherence, stops and starts in Canadians with hypertension. *Can J Cardiol*. 2012; 28:383-89.
283. Quan H, Smith M, Bartlett-Esquilant G, Johansen H, Tu K, Lix L for Hypertension Outcome and Surveillance Team (N Campbell co- lead for HOST). Mining administrative health databases to advance medical science: Geographical considerations and untapped potential in Canada. *Can J Cardiol*. 2012; 28:152-54.
282. Lix LM, Walker R, Quan H, Nesdole R, Yang J, Chen G on behalf of the CHEP ORTF Hypertension Outcomes and Surveillance Team (Campbell N co- lead of the Hypertension Outcomes and Surveillance Team). Features of Physician Services Databases in Canada. *Chronic Diseases and Injuries in Canada*. 2012; 32:186-193.
281. Gee ME, Campbell NRC, Joffres M, Robitaille C, Tremblay MS, McAlister F, Johansen H, Bienek A. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. *Can J Cardiol*. 2012; 28:375-82.
280. Campbell N, Johnson JA, Campbell T. Sodium consumption, an individual's choice? *Int J Hypertension*. 2012; Jan. Article ID 860954, 6 pages, DOI:10.1155/2012/860954.
279. Houle SKD, Tsuyuki RT, Campbell NRC. The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. *Can Pharm J*. 2011; 144:295-304.
278. Campbell NRC, Raine K, McLaren L. "Junk Foods", "Treats" or "Pathogenic foods"? A Call for Changing Nomenclature to Fit the Risk of Today's Diets. *Can J Cardiol*. 2012; 28:403-4.
277. Dutton DJ, Campbell NRC, Elliott C, McLaren L, A ban on marketing of foods/beverages to children: the who, why, what, and how of a population health intervention. *Can J Public Health*. 2012; 103:100-102.
276. Campbell N, Young E, Drouin D, Legowski B, Adams M, Farrell J, Kaczorowski J, Lewanczuk R, Moy Lum-Kwong M, Tobe S. A framework for discussion on how to improve prevention, management and control of hypertension in Canada. *Can J Cardiol*. 2012;28:262-69.
275. 2011 Canadian Hypertension Education Program Recommendations: The Short Clinical Summary - An Annual Update. (Written by Campbell N with the CHEP Executive and contributions by Dr. Tavis Campbell, Dr. Steven Grover, Dr. Michael Hill and Dr. Raj *Padwal*). *Can Fam Physician*. 2011; 57:1393-1397.
274. Bolli P, Campbell NRC. Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experience," *Int J Hypertension*, 2011; Article ID 410754, DOI:10.4061/2011/410754.
273. Campbell NRC, Hemmelgarn BR. The Role of Ambulatory Blood Pressure Monitoring in the Diagnosis of Hypertension. New recommendations? Campbell NRC, Hemmelgarn BR. The Role of Ambulatory Blood Pressure Monitoring in the Diagnosis of Hypertension. New recommendations? *CMAJ*. 2012; Apr 3;184(6):633-4.

- 272. Robitaille C, Dai S, Waters C, Loukine L, Bancej C, Quach S, Ellison J, Campbell N, Tu K, Reimer K, Walker R, Smith M, Blais C, Quan H. Incidence, prevalence and mortality of diagnosed hypertension in Canada. CMAJ. January 10, 2012;184: E49-E56.**
271. Campbell N, Dary O, Cappuccio FP, Neufeld LM, Harding KB, Zimmermann MB Collaboration to optimize dietary intakes of salt and iodine. A critical but overlooked public health issue. Bulletin of the World Health Organization. 2012;90:73-74.
- 270. Gee ME, Bienek A, Campbell NR, Bancej CM, Robitaille C, Kaczorowski J, Joffres M, Dai S, Gwady-Sridar F, Nolan RP. Prevalence of, and barriers to, preventive lifestyle behaviors in hypertension (from a national survey of Canadians with hypertension). Am J Cardiol. 2012; 109:570-5.**
269. Campbell NRC, Willis KJ, L'Abbe M, Strang R, Young E. Canadian Initiatives to Prevent Hypertension by Reducing Dietary Sodium. Nutrients. 2011; 3:756-64.
- 268. Charrois TL, McAlister FA, Cooney D, Lewanczuk R, Kolber M, Campbell NRC, Rosenthal M, Houle SKD, Tsuyuki RT. Improving hypertension management through pharmacist prescribing. The Rural Alberta Clinical Trial in Optimizing Hypertension (Rural RxACTION): Trial Design and Methods. Implementation Science. 2011; 6:94.**
267. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris S. Hypertension in People with Type 2 Diabetes: An Update on Pharmacological Management. Can Family Physician. 2011;57(9):997-1002.
- 266. Gee ME, Janssen I, Pickett W, McAlister FA, Bancej CM, Joffres M, Johansen H, Campbell N. Prevalence, awareness, treatment and control of hypertension among Canadian adults with diabetes, 2007-2009. Can J Cardiol. 2012; 28:367-74.**
265. Campbell N, Correa-Rotter R, Neal B, Cappuccio F. New evidence relating to the health impact of reducing salt intake Statement from an 'ad hoc' Scientific Review Subcommittee of the PAHO/WHO Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction. Nutrition, Metabolism & Cardiovascular Diseases. 2011; 21:617-9.
264. Legetic B, Campbell N. Pan American Health Organization Actions to Facilitate Cardiovascular Disease Prevention Through Population Based Salt Reduction in the Americas. Journal of Health Communication. 2011;16:37-48.
263. Campbell N, Cappuccio FP, Tobe SW. Unnecessary controversy regarding dietary sodium. A lot about a little. Can J Cardiol. 2011; 27:404-6.
262. Van Vliet B, Campbell NRC. Efforts To Reduce Sodium Intake in Canada: Why, What, and When. Can J Cardiol. 2011;27:437-45.
261. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover S, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliche M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NRC, Vallée M, Prasad GVR, Lebel M, Campbell TS, Lindsay P, Herman RJ, Larochelle P, Feldman RD, Arnold JMO, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger J-M, Sharma M, Hamet P, Fodor J, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW, for the Canadian Hypertension Education Program. The 2011 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk and therapy. Can J Cardiol. 2011; 27:415-433.

- 260. Walker RL, Gee ME, Bancej C, Nolan R, Kaczorowski J, Joffres M, Bienek A, Gwadry-Sridhar F, Campbell NRC. Advice from health professional to Canadian adults with hypertension: Results from a national survey. Can J Cardiol. 2011; 27:446-54.**
259. Campbell NRC, Poirier L, Tremblay G, Lindsay P, Reid D, Tobe SW on behalf of the Canadian Hypertension Education Program. Canadian Hypertension Education Program: The science supporting new 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation. Can J Cardiol. 2011; 27:407-414.
- 258. McAlister FA, Wilkins K, Joffres, M, Leenen, FF, Fodor JG, Baclic O, Gee, M, Tremblay, MS, Walker R, Johansen H, Robitaille C, Campbell NRC. Changes in hypertension awareness, treatment, and control rates in Canada over the past two decades. CMAJ. 2011; 183:1007-1013.**
- 257. Khan NA, Wang H, Anand S, Jin Y, Campbell NRC, Pilote L, Quan H. Ethnicity and Sex Impact Diabetes Incidence and Outcomes. Diabetes Care. 2011; 34:96-101.**
256. Campbell NRC, Neal BC, MacGregor GA. Interested in developing a national program to reduce dietary salt? J Human Hypertension. 2011; 25:705-10.
255. Campbell NRC, Strang R, Young E. Hypertension, the need for combining public health and clinical approaches. Can J Cardiol. 2011; 27:34-6.
- 254. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular outcomes in Framingham participants with diabetes: The importance of blood pressure. Hypertension. 2011; 57:891-897.**
- 253. Jones CA, Mawani S, King KM, Allu SO, Mohan S, Campbell NRC. Tackling Health Literacy: Adaptation of Public Hypertension Educational Materials for an Indo-Asian Population in Canada. BMC Public Health. 2011;11:24.**
252. Campbell N. On behalf of CHEP. 2010 Canadian Hypertension Education Program Recommendations - An Annual Update. Can J General Internal Medicine. August 2010;5(2):81-82.
251. Campbell N. On behalf of CHEP. 2010 Canadian Hypertension Education Program Recommendations - An Annual Update. Canadian Family Physician. July 2010;56(7):649-653.
- 250. Gee M, Campbell NRC, Banceja CM, Robitaille C, Bieneka A, Joffres MR, Walker RI, Kaczorowski J, Dai S. Perception of uncontrolled blood pressure and behaviours to improve blood pressure: Findings from the 2009 survey on living with chronic disease in Canada. J Hum Hypertens. 2012; 26:188-95.**
249. Rabkin SW, Feldman R, Tobe SW, Drouin D, McAlister FA, Campbell N. A strategy to improve hypertension control: The Canadian experience. CVD Prevention and Control. CVD Prevention and Control. 2010; 5:107-113.
248. Campbell N, Govig B, Echenberg D On behalf of the CSIM Health Promotion Committee. Me active in health policy? Why? Can J General Internal Medicine. 2011; 5:152-3.
247. Houle S, Campbell NRC, Ross T. Tsuyuki. Home Blood Pressure Monitoring Plays a Key Role in Hypertension Management – Implications for Pharmacists. Can Pharmacy J. 2011; 144:18-20.
- 246. Khan NA, Campbell NRC, Frost S, Gilbert K, Michota F, Usmani A, Lye T, Seal D, Ghali W. Risk of Intraoperative Hypotension with Loop Diuretics: A Randomized Controlled Trial. Am J Med Am J Med. 2010; 123:1059e-59e.**

245. McAlister FA, Herman R, Khan NA, Rabkin SW, Campbell N for the Canadian Hypertension Education Program. Putting ACCOMPLISH into context: Hypertension management in 2010. CMAJ. 2010;182(5):1600-1.

244. Blanco A, Legetic B, Campbell NRC. Los países de las Américas se movilizan para disminuir la hipertensión y las ECV mediante la reducción del consumo de sal en la población. Archivos Latinoamericanos de Nutricion. No 1, Marzo 2010 del Vol. 60.

243. Neutel CI, Campbell NR, Morrison HI. Trends in diabetes treatment in Canadians, 1994–2004. Chronic Disease in Canada. 2010; 30:107-111.

242. Campbell NRC, Tobe SW. The Canadian Effort to Prevent and Control Hypertension. Can Other Countries adopt Canadian Strategies? Current Opinion in Cardiology 2010;25:366-372.

241. Campbell NRC, Legowski B, Legetic B. Mobilizing the Americas for dietary salt reduction. Lancet. 2011; 377:793-795.

240. Quinn RR, Hemmelgarn BR, Padwal RS, Myers MG, Cloutier L, Bolli P, McKay DW, Khan NA, Hill MD, Mahon J, Hackam D, Grover S, Wilson T, Penner B, Burgess E, McAlister FA, Lamarre-Cliché M, Mclean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NRC, Vallée M, Prasad R, Lebel M, Tobe SW MD, for the Canadian Hypertension Education Program. The 2010 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2010; 26:241-248.

239. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NRC, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JMO, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger J-M, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée MD, Prasad GVR, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW. The 2010 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Part 2 – Therapy. Can J Cardiol. 2010; 26:249-58.

238. Campbell NRC, Kaczorowski J, Lewanczuk RZ, Feldman R, Poirier L, Kwong MML, Lebel M, McAlister FA, Tobe S on behalf of the Canadian Hypertension Education Program. The Scientific Summary - An Update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol. 2010; 26:236-40.

237. Klarenbach SW, McAlister FA, Johansen H, Tu K, Hazel M Walker R, Zarnke KB Campbell NRC. Identification of factors driving differences in cost-effectiveness of first line pharmacologic therapy for uncomplicated hypertension. Can J Cardiol. 2010;26: e158-163.

236. Bancej CM, Campbell N, McKay DW, Nichol M, Walker RL, Kaczorowski J. Home blood pressure monitoring among Canadian adults with hypertension: Results from the 2009 Survey on Living with Chronic Diseases in Canada. Can J Cardiol. 2010;26: e152-157.

235. Campbell NRC, Legowski B, Legetic B, Wilks R and Vasconcellos A for the PAHO/WHO Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction. A new initiative to prevent cardiovascular disease in the Americas by reducing dietary salt. CVD Prevention and Control. 2010;4: 185–187.

234. Allu SO, Bellerive J, Walker RL, Campbell NRC. Hypertension: Are you and your patients up to date? Can J Cardiol. 2010; 26:261-4.

- 233. Walker R, Chen G, Campbell N, McAlister FA, Quan H, Tu K, Khan N, Hemmelgran B for the Canadian Hypertension Education Program Outcomes Research Task Force. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. Can J Cardiol. 2011; 27:461-67.**
232. Campbell NRC, Chen G. Canadian Efforts to Prevent and Control Hypertension. Can J Cardiol. 2010;26(Suppl. C):14-17.
231. Thompson A, Semchuk B, Campbell NRC, Kaczorowski J, Tsuyuki RT for the Canadian Hypertension Education Program. Hypertension guidelines for pharmacists:2009 update. Can J Pharm. 2010; 143:20-27.
- 230. Friedman O, McAlister FA, Yun L, Campbell NRC, Tu K, for the CHEP Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among incident elderly hypertensives In Ontario. Am J Med. 2010; 123:173-8.**
- 229. Bryan S, St-Pierre Larose M, Campbell N, Clarke J, Tremblay MS. Resting blood pressure and heart rate measurement in the Canadian Health Measures Survey, cycle 1. Health Reports. 2010;21:71-8.**
- 228. Wilkins K, Campbell NRC, Joffres MR, Johansen HL, McAlister FA, Nichol M, Quach S, Tremblay MS, Blood pressure in Canadian adults. Health Reports. 2010;21: 1-10.**
- 227. Grover S, Coupal L, Kouache M, Lowensteyn I, Marchand S, Campbell N. Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: The MyHealthCheckUp Survey. Can J Cardiol. 2011; 27:159-66.**
226. Campbell NRC, Legowski B, Legetic B, Wilks R and Vasconcellos A for the PAHO/WHO Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction. The Pan American Health Organization Policy Statement in dietary salt. Preventing cardiovascular disease in the Americas by reducing dietary salt intake population wide. CVD Prevention and Control. 2010;4: 189–191.
- 225. Quan H, Khan N, Hemmelgarn B, Tu K, Chen G, Campbell NRC, Hill MD, Ghali W, McAlister F for the Hypertension Outcome and Surveillance Team Validation of a Coding Algorithm to Define Hypertension using Administrative Data: Variation due to Geographic Region and Time Period. Hypertension. 2009; 54:1423-1428.**
224. Jhandir F, Herman R, Campbell NRC. Treating hypertension in the very elderly reduces death and disability. New information from the HYVET trial. Geriatrics and Aging. 2009;12(7):350-2.
223. Mohan S, Campbell NRC, Willis K. Effective population wide public health interventions to promote sodium reduction. CMAJ. 2009; 181:605-9
- 222. Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NRC on behalf of the ASCOT Investigators Baseline Heart Rate, Antihypertensive Treatment and Prevention of Cardiovascular Outcomes in the Anglo-Scandinavian Cardiac Outcomes Trial. JACC 2009; 54:1154-64.**
221. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, MD, Patrick Couture MD, Robert Dufour MD, George Fodor MD, Gordon A, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GBJ, Ng D, Pearson GJ, Sniderman A, Stone J, Ur E. Guidelines for the diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease 2009. 2009 Recommendations. Can J Cardiol. 2009;25:567-79.
- 220. Mohan S, Chen G, Campbell NRC, Hemmelgarn B. Regional variations in treatment for diagnosed hypertension in Canada. Can J Cardiol. 2010; 2010;26(8):409-13.**

219. Campbell NRC, Leiter LA, Laroche P, Tobe S, Chockalingam A, Ward R, Morris D, Tysuyuki R. Hypertension in Diabetes: A call to action. Can J Cardiol. 2009; 25:299-308.
218. Campbell NRC, Tsuyuki R. Hypertension in Diabetes: A call to action. Can Pharm J. [Editorial] 2009;142:52-53.
217. Campbell NRC, Hill M, Khan N, Tremblay G. On behalf of the Canadian Hypertension Education Program. 2009 Canadian Hypertension Education Program Recommendations. The Scientific Summary - An Annual Update. Can J Cardiol. 2009; 25:271-277.
216. Raj S Padwal, Brenda R Hemmelgarn, Nadia A Khan, Steven Grover, Finlay A McAlister, Donald W McKay, Thomas Wilson, Brian Penner, Ellen Burgess, Peter Bolli, Michael D. Hill, Jeff Mahon, Martin G Myers, Carl Abbott, Ernesto L Schiffrin, George Honos, Karen Mann, Guy Tremblay, Alain Milot, Lyne Cloutier, Arun Chockalingam, Simon W Rabkin, Martin Dawes, Rhian M Touyz, Chaim Bell, Kevin D Burns, Marcel Ruzicka, Norman RC Campbell, Marcel Lebel and Sheldon W Tobe, for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2009; 25:279-286.
215. Khan NA, Hemmelgarn B, Herman RJ, Leiter LA, Mahon JL, Bell CM, Rabkin SW, Hill MD, Touyz RM, Padwal R, Laroche P, Feldman RD, Schiffrin EL, Campbell NRC, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor JG, Carruthers G, Burns KD, Prasad R, Ruzicka M, deChamplain J, Pylypchuk G, Petrella R, Boulanger J-M, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Lewanczuk RZ, Tobe S for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2- Therapy. Can J Cardiol. 2009; 25:287-298.
214. Falaschetti E, Campbell N, Mohan S, Poulter N. Implementation of pay for performance policy in England. Hypertension [letter] 2009;54: e5.
- 213. McAlister FA, Baclic O, Wyard K, Feldman R, Campbell NRC, for the CHEP Outcomes Research Task Force. The Impact of the Canadian Hypertension Education Program in its first decade. Eur Heart J. 2009; 30:1434-9.**
212. Campbell N, Mohan S. Selecting initial antihypertensive therapy in the elderly. Geriatrics and Aging. 2009;12(4):178-185.
- 211. Patten SB, Williams JVA, Lavorato DH, Campbell NRC, Eliasziw M, Campbell TS. Major Depression as a Risk Factor for High Blood Pressure: Epidemiologic Evidence from a National Longitudinal Study. Psychosomatic Medicine. 2009 71: 273-279.**
- 210. Chen G, Hemmelgarn B, Alhaider S, Quan H, Campbell N, Rabi D. Adverse cardiovascular outcomes associated with antecedent hypertension after acute myocardial infarction: Systematic review and meta-analysis. Am J Cardiol. 2009; 104:141-147.**
209. Mohan S, Campbell NRC. Salt and High Blood Pressure. Clinical Science. 2009; 117:1-11.
208. Mohan S, Campbell NRC. Hypertension management: time to shift gears and scale up national efforts. (Commentary). Hypertension. 2009; 53:450-1.
- 207. Campbell NRC, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, Gao R-N, Sambell C, Phillips S, McAlister FA for the Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009; 53:128-134.**

206. Interdisciplinary Chronic Disease Management Collaboration (Briggs T, Campbell N, Gordon D, Hemmelgarn B, Husereau D, King K, Klarenbach S, Manns B, McAlister F, Ostlinger F, Sargious P, Strong D, Tonelli M, Tsuyuki R, Viner S). The research to health policy cycle: a tool for better management of chronic non-communicable diseases. *J Nephrol*. 2008; 21:621-631.
205. Chan AHW, Campbell NR, Lewanczuk RZ, Semchuk W, Thompson A, Tsuyuki RT, for the Canadian Hypertension Education Program Implementation Task Force. 2008 Canadian Hypertension Education Program Guidelines for the management of hypertension by pharmacists. *Can Pharm J*. 2008; 141:327-31.
204. Thompson A, Campbell NR, Lewanczuk RZ, Semchuk W, Tsuyuki RT, Kaczorowski J, Dawes M, Hickey J, Costello JA, Cloutier L for the Canadian Hypertension Education Program Implementation Task Force. Tackling the Burden of Hypertension in Canada – Encouraging Collaborative Care. *Can Family Physician*. 2008; 54:1659-62.
203. Campbell NRC. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. *Can J Clin Pharm (Editorial)* 2008;15(3): e383-4.
202. Padwal R, B Hemmelgarn, NA Khan, Grover S, McAlister FA, McKay DW, Wilson T, Penner B, Burgess E, Bolli P, Hill MD, Mahon J, Myers MG, Abbott C, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes M, Touyz R, Bell C, Burns KD, Ruzika M, Campbell NRC, Lebel M, SW Tobe, for the Canadian Hypertension Education Program. *The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy*. *Can J Cardiol*. 2008; 24:465-75.
- 201. Penz ED, Joffres MR, Campbell NRC. Reducing dietary sodium and decreases in cardiovascular disease in Canada. *Can J Cardiol*. 2008; 24:497-501.**
- 200. Campbell NRC, So L, Amankwah E, Quan H, Maxwell C. Characteristics of Hypertensive Canadians Not Receiving Drug Therapy. *Can J Cardiol*. 2008; 24:485-90.**
199. Feldman RD, Baclic, Campbell NR, Wyard K. CHEP: the evolution of hypertension management guidelines in Canada. *Can J Cardiol*. 2008; 24:477-81.
198. Stankus V, Hemmelgarn B, Campbell NRC, Chen G, McAlister FA, Tsuyuki R. Improving hypertension management and reducing costs. *Can J Clin Pharmacol*. 2009;16: e151-155.
- 197. Neutel IC, Campbell NRC. Changes in Lifestyle after Hypertension Diagnosis in Canada. *Can J Cardiol*. 2008; 24:199-204.**
196. Campbell NRC, Spence JD. Stroke prevention and sodium restriction, *Can Journal of Neurological Sciences*. (commentary) 2008; 35:278-9.
- 195. Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan N, Campbell N. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. *Can J Cardiol*. 2008; 24:507-12.**
194. NA Khan, B Hemmelgarn, R Padwal, P Larochelle, JL Mahon, RZ Lewanczuk, FA McAlister, SA Rabkin, MD Hill, RD Feldman, EL Schiffrin, NR Campbell, AG Logan, M Arnold, G Moe, TS Campbell, A Milot, JA Stone, C Jones, LA Leiter, RI Ogilvie, RJ Herman, P Hamet, G Fodor, G Carruthers, B Culleton, KD Burns, M Ruzicka, J deChamplain, G Pylypchuk, N Gledhill, R Petrella, J Boulanger, L Trudeau, RA Hegele, V Woo, P McFarlane, RM Touyz, SW Tobe, for the Canadian Hypertension Education Program. *The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy*. *Can J Cardiol*. 2008; 24:465-75.

193. Canadian Hypertension Education Program (Dr. N. Campbell with the assistance of the CHEP Executive, Dr. B. Hemmelgarn and Dr. G. Tremblay). 2008 Canadian Hypertension Education Program Recommendations: The Scientific Summary - An Annual Update. *Can J Cardiol.* 2008; 24:447-52.
192. Campbell NRC. Checking on Health Check. *CMAJ* (letter to the editor). 2008;179:1186-7.
191. Campbell N, Tsuyuki R, Jarvis B. It's time to reduce sodium additives in food. *Canadian Pharmacy Journal* [editorial]. 2008; 141:8-9.
- 190. Connor Gorber S, Tremblay M, Campbell N, Hardt J. The Accuracy of Self-Reported Hypertension: A Systematic Review and Meta-Analysis. *Current Hypertension Reviews.* 2008; 4:36-62.**
189. Mohan S, Campbell NRC. Hypertension in Canada. On top of the world but important challenges remain. *CMAJ* (commentary). 2008; 178:1158-60.
- 188. Neutel IC, Morrison H, Campbell NRC, de Groh M. Statin Use in Canadians: Trends, Determinants and Persistence. *Can J Publ Health.* 2007; 98:412-6.**
187. Campbell NRC. Hypertension Prevention and Control in Canada. *J Am Soc Hypertens (JASH).* 2008; 2:97-105.
- 186. Jones C, Simpson SH, Mitchell D, Haggarty S, Campbell N, Then K, Lewanczuk RZ, Sebaldt R, Farrell B, Dolovich L, Kaczorowski J, Chambers L. Enhancing Hypertension Awareness and Management in the Elderly: The Airdrie-Community Hypertension Awareness and Management Program (A-CHAMP). *Can J Cardiol.* 2008; 24:561-7.**
- 185. Amankwah E, Campbell NRC, Maxwell C, Onysko J, Quan H. Adult Canadians who do not have blood pressure measured. *J Clin Hypertension.* 2007; 9:944-51.**
184. Khan NA, Hemmelgarn B, Padwal R, Laroche P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NRC, et al for the Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2 – Therapy. *Can J Cardiol.* 2007 May 15;23(7):539-50.
- 183. Neutel IC, Campbell NRC. Antihypertensive Medication Use by Recently Diagnosed Hypertensive Canadians. *Can J Cardiol.* 2007; 23:561-65.**
- 182. McAlister FA, Tu K, Majumdar SR, Padwal R, Chen Z, Campbell NRC. Laboratory testing in newly treated elderly hypertensives without co-morbidities: a population-based cohort study. *Open Medicine.* 2007; 1:60-67.**
181. Canadian Hypertension Education Program (written by Campbell NRC with the CHEP executive). 2007 Canadian Hypertension Education Program Recommendations: The Scientific Summary. *Can J Cardiol.* 2007; 23:521-7.
- 180. Joffres MR, Campbell NRC, Manns B, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health costs in Canada. *Can J Cardiol.* 2007; 23:437-443.**
179. Penner SB, Campbell NRC, Chockalingam A, Zarnke K, Van Vliet B. Dietary Sodium and Cardiovascular Outcomes: A Rational Approach. *Can J Cardiol.* 2007; 23:567-572.

178. Tobe S, Campbell N, Touyz R. CHEP – A Unique Canadian Knowledge Translation Program. Can J Cardiol. 2007; 23:551-555.
177. Campbell, NRC. Canada Chair in Hypertension Prevention and Control. A pilot project. Can J Cardiol. 2007; 23:557-565.
176. McAlister FA, Campbell NRC, Duong-Hua M, Chen Z, Tu K. Antihypertensive prescribing in 27 822 elderly Canadians with diabetes mellitus over the past decade. Diabetes Care. 2007; 29:836-841.
175. Campbell NRC, Tu K, Duong-Hua M, McAlister FA. Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. Can J Cardiol. 2007; 23:783-87.
174. Tu K, Campbell NRC, Chen Z-L, McAlister FA. Accuracy of Administrative Databases in Identifying Patients with Hypertension. Open Medicine. 2007;1(1): E3-11.
173. Campbell NRC, McKay DW, Conradson H, Lonn E, Title LM, Anderson T. Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. J Hum Hypertens. 2007; 21:588-590.
172. Tu K, Campbell NRC (corresponding author), Chen Z, McAlister FA. Initiation of therapy for uncomplicated hypertension with a beta blocker in the elderly. A cause for concern. J Hum Hypertens. 2007; 21(4):271-5.
171. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NRC, et al for the Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2 – Therapy. Can J Cardiol. 2006; 22:583-593.
170. Campbell NRC (corresponding author), Petrella R, Kaczorowski J. Public education on hypertension. A new initiative to improve the prevention, treatment and control of hypertension in Canada. Can J Cardiol. 2006; 22: 599-603.
169. Drouin D, Campbell NRC, Kaczorowski, J for the Canadian Hypertension Education Program and the Implementation Task Force. Implementation of Recommendations on Hypertension: The Canadian Hypertension Education Program. Can J Cardiol. 2006; 22:595-598.
168. Hemmelgarn B, McAlister FA, Grover S, et al, for the Canadian Hypertension Education Program (N Campbell, Chair of the Executive and Steering Committee). The 2006 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 1- Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol. 2006; 22:573-81.
167. Campbell NRC (corresponding author), Onysko J for the Canadian Hypertension Education Program and the Outcomes Research Task Force. The Outcomes Research Task Force, Canadian Hypertension Education Program. Can J Cardiol. 2006; 22:556-558.
166. Chockalingam A, Campbell NRC, Fodor JG. Worldwide Epidemic of Hypertension. Can J Cardiol. 2006; 22:553-555.
165. Mohan S, Campbell NRC, Chockalingam A. Management of hypertension in low- and middle-income countries: challenges and opportunities. Prevention and Control 2005; 1(4):275-284.
164. McAlister FA for the Canadian Hypertension Education Program (N Campbell, Chair of Executive and Steering Committee). The Canadian Hypertension Education Program – A Unique Canadian Initiative. Can J Cardiol. 2006; 22:559-563.

163. Campbell NRC (corresponding author), Khan NA, Grover SA. Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk. J Hypertens. 2006; 24:1683-5. [editorial]

162. Tu K, Campbell NRC, Chen Z, McAlister F. Thiazide Diuretics for Hypertension: Prescribing Practices and Predictors of Use in 194, 761 Elderly Hypertensives. American Journal of Geriatric Pharmacotherapy. 2006; 4:161-7.

161. Onysko J, Maxwell C, Eliasziw M, Zhang JX, Johansen H, Campbell NRC (corresponding author) for the Canadian Hypertension Education Program. Increases in the Diagnosis and Treatment of Hypertension in Canada. Hypertension, 2006; 48:853-60.

160. Sodium Intake and Mortality in the NHANES II Follow-Up Study. Can J General Internal Medicine. 2006; 1:23-24. [article review]

159. Tsuyuki RT, Semchuk B, Poirier L, Killeen RM, McAlister FA, Campbell NRC, Drouin D, Lewanczuk RZ for the Canadian Hypertension Education Program. 2006 Canadian Hypertension Education Program (CHEP). Practice Guidelines for the Management of Hypertension by Pharmacists. Canadian Pharmacists Journal. 2006;139(suppl 1): s11-3.

158. Campbell NRC. Semchuk W, Lewanczuk RZ. Pharmacotherapy of Hypertension. Canadian Pharmacists Journal. 2006; 139 (suppl 1): s5-9.

157. Campbell NRC. The Canadian Hypertension Education Program (CHEP). A Therapeutic Knowledge Translation Program. Can J Clinical Pharmacology. 2006; 13(1): e65-8.

156. Campbell NRC, Tu K, Brant R, Duong-Hua M, McAlister FA. for the Canadian Hypertension Education Program Outcomes Research Task Force. The Impact of The Canadian Hypertension Education Program on Antihypertensive Prescribing Trends. Hypertension. 2006; 47:22-28.

155. Campbell NRC, McAlister FA. Not all the guidelines are created equal. CMAJ. 2006; 174:814-5. [letter]

154. Campbell NRC (corresponding author), Onysko J, Johansen H, Gao R-N. Changes in cardiovascular deaths and hospitalization in Canada. Can J Cardiol. 2006; 22:425-7. [editorial]

153. Choi BCK, Campbell NRC, Taylor G, Kaplan M, Morrison H. Health issues associated with societal evolution. Clin Invest Med. 2006;29(3):129-30. [editorial]

152. Chockalingam A, Campbell N. Management of hypertension: Pharmacotherapy. Indian Heart Journal. 2005; 57: 644-47.

151. Chockalingam A, Campbell N. Management of Hypertension: Diagnosis and lifestyle modification. Indian Heart Journal. 2005; 57:639-643.

150. Thomas CM, Loewen A, Coffin C, Campbell NRC (corresponding author). Improving Rates of Pneumococcal Vaccination on discharge from a Tertiary Center Medical Teaching Unit. A prospective intervention. BMC Public Health. 2005; 5:110.

149. Culleton B, McKay DW, Campbell NRC. Performance of the Automated BpTRU measurement device in the assessment of white coat hypertension and white coat effect. Blood Pressure Monitoring. 2006 11(1):37-42.

148. Bolli P, Myers M, McKay D for the Canadian Hypertension Education Program (N Campbell Chair of CHEP executive). Applying the 2005 Canadian Hypertension Education Program recommendations:1. Diagnosis of Hypertension. CMAJ. 2005; 173:480-483.
- 147. Campbell NRC, Conradson HE, Kang J, Brant R, Anderson T. Automated assessment of blood pressure compared to assessments by a trained technician and a clinic nurse. Blood Pressure Monitoring. 2005; 10:257-62.**
146. Jamnik V, Gledhill N, Touyz RM, Campbell NRC, Logan AG, Padwall R and Petrella R. Lifestyle Modifications to Prevent and Manage Hypertension for Exercise Physiologists and Fitness Professionals. Can J Appl Physiol. 2005;30(6); 754-61.
145. Canadian Hypertension Education Program (Campbell NRC – Chair of executive and steering committees). 2005 Canadian Hypertension Education Program recommendations. What are the new messages? Can J Diagnosis, March 2005, Le Clinicien March 2005, Perspectives in Cardiology January 2005.
144. McAlister FA, Wooltorton E, Campbell NRC. The Canadian Hypertension Education Program- the first 6 years. CMAJ. 2005; 173:508-9.
- 143. Campbell NRC, Culleton BW, McKay DW. Misclassification of blood pressure by usual measurement in ambulatory physician practices. Am J Hypertens. 2005; 18:1522-1527**
142. Khan NA, McAlister F, Lewanczuk R, Touyz R, Rabkin S, Padwal R, Leiter L, Lebel M, Herbert C, Schiffrin E, Herman R, Hamet P, Fodor G, Carruthers G, Culleton B, deChamplain J, Pylypchuk G, Logan A, Gledhill N, Petrella R, Campbell NRC et al for the Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2- Therapy. Can J Cardiol. 2005; 21:657-72.
141. Hemmelgarn B, McAlister F, Myers M et al for the Canadian Hypertension Education Program (Campbell NRC– Chair of executive and steering committees) The 2005 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2005; 21:645-56.
- 140. Tu K, Campbell NRC, Duong-Hua M, McAlister FA Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 - 2002. Hypertension. 2005; 45:1113-8.**
139. Padwal R, Campbell NRC, Touyz RM. Lifestyle Modification to Prevent and Treat Hypertension. CMAJ. 2005;173(7):749-751.
- 138. Khan N, Wardman D, Campbell NRC. Differences in need for antihypertensive drugs among those aware and unaware of their hypertensive status: a cross sectional survey. BMC Cardiovascular Disorders. 2005; 5:4**
- 137. Petrella R, Campbell NRC Awareness and misconceptions of hypertension in Canada: Results of a national survey. Can J Cardiol. 2005; 173:749-751.**
- 136. Coffin CS, Saunders C, Thomas CM, Loewen AHS, Ghali WA, NRC Campbell. Validity of ICD-9-CM Administrative Data for Determining Eligibility for Pneumococcal Vaccination Triggers. Am J Medical Quality. 2005;19;1-6**
135. Campbell NRC, Joffres MR, McKay DW, for an Expert Committee of the Canadian Hypertension Society, the Canadian Coalition for High Blood Pressure Prevention and Control and the Heart and Stroke Foundation of Canada. Hypertension Surveillance in Canada. Minimum Standards for Assessing Blood Pressure in Surveys. Can J Pub Health. 2005; 96:217-220.

134. Campbell N for the CHEP program. Canadian Hypertension Education Program. Brief overview of 2004 recommendations. Can Family Physician. 2004; 50:1411-12
133. Campbell N for the CHEP program. 2004 CHEP Hypertension recommendations: What's new, what's old but still important in 2004? Perspectives in Cardiology. 2004; 20:26-33; Le Clinicien 2004;1-9; Les Actualites du cceur (special insert) 2004, The General Internist. 2004; Spring):16-20; Can J Hosp Pharm. 2004; 57:173-5; Canadian Pharmaceutical J. 2004;137(5):48-49.
132. Feldman RD for the Canadian Hypertension Education Program (Campbell NRC- revised and member of executive and steering committees). 2004 Canadian Hypertension Education Program Recommendations: The Bottom-line Version. Hypertension Canada. 2004; (78):1-5.
131. Canadian Hypertension Education Program (Campbell N principal author). What's old but important and what's new. Canadian Nurse. 2004; 100:26-27
- 130. Khan NA, Taher T, McAlister FA, Ferland A, Campbell NR, Ghali WA for the Canadian Perioperative Research Network Development of a perioperative medicine research agenda: a cross sectional survey. BMC Surgery. 2004, 4:11**
129. Hemmelgard B, Zarnke K, Campbell NRC, Feldman R, McKay DW, McAlister F, Khan N, Schiffrin EL, Myers M, Bolli P, Honos G, Lebel M, Levine M, Padwal R for the Canadian Hypertension Education Program. The 2004 Canadian Recommendations for the management of hypertension. Part I- Blood Pressure Measurement, diagnosis and assessment of risk. Can J Cardiol. 2004;20(1):31-40.
128. Khan N, McAlister F, Campbell NRC, Feldman R, Rabkin S, Mahon J, Lewanczuk R, Zarnke K, Hemmelgard B, Lebel M, Levine M, Herbert for the Canadian Hypertension Education Program. The 2004 Canadian Recommendations for the management of hypertension. Part II- Therapy. Can J Cardiol. 2004;20(1):41-54.
127. Touyz R, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R. for the Canadian Hypertension Education Program. The 2004 Canadian Recommendations for the management of hypertension. Part III- Lifestyle modifications to prevent and control hypertension Therapy. Can J Cardiol. 2004;20(1):55-60.
- 126. Hamet P, Campbell N, Curnew G, Eastwood C, Pradham A. A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension. Exp Clin Cardiol. 2003;7;165-72.**
125. Feldman RD for the Canadian Hypertension Education Program (N Campbell was a Steering committee member and Chair of Central Review Committee). What's new in the 2003 hypertension guidelines. Perspectives in Cardiology. 2003; 19:44-51. Hypertension Canada. June 2003 Bulletin 750.
124. Campbell NRC, McAlister F, Brant R, Levine M, Drouin D, Feldman R, Herman R, Zarnke K for the Canadian Hypertension Education Process and Evaluation Committee. Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens. 2003;21(8):1591-1597.
123. Wilson E, Campbell NRC. A mounting risk: Hypertension and the world health report 2002. Perspectives in Cardiology. 2003; 19:25-29.
- 122. Hamilton SF, Campbell NRC, Kara M, Watson J, Connor M. The Affect of Ingestion of Ferrous Sulfate on the Absorption of Oral Methotrexate in Rheumatoid Arthritis Patients. J Rheumatol. 2003; 30:1948-50.**

121. Campbell NRC, Feldman RD, Drouin D. Hypertension guidelines. Criteria that might make them more clinically useful. *Am J Hypertens*. [letter] 2003; 16:698-9.
120. Campbell NRC, Drouin D and Feldman RD for the Canadian Hypertension Working Group. The 2001 Canadian Hypertension Recommendations. Take home messages. *CMAJ*. 2002; 167:661-8.
119. Hanning R, Campbell NRC. Diet and Hypertension. *Perspectives in Cardiology*. 2002; 18:27-33.
118. Wu C, Cowtan T, Campbell NRC. Antihypertensives: A drug review. *Perspectives in Cardiology*. 2002; 18:34-46.
117. Canadian Hypertension Recommendations Working Group (Chair of steering committee and principal author). The 2001 Canadian Hypertension Recommendations. What has changed? *Can Fam Physician*. 2002; 48:1662-5.
116. Campbell NRC, McKay DW. Do We Need Another Standard for Assessing the Validity of Blood Pressure Measuring Devices? [editorial]. *Blood Pressure Monitoring*. 2002;7;1-2.
115. Khan N, Campbell NRC (corresponding author). Lack of Control of High Blood Pressure and Treatment Recommendations in Canada. *Can J Cardiol*. 2002; 18:657-61.
114. Canadian Hypertension Recommendations Working Group (principal author and Chair of Steering Committee). The 2001 Canadian Hypertension Recommendations. What's new and what's old but still important. *Can J Cardiol* 2002; 18:591-603, *Perspectives in Cardiol*. 2002: Feb:38-46., *Canadian Internist* Spring 2002, *Can Nurse*, *Can J Hosp Pharm*, 2002;55:46-51, *CPJ* 2002: March;26-32, *Le Clinicien* March 2002 *Les Actualités du C'ur* May 2002.
113. Zarnke KB, McAlister FA, Campbell NRC (Chair Steering Committee), Levine M, Schiffrin E et al, for the Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Assessment for diagnosis, cardiovascular risk and lifestyle modification. *Can J Cardiol*. 2002; 18:604-24.
112. McAlister FA, Zarnke KB, Campbell NRC (Chair Steering Committee), Feldman RD, Levine M, Mahon J et al, for the Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: part 1, therapy. *Can J Cardiol*. 2002; 18:625-40.
- 111. Kammila S, Campbell NRC (corresponding author), Brant R, deJong R, Culleton B. Systematic error in the determination of nocturnal blood pressure dipping status by ambulatory blood pressure monitoring. *Blood Pressure Monitoring*. 2002; 7:131-4.**
110. Zarnke KB, Levine M, McAlister FA, Campbell NRC (Chair Steering Committee), Myers M, McKay DW et al, for the Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for managing hypertension: Part 2: Diagnosis and assessment of persons with high blood pressure. *Can J Cardiol*. 2001; 17:1249-63.
109. Wu CM, Hasinoff BB, Campbell NRC (corresponding author). Drug Interactions with iron. Implications for drug therapy in the aged. *Pharmaceutical News*. 2001; 8:36-41.
108. Campbell NRC, Jeffrey P, Kiss K, Jones C, Anton AR. Building capacity for awareness and risk factor identification in the community: the blood pressure assessment program of Calgary Fire Department. *Can J Cardiol*. 2001; 17:1275-9.
107. Khan N, Campbell NRC. White Coat Hypertension. *Perspectives in Cardiol*. 2001;17(4):21-27.

106. Campbell NRC, Nagpal S, Drouin D (from the Heart and Stroke Foundation of Canada). Implementing hypertension recommendations. Can J Cardiol. 2001; 17:851-3.

105. Stone JA, Cyr C, Friesen M, Kenndy-Symonds H, Stene R, Smilovich M on behalf of the Canadian Association of Cardiac Rehabilitation (N Campbell acknowledged as member of guidelines writing group). Canadian guidelines for cardiac rehabilitation and atherosclerotic heart disease prevention: a summary. Can J Cardiol. 2001;17 (suppl b):3-30.

104. Durante KM, Whitmore B, Jones CA, Campbell NRC (corresponding author). Use of vitamins, minerals and herbs: a survey of patients attending family practice clinics. Clin Invest Med. 2001; 24:242-9.

103. Campbell NRC, Khan N. Cocaine-Related Vasculitis Causing Upper-Limb Peripheral Vascular Disease. [letter] Ann Intern Med. 2001; 135:142.

102. McAlister FA, Levine M, Zarnke KB, Campbell N (Chair Steering Committee), Lewanczuk R, Leenen F, Rabkin S, Wright JM, Stone J, Feldman RD, Lebel M, Honos G, Fodor G, Burgess E, Tobe S, Hamet P, Herman R, Irvine J, Culleton B, Petrella R, Touyz R, for the Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: part 1, therapy. Can J Cardiol. 2001; 17:543-59.

101. Campbell NRC, Milkovich L, Burgess E, McKay DW. Self-measurement of blood pressure: accuracy, patient preparation for readings, technique and equipment. Blood Pressure Monitoring. 2001; 6:133-8.

100. Campbell N. (from the Heart and Stroke Foundation) An Ongoing Systematic Update of Hypertension Recommendations. Can J Cardiol. 2001; 17:521-2 (French 524-5).

99. Chockalingam A, Campbell N, Ruddy T, Taylor G, Dery V on behalf of the expert working group. High Blood Pressure Prevention and Control: Canadian National Strategy. CVD Prevention. 2000; 3:81-93

98. Khan N, Campbell NRC. Lifestyle modification for prevention and treatment of hypertension. Canadian Recommendations. Perspectives in Cardiology 2001;17(4):21-27.

97. Canadian Hypertension Recommendations Working Group. Summary of the 2000 Canadian Hypertension Recommendations. Principal author-chair steering committee Published in Can J Cardiol. 2001; 17:535-38 (French 539-42); Perspectives Cardiol. 2001; 17:17-25; Hypertension Canada 2001; bulletin 67:4, 7, Canadian Pharmacy Journal. March 2001:30-3; Canadian Family Physician 2001; 47:793-4 (French 802-4); Canadian Journal of Cardiovascular Nursing 2001; 11:4-6 (French 7-9); The Canadian Internist, spring 2001;11-13; Les Actualités du Coeur 2001;6: (Insert); L'OMNIPRATICIEN special edition on CVD feb 22; Medical Post: May 8, May 22 and June 5; Actualite Medical: May 9, May 23 and June 6.

96. Campbell NRC, Fodor JG, Chockalingam A for the Canadian Hypertension Recommendations Group. Hypertension recommendations. Are they relevant to public health? Can J Public Health. [editorial] 2001; 92:245-6 (French 246-7).

95. McAlister FA, Campbell NRC, Zarnke K, Levine M, Graham ID. The management of hypertension in Canada: A review of current guidelines, their shortcomings, and implications for the future. CMAJ. 2001; 164:517-22.

94. Campbell NRC, Khan N. Hypertension in the elderly: Challenges and treatment recommendations. Perspectives in Cardiol. 2000;16: (supl) 1-10.

93. Khan N, Campbell NRC Alcohol and Blood Pressure. Perspectives in Cardiol. 2000; 16:15-18.

92. Chockalingam A, Campbell NRC, Ruddy T, Taylor G, Stewart P. National High Blood Pressure Prevention and Control Strategy. Can J Cardiol. 2000;16:1087-1093.
91. Zarnke KB, Campbell NRC, McAlister F, Levine M. A Novel Process for Updating Recommendations for Managing Hypertension: Rationale and Methods. Can J Cardiol. 2000;16:1094-1102.
90. Abdullah N, Lemaire JB, Schaefer JP, Campbell NRC. Development of an Internal Medicine Urgent Assessment Clinic and preliminary description of the referred patient population. Annals RCPSC. 2000;33(7):416-8.
89. Campbell NRC. Message from the President (of the Canadian Hypertension Society). Can J Cardiol. 2000;16:1085-6.
88. Feldman RD, Campbell N, Larochelle P. [letter to editor]. Lancet. 2000; 356:509.
- 87. Campbell NRC, Edwards AL, Brant R, Jones C, Mitchell D. Effect on lipid, cbc and blood proteins: standardized compared to usual preparation for blood drawing. A randomized controlled trial. Clin Invest Med. 2000; 23:302-6.**
86. Feldman RD, Larochelle P, Campbell N. Response to letters to the editor. CMAJ. 2000; 162:1556.
85. Khan N, Campbell NRC, Management of Hypertension: Optimizing Therapy Perspectives in Cardiology. 2000; 16:15-23.
84. Campbell NRC 'From the Heart and Stroke Foundation of Canada'. Hypertension management in clinical practice. Can J Cardiol. 2000; 16:574-576 (French) 579-581.
83. Khan N, Campbell NRC. Diagnosing Hypertension. Perspectives in Cardiology. 2000; 16:15-17.
- 82. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NRC (corresponding author). The Relationship between Catechol-O-Methyltransferase (COMT) genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease. Clinical Neuropharmacology. 2000; 23:143-48.**
81. Campbell NRC. Report from the president of the Canadian Hypertension Society. Can J Cardiol. 2000; 16:392-3.
80. Campbell NRC. New Canadian Hypertension Recommendations - So What? [editorial]. Canadian Family Physician. 2000; 46:1413-21.
- 79. Maxwell C J, Hogan DB, Campbell NRC, Ebly EM. Nidedipine and mortality risk in the elderly: Relevance of drug formulation, dose and duration. Pharmacoeconomics and Drug Safety. 2000;9(1):11-23.**
78. Feldman. RD, Campbell NRC, Larochelle P. Clinical problem solving in the treatment of high blood pressure based on the 1999 Canadian recommendations for the management of hypertension. CMAJ. 1999;161(suppl 12):18-22.
77. Feldman RD, Campbell NRC, Larochelle P et al. 1999 Canadian recommendations for the management of hypertension. CMAJ. 1999;161 (suppl 12):1-17.
- 76. Peters GL, Binder S K, Campbell NRC (Corresponding author). The effect of leg crossing on blood pressure. A randomized single blind cross-over study. Blood Pressure Monitoring. 1999; 4:97-101.**

75. Campbell NRC, McKay DW. Accurate blood pressure measurement, why does it matter? Editorial. CMAJ. 1999; 161:277-8.
74. Campbell NRC. Secondary prevention: closing the gap between guidelines and practice. Hypertension and myocardial infarction. CVD Prevention. 1999; 2:13-17.
73. Campbell, NRC, Taylor G. Healthier lifestyles: Bringing down blood Pressure. Perspectives in Cardiology. 1999 (May):47-53.
- 72. Campbell, NRC, Myers MG, McKay DW. Usual measurement of blood pressure is it meaningful? Blood Pressure Monitoring. 1999; 4:71-6.**
71. Campbell NRC. Will lifestyle modification reduce blood pressure? Canadian Family Physician. 1999; 45:1640-2.
70. Campbell NRC, Ashley MJ, Carruthers SG, Lacourciere Y, McKay DW. Lifestyle intervention to prevent and control hypertension. Recommendations on alcohol consumption. CMAJ. 1999;160(suppl 9):13-20.
69. Leiter LA, Abbott D, Campbell NRC, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle Modification to Prevent and Control Hypertension: 2. Recommendations on obesity and weight loss. CMAJ. 1999;160(suppl 9):7-12.
68. Campbell NRC, Burgess E, Choi BCK, Taylor G, Wilson E, Cleroux J, Fodor JG, Leiter L, Spence D. Lifestyle intervention to prevent and control hypertension. Methods and an overview of Canadian Recommendations. CMAJ. 1999;160(suppl 9):1-6.
67. Campbell NRC, Burgess E, Taylor G, Wilson E, Cleroux J, Fodor JG, Leiter L, Spence D, Lifestyle changes to prevent and control hypertension. Do they work? CMAJ. 1999; 160:1341-43.
- 66. Campbell NRC, Brant R, Stalts H, Stone J, Mahallati H. Fluctuations in lipid levels during furosemide therapy. A randomized double-blind placebo-controlled crossover trial. Arch Intern Med. 1998; 158:1461-3.**
65. Huston P, Campbell NRC. Influencing prescribing patterns. Evidence-based recommendations are not enough. (Response to Letter to the Editor). Can Family Physician. 1998; 44:1237.
64. Huston P, Campbell NRC. Influencing prescribing patterns. Evidence-based recommendations are not enough. Can Family Physician (editorial). 1998; 44:221-2
63. Campbell NRC. Ambulatory Blood Pressure Monitoring. A Physicians Guide. Perspectives in Cardiology. 1998;14:77-83.
- 62. Schaefer JP, Tam Y, Hasinoff BB, Tawfik S, Peng Y, Reimche L, Campbell NRC. (Corresponding author). Ferrous sulfate interacts with captopril. Br J Clin Pharmacol. 1998; 46:377-82.**
- 61. Campbell NRC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. The effect of gender on heparin therapy. Clin Invest Med. 1998;21:71-78.**
60. Feldman R, Bacher M, Campbell NRC, Drover A, Chockalingam A. Adherence to pharmacological management of hypertension. Can J Public Health. 1998;89(suppl I).16-18.
59. Chockalingam A, Bacher M, Campbell NRC, Cutler H, Drover A, Feldman R, Fodor JG, Irving J, Ramsden V, Thivierge R, Tremblay G. Adherence to management of high blood pressure: Recommendations of the

Canadian Coalition for High Blood Pressure Prevention and Control. Can J Public Health. 1998;89(suppl I):5-11.

58. Ebly EM, Schaefer JP, Campbell NRC, Hogan DB. Folate status, vascular disease and cognition in elderly Canadians. Age and Ageing. 1998; 27:485-91.

57. The Ad-Hoc Advisory Committee for the Prairie Provinces. Controversies in Calcium Channel Blocker Therapy: Finding a consensus. Perspect Card. 1996; Sept. Suppl.

56. Scott-Douglas NW, Campbell, N. How do I handle a hypertensive emergency? Perspect Card. 1996:19-33.

55. Campbell NRC. How safe are folate supplements? Arch Intern Med. 1996; 156:1638-1644.

54. Campbell NRC, Wasi S. Hypertension in Women. [Editorial] Can J Cardiol. 1996;12(suppl D):4.

53. Partlow ES, Campbell NRC (corresponding author), Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine following concurrent ingestion. Clin Pharmacol Ther. 1996; 59:389-93.

52. Brager NPD, Campbell NRC (corresponding author), Reicsh H, Chaudhuri M, Rabin HR. Reduced renal fractional excretion of lithium in cystic fibrosis. Br J Clin Pharmac. 1996; 41:157-9.

51. Hogan D, Campbell NRC, Jennett P, MacLeod N, Brant R. NSAIDS and increased cardiovascular medication use in the elderly. Clin Invest Med. 1996; 19:46-54.

50. Campbell NRC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Ageing and heparin related bleeding. Arch Intern Med. 1996; 156:857-60.

49. Bannerman J, Campbell NRC, Hasinoff BB, Venkataram S. The dissolution of iron from various commercial preparations is highly variable. Pharm Acta Helvetiae. 1996;71;129-139.

48. Birkett N, Abbott D, Campbell NRC, Chockalingam A, Dagenais G, Hogan G for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-measurement of blood pressure: Issues related to the training of patients. Can J Cardiol. 1995;11(suppl H):23-28.

47. Campbell NRC, Abbott D, Bass M, Birkett N, Chockalingam A, Dagenais G, Hogan K, Ku LF, Lebel M, Milkovich L, McKay DW, Small C, Wasi S for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-measurement of blood pressure. Recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Cardiol. 1995;11(suppl H):5-17.

46. McKay DW, Campbell NRC, Chockalingam A, Ku LF, Small C, Wasi S. for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-Measurement of Blood Pressure: Equipment and Standards. Can J Cardiol. 1995;11(suppl H):29-34.

45. Campbell NRC, Bass M, Chockalingam A, Lebel M, Milkovich L for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-Measurement of Blood Pressure: Benefits, risks and interpretation of readings. Can J Cardiol. 1995;11(suppl H):18-22.

44. Campbell NRC, Chockalingam A. Prevention and control of high blood pressure: Challenges and opportunities. Can Med Assoc J. [Editorial] 1995; 152:1969-70.

43. Campbell NRC, Skerjanec A, Tam YK, Robertson S, Burgess E. Methyldopa kinetics before and after the ingestion of methyldopa for eight weeks. Eur J Clin Pharmacol. 1995; 35:275-80.

42. Skerjanec A, Campbell NRC, Robertson S, Tam YK. Pharmacokinetics and presystemic metabolism of methyldopa in healthy human subjects. *J Clin Pharmacol*. 1995; 35:275-80.
41. Campbell NRC, Purchase LH, Longerich LL, Gault MH. Prediction of reduction in predialysis concentrations due to interdialysis weight gain. *Nephron*. 1995; 71:65-74.
40. Campbell NRC, Wickert W, Shumak SL. Restriction of fluid during fasting increases lipid concentrations. *Clin Invest Med*. 1994; 17:570-6.
39. Abbott D, Campbell N, Carruthers-Czyzewski P, Chockalingam A, David M, Dunkley G, Ellis E, Fodor JG, McKay D, Ramsden VR (Canadian Coalition for High Blood Pressure Prevention and Control Working Group). Guidelines for measurement of blood pressure, referral and follow-up, and lifestyle counselling. *Can J Public Health*. 1994; 2:29s-43s.
38. Campbell NRC, DB Hogan, DW McKay. Pitfalls to avoid in the measurement of blood pressure in the elderly. *Can J Public Health*. 1994; 2:26s-28s.
37. Campbell NRC, Chockalingam A, Fodor JG, McKay DW. Errors in assessment of blood pressure. Patient factors. *Can J Public Health*. 1994; 2:12s-17s.
36. Campbell NRC, Chockalingam A, Fodor JG, McKay DW. Errors in assessment of blood pressure. Blood pressure measuring technique. *Can J Public Health*. 1994; 2:18s-21s.
35. Campbell NRC, Chockalingam A, Fodor JG, McKay DW. Errors in assessment of blood pressure. Sphygmomanometers and blood pressure cuffs. *Can J Public Health*. 1994; 2:22s-25s.
34. Wickert W, Campbell NRC (corresponding author), Martin L. An acute illness resembling systemic lupus erythematosus following therapy with clozapine. *Postgrad Med J*. [letter] 1994; 70:940-1.
33. Vasdev S, Ford CA, Longerich L, Barrett B, Parai S, Campbell N. Oral treatment with low molecular weight heparin normalizes blood pressure in hypertensive rats. *Artery*. 1994; 21:1-28.
32. Sussex B, Campbell NRC (corresponding author), Raju M, McKay DW. Treatment with a diuretic decreases nitrate tolerance. *Clin Pharmacol Ther*. 1994; 56:229-234.
31. Campbell NRC, Hasinoff BB, Singh M, Robertson S. Ferrous sulfate does not directly affect pteroylmonoglutamic acid absorption in rats. *Br J Nutr*. 1994; 72:447-453.
30. Hogan D, Campbell NRC, Crutcher R, Jennett P, MacLeod N. Prescription of non-steroidal anti-inflammatory drugs for Albertan seniors. *Can Med Assoc J*. 1994; 151:315-322.
29. Campbell NRC, Wickert W, Shumak SL. Furosemide causes acute increases in fasting lipid concentrations. *Br J Clin Pharmacol*. 1993; 36:607-609.
28. Shumak SL, Campbell NRC. Intraindividual variation in lipid and lipoprotein levels: Magnitude of the problem and recommendations to reduce the clinical impact. *Can Med Assoc J*. 1993; 149:843-844.
27. Campbell NRC, Hasinoff BB, Robertson S, Singh M. Absence of an effect of ferrous sulfate on phenytoin absorption in the rat. *Clin Invest Med*. 1993; 16:280-284.
26. McKay DW, Campbell NRC (corresponding author), A Chockalingam, JG Fodor. Skills in blood pressure measurement and physician characteristics. *Can J Cardiol*. 1993; 9 (suppl D):116d-118d.

25. Campbell NRC, Hasinoff BB, Meddings JB, Anderson WB, Robertson S, Granberg K. Ferrous sulfate reduces cimetidine absorption. *Dig Dis Sci*. 1993; 38:950-954.
24. Campbell NRC, Hasinoff BB, Stalts H, Rao B, Wong NCW. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. *Ann Intern Med*. 1992; 117:1010-1013.
23. McKay DW, Raju MK, Campbell NRC. Assessment of blood pressure measuring techniques. *Med Educ*. 1992; 26:208-212.
22. Campbell NRC, Patrick W. Changes in methyldopa absorption and renal excretion following multiple doses. *J Clin Pharmacol*. 1992; 32:450-454.
21. Campbell NRC, Baylis B. Renal impairment associated with an acute paracetamol overdose in the absence of hepatotoxicity. *Postgrad Med J*. 1992; 68:116-118.
20. Campbell NRC, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. *Br J Clin Pharmacol*. 1992; 33:1156-116.
19. Campbell NRC, Hasinoff BB. Iron supplements: A common cause of drug interactions. *Br J Clin Pharmacol*. 1991; 31:251-255.
18. Kara M, Hasinoff BB, McKay DW, Campbell NRC (corresponding author). Clinical and chemical interactions between iron preparations and ciprofloxacin. *Br J Clin Pharmacol*. 1991; 31:257-261.
17. Vasdev S, Campbell N, Prabhakaran V, Esquivel M and Sampson CA. Increased calcium uptake in vascular tissue by plasma of patients with essential hypertension. *Clin Biochem*. 1991; 24:189-194.
16. Campbell NRC, Campbell RRA, Hasinoff BB. Ferrous sulfate reduces methyldopa absorption: Methyldopa: iron complex formation as a likely mechanism. *Clin Invest Med*. 1990; 13:329-332.
15. McKay DW, Campbell NRC, Parab LS, Chockalingam A, Fodor JG. Clinical assessment of blood pressure. *J Hum Hypertens*. 1990; 4:639-645.
14. Campbell NRC, Rankin D, Goodridge AE, Hasinoff BB, Kara M. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. *Br J Clin Pharmacol*. 1990; 30:599-605.
13. Campbell NRC, Chockalingam A, Fodor JG, McKay DW. Accurate reproducible measurement of blood pressure. *Can Med Assoc J*. 1990; 143:19-24.
12. O'Neill SK, McKay DW, Campbell N, Triggle CR, Crowley M, Bolger GT. Comparative behavioral neurochemical and pharmacological activities of dihydropyridine calcium channel activating drugs. *J Pharm Exp Ther* 1990; 253:905-912.
11. Campbell RRA, Hasinoff B, Chernenko G, Barrowman J, Campbell NRC (corresponding author). The effect of ferrous sulfate and pH on l-dopa absorption. *Can J Physiol Pharmacol*. 1990; 68:603-607.
10. Campbell NRC, Hasinoff B. Ferrous sulfate reduces l-dopa bioavailability: Chelation as a possible mechanism. *Clin Pharmacol Ther*. 1989; 45:220-225.
9. Campbell N, Paddock V, Sundaram R. Alteration of methyldopa absorption, metabolism and blood pressure control caused by ferrous sulfate and ferrous gluconate. *Clin Pharmacol Ther*. 1988; 43:381-386.
8. Gault MH, Campbell NRC, Aksu AE. Spurious Stones. *Nephron* 1988; 48:274-279.

7. **Campbell NRC**, Van Loon JA, Sundaram RS, Ames MM, Hansch C, Weinshilboum RM. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates. *Mol Pharmacol.* 1987; 32:813-819.
6. **Campbell NRC**, Van Loon JA, Weinshilboum RM. Human liver phenol sulfotransferase: Assay conditions, biochemical properties and partial purification of isozymes of the thermostable form. *Biochem Pharmacol.* 1987; 36:1435-1446.
5. **Campbell NRC**, Nath C, Snedden W, Fernandez P. Hemodynamic effects of calcium channel blockers. *Perspect Card.* 1986; 2:21-25.
4. Studelska DR, **Campbell NRC**, Brimijoin WS. Catecholamine binding by adrenal medullary protein can interfere with a sensitive radioenzymatic assay for norepinephrine. *Life Sci.* 1985; 36:881-887.
3. **Campbell NRC**, Sundaram RS, Werness PG, Van Loon J, Weinshilboum RM. Sulfate and methyldopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity. *Clin Pharmacol Ther.* 1985; 37:308-315.
2. **Campbell NRC**, Dunnette JH, Mwaluko G, Van Loon J, Weinshilboum RM. Platelet phenol sulfotransferase and erythrocyte catechol-o-methyltransferase activities: Correlation with methyldopa metabolism. *Clin Pharmacol Ther.* 1984; 35:55-63.
1. Fernandez PG, Sharma JN, Galway AB, **Campbell N**, Kim BK, Snedden W, Granter-Button S, MacDonald J, Gill V. Potassium conservation with amiloride/hydrochlorothiazide (Moduret) in thiazide-induced hypokalemia in hypertension. *Curr Med Res Opin.* 1982; 8:120-127.

ii. MANUSCRIPTS AND COMMUNICATIONS IN NON-PEER REVIEWED JOURNALS:

Note: Documented to 2009.

54. Canadian Hypertension Education Program (*was written by Dr. N. Campbell with the assistance of the CHEP Executive and Dr. G. Tremblay*). 2008 Canadian Hypertension Education Program Recommendations: The Short Clinical Summary - An Annual Update. *Can J Diagnosis* 2008; 25:103-9., *Perspectives in Cardiol* 2008;24:20-8
53. **Campbell NRC**, Mohan S. Choosing antihypertensive therapy. *Perspectives in Cardiol.* 2008; 24:27-31.
52. **Campbell NRC**, Godwin M. Do you eat an unhealthy amount of salt or sodium? *Family Health.* 2008.
50. Kaczorowski J, Smith M, **Campbell N**. Hypertension Resources for your Patients. *Perspectives in Cardiology* 2007 (August),32-34.
49. Kaczorowski J, Smith M, **Campbell N**. Useful hypertension resources. *Hypertension Canada* 2007
48. Silzer J, Shah W, **Campbell NRC**. Sodium, Blood Pressure, and Hypertension. *Perspectives in Cardiology.* 2007 (Sept) 33-37.
47. **Campbell NRC**, Dawe Martin. What's new in monitoring recommendations for 2007. April 2007. *STA MD passport newsletter*
46. **Campbell NRC**, Dawe Martin. What's new in lifestyle for 2007. May 2007 *STA MD passport newsletter*

45. Campbell NRC, Dawe Martin. What's new in treatment recommendations for 2007. June 2007 STA MD passport newsletter
44. Campbell NRC, Dawe Martin. Adherence to therapy. July 2007 STA MD passport newsletter
43. Campbell NRC, Dawe Martin. White coat hypertension and masked hypertension. August 2007 STA MD passport newsletter
42. Campbell NRC, Dawe Martin. Treatment targets and resistant hypertension. Sept 2007 STA MD passport newsletter
41. Campbell NRC, Dawe Martin. Home Blood Pressure Measurement What's New in Home Blood Pressure Measurement? Feb 2008 STA MD passport newsletter
40. Campbell NRC on behalf of CHEP. Pass the salt. Sodium recommendations. Perspectives in Cardiology. 2007; March;24-26.
39. The Canadian Hypertension Education Program (Primary author R Touyz, N Campbell chair of CHEP Executive). 2006 Canadian Hypertension Education Program Recommendations: The Bottom-Line Version. Hypertension Canada. 2006; 86:1-3;8.
38. Campbell NRC. Beta blockers questions and answers. Endorsed by CHEP. Brochure for distribution.
37. Campbell NRC. Epidemiology of Hypertension in Canada: in Hypertension Update. Medica Illustrata 2006.
36. Campbell NRC. Role of Diuretics in the Prevention of Heart Failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. A Commentary. Comprehensive Cardiology Canada. 2006; 1:18
35. Campbell NRC. Blood Pressure Disparity. Perspectives in Cardiology (answers to questions section). 2006; 28:13.
34. Campbell NRC, Fodor JG, Herman R, Hamet P for the Canadian Hypertension Education Program. Hypertension in the Elderly. An update on Canadian Hypertension Education Program Recommendations and Hypertension in the Elderly. Geriatrics and Aging; 2005 8:35-40.
33. Campbell NRC, Drouin D, McAlister F, Onysko J, Tobe S and Touyz R M for the Canadian Hypertension Education Program. The Canadian Hypertension Education Program (CHEP). A national program to improve the treatment and control of hypertension. ISH Newsletter 2005 Opus 7 May 5, 2005.
32. Canadian Hypertension Education Program (Member of steering and executive committee). Canadian Hypertension Program Recommendations: 2005 Update. Hypertension Canada. Bulletin 82 March 2005 1-5.
31. Campbell NRC, Drouin D, Feldman R. A brief History of Canadian Hypertension Recommendations. Hypertension Canada. Bulletin 82 March 2005 1,5,7.
30. Campbell NRC, Drouin D, McAlister F, Onysko J, Tobe S and Touyz R M for the Canadian Hypertension Education Program. The Canadian Hypertension Education Program (CHEP). A national program to improve the treatment and control of hypertension. Hypertension Canada.
29. Campbell NRC. "Ask the expert" "What is the main objective in the control of hypertension? Blood pressure

normalization? 'CME journal. 2004; 16:31.

28. Campbell NRC. "Ask the expert on LVH" *The Canadian Journal of Diagnosis*. 2004; 21:25.

27. Campbell NRC. "Ask the expert" "What errors do family physicians make in the detection and management of hypertension and what might be the opportunities to improve treatment outcomes?" CME journal. 2004;16 (6):33-34.

26. Feng X, Campbell NRC. Screening for Secondary Causes of Hypertension in the Elderly. *Geriatrics and aging*. 2003; 6:31-33.

25. Campbell NRC. Report from the Canadian Coalition for High Blood Pressure Prevention and Control. *The General Internist*. Spring 2002.

24. Campbell NRC. Nonpharmacological management of hypertension. *Compendium of Pharmaceuticals and Specialties*. 2001.

23. Campbell NRC. Canadian hypertension management recommendations and new clinical trials. In *Hypertension past present and future*. P Hamet eds. Pulsus communications.

22. Campbell NRC. What is considered a 'normal' blood pressure for ambulatory blood pressure monitoring? *Canadian Journal of Diagnosis* 2001; 18:34.

21. Campbell NRC. What is the significance of nocturnal dips on 24-hour blood pressure monitoring? *Canadian Journal of Diagnosis* 2001; 18:33.

20. Campbell NRC. Nonpharmacological therapy of hypertension. *Compendium of Pharmaceuticals and Specialties*. 2000.

19. Campbell NRC. Update on Hypertension Recommendations and Trials. *The General Internist*. Fall, 2000.

18. Campbell NRC. Report from the research committee. *The General Internist*. Fall 2000.

17. Campbell NRC. Report from the Canadian Coalition for High Blood Pressure Prevention and Control. *The General Internist*. Fall 2000.

16. Campbell NRC. Managing hypertension: Guidelines for a millennium. *Physicians Perspective*. 2000.

15. Campbell NRC. Taylor G, Chockalingam A, Wilson E. Lifestyle changes have a key role in reducing hypertension. *Hypertension Canada*. 2000; 5(bulletin 63).

14. Campbell NRC. Canadian Coalition for High Blood Pressure Prevention and Control. *Hypertension Canada* 1999;62:3-4.

13. Campbell NRC. Presidents Report. *Hypertension Canada* 1999;62 (suppl):3.

12. Kline GA and Campbell NRC (Corresponding author). Hypertension in diabetes: Adopting an aggressive approach to management. *Canadian Diabetes* 1999;12(4):4-7.

11. Campbell NRC. Nonpharmacologic therapy for hypertension. In the *Compendium of Pharmaceuticals and Specialties*. 34th edition 1999. Ottawa Canada.

10. Campbell NRC. Nonpharmacologic therapy for hypertension. In the *Compendium of Pharmaceuticals and Specialties*. 33rd edition 1998. Ottawa Canada.

9. Campbell NRC. Secondary Prevention: Closing the gap between guidelines and practice. Hypertension post myocardial infarction. Eight Annual Symposia and General Meetings of the Canadian Association of Cardiac Rehabilitation 1998. Ottawa Canada.
8. Campbell NRC. Yuksel N. Anticoagulants-commonly used by seniors but at what efficacy and risk. DUE Quarterly Issue 15 July 1997.
7. Campbell NRC. Hypertension in the elderly. [editorial]. Can J Geriatr. 1995; 11:1.
6. Campbell NRC. The safety of folate supplementation. National Workshop on the primary prevention of neural tube defects. Ottawa 1995;27-46.
5. Campbell NRC. Abbott D. Measurement of blood pressure in children. J Hypertens Control. 1994; 4:5-6.
4. Campbell NRC. Pharmacotherapy. A Pathophysiologic Approach. [book review]. Ann Intern Med. 1993; 119:865.
3. Campbell NRC. Iron stores, hemoglobin and the risk of developing coronary heart disease. Hypertens Canada. 1993; March:1-2.
2. McKay DW, Campbell NRC. Assessment of blood pressure measurement techniques and equipment in the ambulatory care setting. J Hypertens Control 1992; 2:6-7.
1. Gault MH, Campbell NR, Barrett B, Vasdev S, Chafe L, Veinnott G, Asku AE, Parfrey P. Spurious Stones. Urolithiasis. Editors VR Walker, RAL Sutton, ECB Cameron, CYC Pak, WG Robertson. Plenum Press, New York. 1989;315.

iii. BOOKS AND MONOGRAPHS: (documented to 2007)

- 1) Campbell NRC. Hypertension in Therapeutic Choices. Canadian Pharmacy Association. Eds J Gray. Ottawa 2007
- 2) Campbell N, Kaczorowski J, Ward R, Drouin D. Health Care Professional Education: A 'case study' of a successful education program that improved patient outcomes. [expert commentary] in: Perspectives on Health Education.
- 3) Campbell NRC. Systolic Hypertension in Cardiovascular Risk Management. Editor: W.S. Waring. Churchill Livingstone. Edinburgh 2007.
- 4) Campbell NRC. Hypertension in Therapeutic Choices. Editor: Gray J. Canadian Pharmacy Association. Ottawa, 2006
- 5) Campbell NRC Hypertension in Therapeutic Choices (electronic version) Editor Gray J. Canadian Pharmacy Association Ottawa 2005
- 6) Campbell NRC. Hypertension. in Therapeutic Choices (4th edition). Editor Gray J. Canadian Pharmacy Association Ottawa 2003 pg216-38.
- 7) Campbell NRC, Muirhead N, Onrot J, Remuzzi G, Ruggenenti P, Schieppati A. The challenge of hypertension and nephropathy in diabetes. Biotex Inc. Guelph Canada 2003

8) Campbell NRC. Risk Management in systolic hypertension. Drouin D, Liu P eds. Excerpta Medica Canada 2002

iv. ProCOR electronic communications (international electronic network to aid developing countries keep up with literature (Hypertension editor 2005-2008):

Jan 2008: Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale for salt restriction and salt-restriction target level for the management of hypertension, (2) Assessment of salt intake in the management of hypertension. Authors: Kawano Y et al.
Reference: *Hypertens Res* 2007; 10:879-86 and *Hypertens Res* 2007; 10:887-93.
Reviewers: Sailesh Mohan, Norm Campbell.

Nov 2007 Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial.
Authors: Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH.
Reference: *BMJ* 2007; 335:1030, DOI:10.1136/bmj.39360.617986
Reviewers: Sailesh Mohan, Norm Campbell

Sep 2007 WHO sodium report.
Reviewers: Sailesh Mohan, Norm Campbell

Aug 2007: Cardiovascular health among adults in Syria: a model from developing countries. Authors: Maziak W, Rastam S, Mzayek F, Ward KD, Eissenberg T, Keil U.
Reference: *Annals of Epidemiology* 2007 (in Press); doi: 10.1016/j.annepidem.2007.03.016
Reviewers: Sailesh Mohan, Norm Campbell

July 2007: Prevalence of dyslipidemia and associated factors among the hypertensive rural Chinese population.
Authors: Zhang X, Sun Z, Zheng L, Li J, Liu S, Xu C, Li J, Zhao F, Hu D, Sun Y.
Reference: *Archives of Medical Research* 2007; 38:432-39
Reviewers: Sailesh Mohan, Norm Campbell

Feb 2007: Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country.
Authors: A Chiolerio, G Madeleine, A Gabriel, M Burnier, F Paccaud and P Bovet.
Reference: *Journal of Human Hypertension* 2007; 21:120-27.
Reviewers: Sailesh Mohan, Norm Campbell

2006: Commentary on 'Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition, costs, and conformity to international guidelines in a tertiary-care setting. *J Hum Hypertens*.'

April 2006: Commentary on 'Pattern of Declining Blood Pressure Across Replicate Population Surveys of the WHO-MONICA Project Mid 1980's – Mid 1990's and the Role of Medication. Published *BMJ* March 2006.'

June 2006: Commentary with Dr. S Mohan on 'Under-treatment and under diagnosis of hypertension: A serious problem in the United Arab Emirates: *BMC Cardiovascular Disorders* 2006 6:24'.

Oct 2005: The relationship between pulse pressure and cardiovascular mortality in 12763 middle aged men from various parts of the world.

2005: Commentary on 'Low-fat dairy consumption and reduced risk of hypertension: the Seguimiento Universidad de Navarra (SUN) cohort. Alonso A et al. *Am J Clin Nutr* 2005; 82:972-979

Sept 2005: Identification and management of patients with hypertension in the polyclinic system of the Russian Federation

May 16th, 2005, Commentary on hypertension vs global CVD risk assessment. With N Khan

April 26th, 2005, Commentary on Red Wine and beer elevate Blood pressure in normotensive men. Zilkens RR, Burke V, Hodgson JM, Barden A, Beilin LJ, Puddey IB. *Hypertension* 2005;45:874-879.

April 20, 2005, Commentary on: General Practitioners' Approach to Hypertension in Urban Pakistan. Disturbing Trends in Practice. TH. Jafar et al *Circulation*. 2005; 111:1278-1283.

April 12: Commentary on 'World Hypertension Day' May 14, 2005

April 7, 2005: Commentary on BMJ 2005; 330:610-611 Drugs for preventing cardiovascular disease in China. Risk factor thresholds should vary according to resources.

v. ABSTRACTS: (documented to 2009).

93. Vardy L, Campbell N, Johansen H, Walker, R, Wielgosz A, Onysko J, Ru-Nie G, Sambell C, Phillips S for the Canadian Hypertension Education Program. Increases in anti-hypertensive prescriptions and reductions in cardiovascular events in Canada. *J Hypertens* 2008;26 (suppl 1):51.

92. Drouin D, Kaczorowski J, Campbell NR, Lewanczuk RR. Implementing guidelines. It is working in Canada! Report on behalf of the Canadian Hypertension Education Program. *J Hypertens* 2008;26 (suppl 1):14.

91. Amankwah E, Quan H, Campbell N, Maxwell C, Onysko J. Hypertensives without regular physicians are under-treated. *The Canadian Journal of Cardiology* 2006; 22(Suppl D):113D.

90. Campbell NRC, Brant R, Johansen H, Onysko J, Gao R-N. University of Calgary, Public Health Agency of Canada & Statistics Canada. Decreases in Death from Stroke, Acute Myocardial Infarction and Congestive Heart Failure in Relationship to Increases in Total Antihypertensive Drug Prescriptions in Regions of Canada between 1998 and 2003. International Society of Hypertension, October 2006. *J Hypertens* 2006; 24(Suppl 6): S42.

89. Maxwell CJ, Onysko J, Eliasziw M, Zhang, JX, Campbell NRC, Johansen H. Trends in the diagnosis and treatment of hypertension in Canada (poster presentation presented at the Annual Conference of the Canadian Association for Population Therapeutics & the 3rd Canadian Therapeutics Congress, Toronto, ON, May 10-13, 2006. *Canadian Journal of Clinical Pharmacology* 2006; 13(1): e185.

88. Drouin D, Campbell NR, Touyz R, Tobe S, Onysko J. Implementing guidelines: Knowledge transfer initiatives by the Canadian hypertension education program. *Can J Cardiol*. 2005;21 (suppl C) #092.

87. Campbell NRC, McAlister F, Tu K of the Canadian Hypertension Education Program Time trends in initiation of antihypertensive therapy in Elderly Hypertensive Diabetic and Non-Diabetic Ontarians (1994-2002). *Can J Cardiol*. 2005;21 (suppl C) #006.

86. Campbell NRC, Onysko J, Maxwell C, Eliasziw M, Zhang JX. Increases In the Diagnosis and Drug Treatment of Hypertensive Canadians. *Can J Cardiol*. 2005;21(suppl C): #123.

85. Gardner L, Tu K, McAlister A, Campbell NRC. Use of two or more antihypertensive drugs to treat hypertension in elderly Ontarians, *Can J Clin Pharmacol* 2005;12: e123.

84. Drouin D, Campbell N, Tobe S, Touyz R of the Canadian Hypertension Education Program. Knowledge translation efforts by the Canadian Hypertension Education Program. J Hypertension 2005;23: s298.
83. Drouin D, Campbell NRC, Feldman R, Tobe S. Implementing recommendations on hypertension: A Canadian Experience. J Hypertens 2004;22(suppl 2): s237.
82. Lowen A, Thomas C, Coffin CS, Cowtan T, Campbell NRC and the Pneumococcal Vaccination Working Group for the University of Calgary Medical Teaching Unit Quality Improvement Research Group. Missed opportunities no more: Improving pneumococcal vaccination on the medical teaching unit. Clin Invest Med 2002; 25:200.
- Coffin CS, Thomas C, Lowen A, Cowtan T, Campbell NRC and the Pneumococcal Vaccination Working Group for the University of Calgary Medical Teaching Unit Quality Improvement Research Group. Validity of ICD-9 code, administrative data in determining the eligibility for pneumococcal vaccination. Clin Invest Med 2002;25:195
80. Khan N, Tahir T, McAlister F, Ferland A, Campbell N, Ghali W. Development of a perioperative research agenda. Clin Invest Med. 2001; 24:277
79. Kammila S, Campbell NRC, Brant R, deJong R, Culleton B. Systematic error in the determination of nocturnal blood pressure dipping status by ambulatory blood pressure monitoring. Clin Invest Med. 2001; 24:276
78. Abdullah N, Lemaire JB, Schaefer JP, Campbell NRC. Internal Medicine Urgent Assessment. Clin Invest Med. 2000;23: S13
77. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RW, Campbell NRC. Prediction of effectiveness of tolcapone, a catechol-o-methyltransferase inhibitor in patients with Parkinson's Disease by COMT genotype. Ann Neurol. 1999; 46:477.
76. Maxwell CJ, Hogan DB, Campbell NRC, Ebly EM. Nifedipine and mortality risk in the elderly: Relevance of drug formulation, dose and duration. The Canadian Journal of Clinical Pharmacology. 1999; 6:47.
75. Campbell NRC. Canadian Coalition activities to prevent and control hypertension in the Elderly. World Hypertension League. 1999.
74. Campbell NRC, Myers MG, McKay DW. Differences in blood pressure when measured by physicians' usual technique and a standardized technique. Can J Cardiol. 1998; 14:146F.
73. Sandham JD, Abbott K, Brant R, Poon M, Campbell N, Todd K. A prospective randomized trial of CBC utilization in a tertiary care teaching hospital. Clin Invest Med. 1998;21: s47.
72. Campbell NRC, Brant R, Stalts H, Stone J, Mahallati H. Spurious increases in blood lipid levels during furosemide therapy. a randomized double-blind placebo controlled cross-over study. Clin Invest Med. 1997;20: s11.
71. Peters GL, Binder SK, Campbell NRC. Crossing legs increases systolic blood pressure. a randomized single blind cross-over study. Clin Invest Med. 1997;20: s37
70. Chockalingam A, Fodor JG, Feldman RD, Campbell NRC, Ramsden VR, Bacher M, Cutler H, Drover A, Irvine J, Thivierge R, Tremblay G. Importance of patient adherence to antihypertensive therapy. The 4th International Conference on Preventive Cardiology July 1997, Montreal Canada.

69. Campbell NRC, Chockalingam A, Ramsden V, McKay D, Fodor G, Shuaib A for the Canadian Coalition for High Blood Pressure Prevention and Control (Coalition): Progress since the World Conference on Hypertension Control, Ottawa, World Hypertension League. June 1997.
68. Campbell NRC, Milkovich L, Burgess E, McKay DW. Accuracy of self-measured blood pressure. The 4th International Conference on Preventive Cardiology July 1997, Montreal Canada.
67. Campbell NRC, Schaefer JP, Hasinoff BB, Tam Y, Tawfik Y, Peng Y, Reimche L. Ferrous sulfate-captopril interaction. Clin Invest Med 1996;19: s13.
66. Milkovich L, Burgess E, McKay DW, Campbell NRC. Accuracy of self-measured blood pressure. Clin Invest Med. 1996;19: s49.
65. Abbott D, Burgess E, Campbell N, Gant P, Milkovich L, Stewart D. Calgary Fire Department Blood Pressure Program. Proceedings of the 11th Canadian Heart Health Network Meeting 1996; p38.
64. Birkett N, Abbott D, Campbell NRC, Chockalingam A, Dagenais G, Hogan K for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-measurement of blood pressure. Issues related to the training of patients and health care professionals. Can J Cardiol. 1995;11(supl. d):38d
63. Campbell NRC, Abbott D, Bass M, Birkett B, Chockalingam A, Dagenais G, Hogan K, Ku LF, Lebel M, Milkovich L, McKay DW, Wasi S, Small C for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-measurement of blood pressure. Recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Cardiol. 1995;11(supl d):37d
62. McKay DW, Ku LF, Campbell NRC, Chockalingam A, Wasi S, Small C for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-Measurement of Blood Pressure: Recommendations on Equipment and Standards from the Canadian Coalition for High Blood Pressure prevention and Control. Can J Cardiol. 1995;11(supl d):38d.
61. Campbell NRC, Bass M, Chockalingam A, Lebel M, Milkovich L for the Canadian Coalition for High Blood Pressure Prevention and Control. Self-Measurement of Blood Pressure: Benefits, risks and interpretation of readings. Can J Cardiol. 1995;11(supl d):38d
60. Abbott D, Campbell N, Carruthers-Czyzewski P, Chockalingam A, David M, Dunkley G, Ellis E, Fodor JG, McKay D, Ramsden VR (Canadian Coalition for High Blood Pressure Prevention and Control Working Group). Guidelines for measurement of blood pressure, referral and follow-up, and lifestyle counselling. Proceedings of the 2nd International Heart Health Conference. Barcelona Spain 1995.
59. Sussex B, Campbell NRC, Raju M, McKay DW. Treatment with a diuretic decreases nitrate tolerance. Clin Pharmacol Ther. 1994; 56:229-234 abstracted in Drug interaction reports 1994;13;90.
58. Gault MH, Longerich L, Purchase L, Prabhakaran V, Campbell N. Predicting corrections for low pre-hemodialysis concentrations of proteins and lipids due to interdialysis weight gain. Clin Invest Med 1994;17: B91.
57. Vasdev S, Sampson CA, Longerich L, Barrett B, Parai S, Campbell N. Oral treatment with low molecular weight heparin normalizes blood pressure in hypertensive rats. Clin Invest Med. 1994;17: B69.
56. Hogan D, Campbell N, Jennett P, MacLeod N, Brant R. NSAIDS and increased cardiovascular medication use in the elderly. Clin Invest Med. 1994;1994;17: B57.
55. Campbell NRC, Hull R, Brant R, Hogan D, Pineo G. Age and gender effects on heparin levels and aPTT response in patients with proximal deep vein thrombosis. Clin Invest Med. 1994;17: B16.

54. Partlow ES, Chan SC, Pap KM, Hasinoff BB, Campbell NRC. The effect of ferrous sulfate on famotidine serum levels in healthy volunteers. Clin Invest Med. 1994;17: B15.
53. Campbell NRC, Skerjanec A, Tam YK, Robertson S. Changes in methyldopa renal clearance and absorption following eight weeks of ingestion. Clin Invest Med. 1994;17: B13.
52. Campbell NRC, Hull R, Brant R, Hogan D, Pineo G. Age-gender effect on heparin levels during therapy. Clinical Abstracts/ Current Therapeutic Findings 1994; 13:43.
51. Campbell NRC, Hull R, Brant R, Hogan D, Pineo G. Age-gender effect on heparin levels during therapy. Clin Pharmacol Ther 1994; 55:172.
50. Campbell NRC, Hull R, Brant R, Hogan D, Pineo G. The effect of age and gender on aptt response to heparin in patients with proximal deep vein thrombosis. Clin Pharmacol Ther. 1994; 55:172.
49. Gault MH, Campbell N, Purchase L, Longerich L. Interdialysis weight gain with low predialysis concentrations of proteins and lipids and high end-dialysis values after weight removal. J Am Soc Neph. 1993; 4:347.
48. Skerjanec A, Campbell NRC, Tam YK. Presystemic gut metabolism of methyldopa (MD) in healthy human subjects. Pharm Res. 1993; 10:398s.
47. Gault MH, Campbell NRC, Purchase L, Longerich L. Weight loss and rise in concentration of proteins and lipids during hemodialysis (HD). Clin Invest Med 1993;16: B103.
46. Wulffhart ZA, Harris JA, Campbell NRC, MacKay DW. A novel method for arm weight measurement shows effect of isometric exercise on blood pressure. Clin Invest Med 1993;16: B15.
45. Mazuryk M, Campbell NRC, Hull RD. Unusual complications of anticoagulant therapy in a post operative patient. Clin Invest Med 1993;16: B84.
44. Partlow ES, Campbell NRC, Hasinoff BB, Chan SC, Pap KM. Little effect of ferrous sulfate on cimetidine levels in healthy volunteers. Clin Invest Med 1993;16: B19.
43. Campbell NRC, Wickert WA, Shumak S. The effect of acute furosemide and fasting on serum lipid and lipoprotein levels. Cardiovasc Drugs Ther 1993; 7:399.
42. Wickert WA, Campbell NRC, Shumak S. The effect of hydration on fasting lipid and lipoprotein levels. Clin Invest Med 1993;16: B10.
41. Wickert W, Campbell NRC, Shumak SL. The acute effects of furosemide on lipid concentrations. Clin Invest Med 1993;16: B10.
40. Partlow ES, Chan SC, Pap KM, Campbell NRC. The effect of ferrous sulfate on cimetidine levels in healthy volunteers. Clin Pharmacol Ther 1993; 53:163.
39. Campbell NRC, Hasinoff BB, Rao B, Stalts H, Wong N. Interaction between iron and thyroxine. Yearbook of Endocrinology. 1993.
38. Campbell NRC, Hasinoff BB, Rao B, Stalts H, Wong N. Thyroxine-Ferrous sulfate. Clinical Abstracts-Current Therapeutic Findings. Drug interaction reports. 1993; 12:18.

37. Campbell NRC, Hasinoff BB, Rao B, Stalts H, Wong N. Interaction between iron and thyroxine. *Inpharm*. 1993; January 9:21.
36. Campbell NRC, Hasinoff B. Iron tablets can inhibit thyroxine action. *RN*. 1993.
35. Campbell NRC, Hasinoff BB, Rao B, Stalts H, Wong N. Iron may reduce thyroxine absorption. *Journal Watch*. 1993; 11:5.
34. Campbell NRC, Hasinoff B. Ferrous sulfate found to reduce levodopa bioavailability. *The Pharmaceutical Journal*. June 3, 1989
33. Campbell NRC, Hasinoff BB, Robertson S. Absence of an effect of ferrous sulfate on phenytoin absorption. *Clin Invest Med* 1992;15: A20.
32. Campbell NRC, Wickert W, Purchase L, Longerich L, Gault MH. Hemodialysis, weight loss, and increased concentrations of plasma cholesterol and proteins. *Clin Invest Med* 1992;15: A96.
31. Meddings JB, Campbell NRC, Hasinoff BB, Anderson WD, Robertson S, Granberg K. Ferrous sulfate reduces cimetidine absorption. *Clin Invest Med* 1992;15: A18.
30. Campbell NRC, Wong N, Hasinoff BB, Rao B, Stalts H. Ferrous sulfate reduces thyroxine efficacy. *Clin Pharmacol Ther*. 1992; 51:165.
29. Campbell NRC, Hasinoff BB. Iron supplements. A common cause of drug interactions. *Pharmacy Digest*. 1992; 1:21-22.
28. McKay DW, Raju MK, Campbell NRC. Skills and knowledge of blood pressure measurement technique in recent medical graduates. *International Heart Health Conference*. 1992.
27. Brager PDN, Campbell N, Rabin H. Lithium psychopharmacodynamics in Cystic Fibrosis. *IX International Cystic Fibrosis Congress*. 1992.
26. Brager N, Campbell N, Rabin H. Lithium Pharmacokinetics in Cystic Fibrosis. *World Lithium Conference/ 3rd British Lithium Congress*. 1992;41.
25. Campbell NRC, Kara M, Hasinoff BB, McKay DW. Clinical and chemical interactions between norfloxacin and clinically used metal ions. *Clin Invest Med* 1991;14: A18.
24. Campbell NRC, Kara M, Hasinoff BB, McKay DW. Clinical and chemical interactions between norfloxacin and clinically used metal ions. *Clin Pharmacol Ther*. 1991; 49:200.
23. Campbell NRC, Patrick W. Changes in methyl dopa absorption and renal excretion following multiple doses: Suggestive evidence for induction of drug transport. *Clin Pharmacol Ther*. 1991; 49:130.
22. Sussex BA, Campbell NRC, Raju MK. Treatment with a diuretic decreases nitrate tolerance. *Circulation* 1990; 82:200s.
21. Vasdev S, Campbell NRC, Prabhakaran V, Esquivel M, Sampson CA. Increased calcium uptake in rat vascular tissue by plasma of patients with essential hypertension. *Clin Invest Med* 1990;13: B57.
20. Sussex BA, Campbell NRC, Raju MK. Treatment with a diuretic decreases nitrate tolerance. *Clin Invest Med* 1990;13:C98.

19. Vasdev S, Campbell NRC, Prabhakaran V, Esquivel M, Sampson CA. Increased calcium uptake in vascular tissue by plasma of patients with essential hypertension. Clin Chem 1990; 36:1170.
18. Vasdev S, Campbell NRC, Prabhakaran V, Esquivel M, Sampson CA. Increased calcium uptake in rat vascular tissue by plasma of patients with essential hypertension. J Hypertens 1990; 8:3(IC 01).
17. Campbell NRC, Hasinoff B. Ferrous sulfate reduces l-dopa bioavailability. Chelation as a possible mechanism. Parkinson/Alzheimer Digest 1989; 5:15-16.
16. Campbell NRC, McKay DW, Chockalingam A, Fodor JG. Techniques of blood pressure determination and accuracy of sphygmomanometers in general ambulatory clinics. Clin Invest Med 1989;12: B54.
15. Rankine D, Campbell NRC, Goodridge A, Kara M, Hasinoff B. Ferrous sulfate, Sinemet interaction in patients with Parkinson's disease. Can J Neurol Sc 1989; 16:241.
14. Barrett B, Gault MH, Campbell NRC, Vasdev S, Chafe L, Veinnott G, Asku AE, Parfrey P. Spurious stones. Clin Invest Med 1988;11:C86.
13. Chockalingam A, Fodor JG, Drover A, Campbell NRC. Practical experience with 24-hour ambulatory BP monitoring in outpatient setting. Clin Invest Med 1988;11:C62.
12. Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability. Clin Invest Med 1988;11:C17.
11. Campbell NRC. Reduction in levodopa bioavailability associated with ferrous sulfate administration. Clin Pharmacol Ther 1988; 43:167.
10. Campbell NRC, Paddock V and Sundaram R. Methyldopa: Effects of ferrous sulfate and ferrous gluconate on absorption and metabolism. Clin Invest Med 1987;10: B27.
9. Maidak B, Campbell NRC, Weinshilboum R. Phenol Sulfotransferase: Correlation of hepatic isozymes with familial thermal stability variants. Proceedings of the 7th International Congress of Human Genetics. 1986.
8. Campbell NRC, Weinshilboum RM. Human Phenol Sulfotransferase (PST): Correlation of liver and platelet activities. Clin Invest Med 1986;4: A15.
7. Campbell NRC, Weinshilboum, RM. Human liver phenol sulfotransferase (PST): Partial purification of the "TS" form. Fed Proc 1984; 43:339.
6. Campbell NRC, Sundaram RS, Werness P, Van Loon J, Weinshilboum RM. Methyldopa metabolism: Importance of sulfate availability. Clin Invest Med 1984; 7:34.
5. Campbell NRC, Dunnette JH, Mwaluko G, Van Loon J, Weinshilboum RM. Catechol-o-methyltransferase, phenol sulfotransferase and methyldopa metabolism in man. II World Conf Clin Pharmacol Ther. 108, 1983.
4. Fernandez PG, Kim BK, Galway B, Campbell NRC, Granter-Button S, McDonald J. Blood pressure behaviour and predictability: a new therapeutic regimen in hypertension. Proc Clin Res 1982; 30:49A.
3. Fernandez PG, Kim BK, Galway B, Campbell N, Granter-Button S, McDonald J. Potassium conservation in thiazide induced hypokalemia in uncomplicated essential hypertension: Proc Clin Res 1982; 30:25A.9
2. Fernandez PG, Galway B, Kim BK, Granter-Button S, McDonald J, Campbell NRC. Moduret (amiloride plus hydrochlorothiazide) versus hydrochlorothiazide: an evaluation of potassium conservation in uncomplicated essential hyper-tension: Clin Invest Med 1981; 4:6B.

1. Fernandez PG, Galway B, Kim BK, Granter-Button S, McDonald J, Campbell NRC. Stepwise discriminant analysis: prediction of blood pressure behaviour in uncomplicated essential hypertension. Clin Invest Med 1981; 4:26B.